	    		            		                                                                                                                                          	    		   		   	  	   	    							    	    																																			    																	    	    	                             		       	                                                                                                           	        						    	    																																			    																	    	    	                             		       	                                                                                                       									    	    																																			    																	    	    	                             		       	                                                                                                       									    	    																																			    																	    	    	                             		       	                                                                                                       	            			        	                            						    	    																																			    																	    	    	                             		       	                                                                                                                                                                                                               	     <!DOCTYPE html><html><head>        	<meta http-equiv="X-UA-Compatible" content="IE=edge,chrome=1" />    <meta charset="utf-8" />        	<title>DailyMed - INVIRASE- saquinavir mesylate capsule  INVIRASE- saquinavir mesylate tablet, film coated  </title>                <!--[if lt IE 9]>        <script src="//html5shim.googlecode.com/svn/trunk/html5.js"></script>    <![endif]-->    <link rel="stylesheet" type="text/css" media="screen" href="dailymed/css/skeleton.min.css" />    <link rel="stylesheet" type="text/css" media="screen" href="dailymed/css/jquery.jqzoom.min.css" />    <link rel="stylesheet" type="text/css" media="screen" href="dailymed/css/style.min.css" />    <link rel="stylesheet" type="text/css" media="screen" href="dailymed/css/header-search.min.css" />    <link rel="stylesheet" type="text/css" media="all" href="dailymed/css/responsive.min.css" />    <link rel="stylesheet" type="text/css" media="print" href="dailymed/css/print.min.css" />    <!--[if !IE]><!-->    <link rel="stylesheet" type="text/css" media="all" href="dailymed/css/responsive-tables.min.css" />    <!--<![endif]-->    <link rel="icon" href="dailymed/images/favicons/favicon.ico" type="image/x-icon" />    <link rel="shortcut icon" href="dailymed/images/favicons/favicon.ico" type="image/x-icon"/>        <link rel="apple-touch-icon" sizes="57x57" href="dailymed/images/favicons/apple-touch-icon-57x57.png">    <link rel="apple-touch-icon" sizes="114x114" href="dailymed/images/favicons/apple-touch-icon-114x114.png">    <link rel="apple-touch-icon" sizes="72x72" href="dailymed/images/favicons/apple-touch-icon-72x72.png">    <link rel="apple-touch-icon" sizes="144x144" href="dailymed/images/favicons/apple-touch-icon-144x144.png">    <link rel="apple-touch-icon" sizes="60x60" href="dailymed/images/favicons/apple-touch-icon-60x60.png">    <link rel="apple-touch-icon" sizes="120x120" href="dailymed/images/favicons/apple-touch-icon-120x120.png">    <link rel="apple-touch-icon" sizes="76x76" href="dailymed/images/favicons/apple-touch-icon-76x76.png">    <link rel="apple-touch-icon" sizes="152x152" href="dailymed/images/favicons/apple-touch-icon-152x152.png">    <link rel="icon" type="image/png" href="dailymed/images/favicons/favicon-196x196.png" sizes="196x196">    <link rel="icon" type="image/png" href="dailymed/images/favicons/favicon-160x160.png" sizes="160x160">    <link rel="icon" type="image/png" href="dailymed/images/favicons/favicon-96x96.png" sizes="96x96">    <link rel="icon" type="image/png" href="dailymed/images/favicons/favicon-16x16.png" sizes="16x16">    <link rel="icon" type="image/png" href="dailymed/images/favicons/favicon-32x32.png" sizes="32x32">    <meta name="msapplication-config" content="/dailymed/images/favicons/browserconfig.xml" />    <meta name="msapplication-TileColor" content="#da532c">    <meta name="msapplication-TileImage" content="/dailymed/images/favicons/mstile-144x144.png">    <meta name="description" content="" />    <meta name="keywords" content="" />     <meta name="robots" content="noimageindex, noodp, noydir" />     <meta name="viewport" id="viewport" content="width=device-width,minimum-scale=1.0,maximum-scale=10.0,initial-scale=1.0" />    <script src="/dailymed/scripts/modernizr-2.0.6.min.js"></script>        <script type="text/javascript" src="//ajax.googleapis.com/ajax/libs/jquery/1.10.2/jquery.min.js"></script>        <script type="text/javascript">        if (typeof jQuery == 'undefined')        {              document.write('\x3Cscript type="text/javascript" src="/dailymed/scripts/jquery-1.10.2.min.js">\x3C/script>');        }    </script>                	                	            	    	<script type="text/javascript">		var basepath = "/dailymed";;		var availableClasses =  new Array();;		for(var i = 0; i < availableClasses.length; i++){			availableClasses[i] = availableClasses[i].replace(/"/g, '').trim();		}		var labeltitle = "INVIRASE- saquinavir mesylate capsule <br>INVIRASE- saquinavir mesylate tablet, film coated <br>";;		var emailLink = "";;		var emailrequest = "0";;	</script>    <script src="/dailymed/scripts/javascript-html-attribute-encoding.min.js"></script>    <script src="/dailymed/scripts/spin.min.js"></script>	<script src="/dailymed/scripts/scripts.min.js"></script>            <script type='text/javascript' src="//ajax.googleapis.com/ajax/libs/jqueryui/1.11.0/jquery-ui.min.js"></script>    <script type="text/javascript">        if (typeof jQuery.ui == 'undefined')        {            document.write('\x3Cscript type="text/javascript" src="/dailymed/scripts/jquery-ui-1.10.4.custom.min.js">\x3C/script>');            document.write('\x3Clink rel="stylesheet" type="text/css" media="all" href="dailymed/css/jquery-ui-1.10.4.custom.min.css">');        }        else{            document.write('<link rel="stylesheet" href="/ajax.googleapis.com/ajax/libs/jqueryui/1.11.0/themes/smoothness/jquery-ui.min.css">');        }    </script>    <script type='text/javascript' src='/dailymed/scripts/jquery.elevateZoom-3.0.8.min.js'></script>      <script type="text/javascript" src="/dailymed/scripts/jquery.placeholder.min.js"></script>    <script src="//www.accessdata.fda.gov/spl/stylesheet/spl.js" type="text/javascript" charset="utf-8">/* */</script>    <!-- Magnific Popup core CSS file -->    <link rel="stylesheet" href="dailymed/css/magnific-popup.min.css">        <!-- Magnific Popup core JS file -->    <script src="/dailymed/scripts/jquery.magnific-popup.min.js"></script>        <meta name = "format-detection" content = "telephone=no"></head><body class="inner drug-info">	<div class="container_1000 bg_shadow">        <div style="width: 0; height: 0;"><a href="#" id="top-of-page"></a></div><header>	<div class="topHeader">				<ul id="skip">		<li><a href="#skip-main-content">Skip to Main Content</a></li></ul>		<nav class="topHeaderNav">        	<div class="topNIHLogo mobileview">        		<a href="http://www.nih.gov" class="top-logo" title="National Institutes of Health" target="_blank"><img src="/dailymed/images/nih-toplogo.png" alt="NIH Logo"/></a>            	<a href="/www.nlm.nih.gov" title="U.S. National Library of Medicine" target="_blank">U.S. National Library of Medicine</a></div>			<div class="container">				<div class="sixteen columns">                	<div class="topNIHLogo"><a href="http://www.nih.gov" title="National Institutes of Health" target="_blank"><img src="/dailymed/images/nih-toplogo.png" alt="NIH Logo"/></a>                    <a href="/www.nlm.nih.gov" title="U.S. National Library of Medicine" target="_blank">U.S. National Library of Medicine</a></div>					<ul>																		<li class="safety"><a title="Report Adverse Events" href="/www.accessdata.fda.gov/scripts/medwatch/" target="_blank">Report Adverse Events </a><span>|</span><a title="FDA Safety Reporting and Recalls" href="http://www.fda.gov/Safety/Recalls" target="_blank">Recalls</a></li>					</ul>				</div>			</div>		</nav>		<div class="divider"></div>	</div>	<div class="dailymedlogoprint"><img src="/dailymed/images/logo.png" alt="DailyMed" /></div>	<div class="bottomHeader">		<div class="header-image">						<div class="mobile-menu-btn closed hasjs" tabindex="0"></div><div class="mobile-menu">		<div class="mobile-menu-container">		<div class="pro-menu active">			<div class="first half">				<ul>					<li><a href="dailymed/index.cfm">Home</a></li>					<li>						News						<ul>							<li><a href="dailymed/dailymed-announcements.cfm">DailyMed Announcements</a></li>							<li><a href="dailymed/rss-updates.cfm">Get RSS News &amp; Updates</a></li>						</ul>					</li>					<li><a href="dailymed/about-dailymed.cfm">About Dailymed</a></li>					<li><a href="dailymed/contact-us.cfm">Contact Us</a></li>					<li>						Safety Reporting &amp; Recalls						<ul>							<li><a href="/www.accessdata.fda.gov/scripts/medwatch/">Report Adverse Events</a></li>							<li><a href="http://www.fda.gov/Safety/Recalls">FDA Saftey Recalls</a></li>						</ul>					</li>					<li>						<a href="dailymed/fda-drug-guidance.cfm">FDA Guidances &amp; Information</a>											</li>				</ul>			</div>			<div class="last half">				<ul>					<li>						NLM SPL Resources						<ul>							<li>								<a href="dailymed/spl-resources.cfm">Download Data</a>								<ul>									<li><a href="dailymed/spl-resources-all-drug-labels.cfm">- All Drug Labels</a></li>									<li><a href="dailymed/spl-resources-all-indexing-files.cfm">- All Indexing Files</a></li>									<li><a href="dailymed/spl-resources-all-mapping-files.cfm">- All Mapping Files</a></li>								</ul>							</li>							<li><a href="dailymed/splimage-guidelines.cfm">SPL Image Guidelines</a></li>							<li><a href="dailymed/spl-resources-all-mapping-files.cfm">Articles &amp; Presentations</a></li>						</ul>					</li>					<li>						Application Development Support						<ul>							<li>								<a href="dailymed/app-support.cfm">Resources</a>								<ul>									<li><a href="dailymed/app-support-web-services.cfm">- Web Services</a></li>																		<li><a href="dailymed/app-support-mapping-files.cfm">- Mapping Files</a></li>								</ul>							</li>						</ul>					</li>					<li><a href="dailymed/help.cfm">Help</a></li>				</ul>			</div>		</div>			</div></div>			<a href="dailymed/index.cfm" class="logo" title="DailyMed">DailyMed</a>						<div class="header-search-container">				<div id="header-search">									    					    				    <form action="/dailymed/search.cfm">		<div class="searchNav">		<ul class="searchType">			<li class="all active">									<input type="radio" class="hidden" name="labeltype" id="labeltype-all" value="all" />					<label for="labeltype-all">All Drugs</label>							</li>			<li class="human">									<input type="radio" class="hidden" name="labeltype" id="labeltype-human" value="human"/>					<label for="labeltype-human">Human Drugs</label>							</li>			<li class="animal">									<input type="radio" class="hidden" name="labeltype" id="labeltype-animal" value="animal" />					<label for="labeltype-animal">Animal Drugs</label>							</li>							<li class="more-ways" id="header-search-more-ways">					<a href="#" id="more-ways-button" class="more-ways-label">More ways to search</a>					<ul id="more-ways-dropdown" class="dropdown" style="display:none;">						<li>							<a href="dailymed/advanced-search.cfm">Advanced Search</a>						</li>						<li>							<a href="dailymed/browse-drug-classes.cfm">Browse Drug Classes</a>						</li>						<li>							<a href="dailymed/archives/index.cfm">Label Archives</a>						</li>						<li>							<a class="external-link" href="http://pillbox.nlm.nih.gov" target="_blank">Tablet/Capsule ID Tool</a>						</li>					</ul>				</li>					</ul>	</div>			<div class="searchForm">					<div class="searchInput">				<input id="searchQuery" name="query" tabindex="0" type="text" placeholder="Enter drug, NDC code, drug class, or Set ID" autocorrect="off" autocapitalize="off">									<button class="search-button">  </button>							</div>								<input class="search" tabindex="0" title="Search" type="submit" value="Search">	</div></form>									</div>			</div>			<div class="mobile-search-btn" tabindex="0"></div>												<div class="header-bg">																										</div>			<div class="divider"></div>		</div>		<div class="bottomHeaderContent">									<div class="search mobile-search">				<div class="divider_10 nomargin mobileview"></div>																			<form action="/dailymed/search.cfm">		<div class="searchNav">		<ul class="searchType">			<li class="all active">									<input type="radio" class="hidden" name="labeltype" id="labeltype-all-2" value="all" />					<label for="labeltype-all-2">All Drugs</label>							</li>			<li class="human">									<input type="radio" class="hidden" name="labeltype" id="labeltype-human-2" value="human"/>					<label for="labeltype-human-2">Human Drugs</label>							</li>			<li class="animal">									<input type="radio" class="hidden"  name="labeltype" id="labeltype-animal-2" value="animal" />					<label for="labeltype-animal-2">Animal Drugs</label>							</li>					</ul>	</div>			<div class="searchForm">					<div class="searchInput">				<input id="searchToolsQuery" name="query" tabindex="0" type="text" placeholder="Enter drug, NDC code, drug class, or Set ID" autocorrect="off" autocapitalize="off">			</div>								<input class="search" tabindex="0" title="Search" type="submit" value="Search">	</div></form>								<div class="divider"></div>								<nav class="bottomHeaderNav">                <noscript>                <div class="tabletnav no-js">                    <div class="col">                        <ul>                            <li><a href="dailymed/index.cfm">Home</a></li>                            <li>News                                <ul>                                    <li><a href="dailymed/dailymed-announcements.cfm">DailyMed Announcements</a></li>                                    <li><a href="dailymed/rss-updates.cfm">Get RSS News & Updates</a></li>                                </ul>                            </li>                        </ul>                    </div>                                    <div class="col">                        <ul>                            <li>Search                                <ul>                                    <li><a href="dailymed/advanced-search.cfm">Advanced Search</a></li>                                    <li><a href="dailymed/browse-drug-classes.cfm">Browse Drug Classes</a></li>                                    <li><a href="dailymed/archives/index.cfm">Labels Archives</a></li>                                                                        <li><a href="http://pillbox.nlm.nih.gov">Tablet/Capsule ID Tool</a></li>                                </ul>                            </li>                        </ul>                    </div>                                    <div class="col">                        <ul>                            <li><a href="dailymed/fda-drug-guidance.cfm">FDA Guidances &amp; Information</a></li>                            <li>NLM SPL Resources                                <ul>                                    <li><a href="dailymed/spl-resources.cfm">Download Data</a>                                        <ul>                                            <li><a href="dailymed/spl-resources-all-drug-labels.cfm">All Drug Labels</a></li>                                            <li><a href="dailymed/spl-resources-all-indexing-files.cfm">All Index Files</a></li>                                            <li><a href="dailymed/spl-resources-all-mapping-files.cfm">All Mapping Files</a></li>                                        </ul>                                    </li>                                    <li><a href="dailymed/splimage-guidelines.cfm">SPL Image Guidelines</a></li>                                    <li><a href="dailymed/spl-resources-presentations-articles.cfm">Presentations &amp; Articles</a></li>                                </ul>                            </li>                        </ul>                    </div>                                    <div class="col">                        <ul>                            <li>Application Development Support                                <ul>                                    <li><a href="dailymed/app-support.cfm">Resources</a>                                        <ul>                                            <li><a href="dailymed/app-support-web-services.cfm">Web Services</a></li>                                            <li><a href="dailymed/app-support-mapping-files.cfm">Mapping Files</a></li>                                        </ul>                                    </li>                                </ul>                            </li>                            <li><a href="dailymed/help.cfm">Help</a></li>                        </ul>                    </div>                </div>           		</noscript>                					<ul class="webview hasjs">						<li><a href="dailymed/index.cfm" title="Home">Home</a></li>						<li>													<a href="#" title="News">												News</a>							<ul class="sub-menu">								<li><a href="dailymed/dailymed-announcements.cfm">DailyMed Announcements</a></li>								<li><a href="dailymed/rss-updates.cfm">Get RSS News &amp; Updates</a></li>							</ul>						</li>						<li>																				<a href="dailymed/fda-drug-guidance.cfm" title="FDA Guidances &amp; Info">												FDA Guidances &amp; Info</a>													</li>						<li>													<a href="#" title="Structured Product Labeling (SPL) resources for industry professionals.">												NLM SPL Resources</a>														<ul class="sub-menu">								<li><a href="dailymed/spl-resources.cfm">Download Data</a>									<ul>										<li><a href="dailymed/spl-resources-all-drug-labels.cfm">All Drug Labels</a></li>										<li><a href="dailymed/spl-resources-all-indexing-files.cfm">All Indexing Files</a></li>										<li><a href="dailymed/spl-resources-all-mapping-files.cfm">All Mapping Files</a></li>									</ul>								</li>								<li><a href="dailymed/splimage-guidelines.cfm">SPL Image Guidelines</a></li>								<li><a href="dailymed/spl-resources-presentations-articles.cfm">Presentations &amp; Articles</a></li>							</ul>						</li>						<li>													<a href="#" title="Application Development Support">												Application Development Support</a>							<ul class="sub-menu">								<li><a href="dailymed/app-support.cfm">Resources</a>									<ul>										<li><a href="dailymed/app-support-web-services.cfm">Web Services</a></li>																				<li><a href="dailymed/app-support-mapping-files.cfm">Mapping Files</a></li>									</ul>								</li>							</ul>						</li>									  						<li>													<a href="dailymed/help.cfm" title="Help">												Help</a></li>   					</ul>					<ul class="tabletview hasjs">						<li><a href="dailymed/advanced-search.cfm" title="Advanced Search">Advanced Search</a></li>						<li class="viewmore"><a href="#" title="View More">View More</a>							<ul>								<li><span>News</span>									<ul>										<li><a href="dailymed/dailymed-announcements.cfm">DailyMed Announcements</a></li>										<li><a href="dailymed/rss-updates.cfm">Get RSS News &amp; Updates</a></li>									</ul>								</li>								<li><span>Safety Reporting and Recalls</span>									<ul>										<li><a href="/www.accessdata.fda.gov/scripts/medwatch/" target="_blank">Report Adverse Events</a></li>										<li><a href="/www.fda.gov/Safety/Recalls" target="_blank">FDA Saftey Recalls</a></li>									</ul>								</li>								<li>									<a href="dailymed/fda-drug-guidance.cfm">FDA Guidances &amp; Information</a>								</li>																<li><span>NLM SPL Resources</span>									<ul>										<li><a href="dailymed/spl-resources.cfm">Download Data</a>											<ul>												<li><a href="dailymed/spl-resources-all-drug-labels.cfm">- All Drug Labels</a></li>												<li><a href="dailymed/spl-resources-all-indexing-files.cfm">- All Indexing Files</a></li>												<li><a href="dailymed/spl-resources-all-mapping-files.cfm">- All Mapping Files</a></li>											</ul>										</li>										<li><a href="dailymed/splimage-guidelines.cfm">SPL Image Guidelines</a></li>										<li><a href="dailymed/spl-resources-presentations-articles.cfm">Presentations &amp; Articles</a></li>									</ul>								</li>   								<li><span>Application Development Support</span>									<ul>										<li><a href="dailymed/app-support.cfm">Resources</a>											<ul>												<li><a href="dailymed/app-support-web-services.cfm">- Web Services</a></li>																								<li><a href="dailymed/app-support-mapping-files.cfm">- Mapping Files</a></li>											</ul>										</li>									</ul>								</li>   								<li><a href="dailymed/help.cfm" title="Help">Help</a></li>   							</ul>						</li>						<li class="mobileview viewmore" tabindex="0"><a title="View More" href="#">More ways to search</a>							<ul>								<li tabindex="0"><a title="Browse Drug Classes" href="dailymed/browse-drug-classes.cfm">Browse Drug Classes</a></li>								<li tabindex="0"><a title="Label Archives" href="dailymed/archives/index.cfm">Label Archives</a></li>																<li tabindex="0"><a target="_blank" title="Tablet/Capsule ID Tool" href="http://pillbox.nlm.nih.gov/">Tablet/Capsule ID Tool</a></li>   							</ul>						</li>					</ul>										<ul class="mobileview hasjs">						<li><a href="dailymed/advanced-search.cfm" title="Advanced Search">Advanced Search</a></li>						<li tabindex="0" class="viewmore"><a href="#" title="View More">View More</a>							<ul>								<li tabindex="0"><a href="dailymed/browse-drug-classes.cfm" title="Browse Drug Classes">Browse Drug Classes</a></li>								<li tabindex="0"><a href="dailymed/archives/index.cfm" title="Label Archives">Label Archives</a></li>																<li tabindex="0"><a href="http://pillbox.nlm.nih.gov/" title="Tablet/Capsule ID Tool" target="_blank">Tablet/Capsule ID Tool</a></li>   							</ul>						</li>					</ul>				</nav>				<div class="divider_10 nomargin"></div>			</div>					</div>				<div class="divider"></div>	</div></header><div id="skip-main-content"></div>        <div class="container">             <div class="main-content">                <div class="header long">                    <div class="header-top">                            <h1>Label: <span class="long-title">INVIRASE- saquinavir mesylate capsule <br>INVIRASE- saquinavir mesylate tablet, film coated <br></span></h1>                    </div>                                        <ul class="tools">                    	                        <li class="rss"><a href="#modal-label-rss" class="modal-open">Label RSS</a></li>                        <li class="share">Share                            <noscript>: JavaScript needed for Sharing tools</noscript>                            <!-- AddThis Button BEGIN -->                            <div class="addthis_toolbox addthis_default_style addthis_16x16_style">                                                                                                    	                                	            			        	                                                                        <a class="email-share" href="mailto:?subject=DailyMed%20Web%20site%20information&amp;Body=I%20would%20like%20to%20share%20this%20page%20from%20the%20DailyMed%20website%20with%20you%3A%0A%0AINVIRASE%2D%20Saquinavir%20Mesylate%20Capsule%20INVIRASE%2D%20Saquinavir%20Mesylate%20Tablet%2C%20Film%2E%2E%2E%0Ahttps%3A%2F%2Fdailymed%2Enlm%2Enih%2Egov%2Fdailymed%2FdrugInfo%2Ecfm%3Fsetid%3Dc00d1607%2Dac36%2D457b%2Da34b%2D75ad74f9cf0a%0A%0ADailyMed%20is%20a%20site%20provided%20by%20The%20National%20Library%20of%20Medicine%20%28NLM%29%20and%20is%20the%20official%20provider%20of%20FDA%20drug%20label%20information%20%28package%20inserts%29%2E" title="Share by Email"></a>                                <a class="addthis_button_facebook"></a>                                <a class="addthis_button_twitter"></a>                                                                <a class="at300bs at15nc at15t_compact reveal" title="Bookmark &amp; Share" href="/www.addthis.com/bookmark.php?pub=DailyMed&amp;title=DailyMed" target="_blank" style="display: block;">                                    <span style="left: -9999px; position: absolute;">Bookmark &amp; Share</span><img style="width:17px" src="/dailymed/images/addthis-image.jpg"></img>                                </a>                            </div>                            <script type="text/javascript">var addthis_config = {"data_track_addressbar":false};</script>                            <script type="text/javascript" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=ra-542300cc2097c8b5" ></script>                             <!-- AddThis Button END -->                                                    </li>                    </ul>                  </div>                <div class="four columns sidebar" id="leftmenu">                    <section>                        <article>                                                        <div class="w-photos">                            	                                                                <div class="mod drug-photos">                                <h2><a>View Package Photos</a></h2>                                <ul>                                    <li>                                                                               <ul>                                                                                                                        	                                            	 <li class="img package-photo"><a href="image.cfm?type=img&name=invirase-02.jpg&setid=c00d1607-ac36-457b-a34b-75ad74f9cf0a" class="thumbnail" title="Package Photo" data-photo-type="package" data-slideorder="0">                                                 	<img id="zoom_1" title="Package Photo" alt="Package Photo"                                                     data-zoom-image="image.cfm?type=img&name=invirase-02.jpg&setid=c00d1607-ac36-457b-a34b-75ad74f9cf0a" src="image.cfm?type=img&name=invirase-02.jpg&setid=c00d1607-ac36-457b-a34b-75ad74f9cf0a" data-photo-type="package">                                                 	<span class="enlarge"></span>                                                    </a></li>                                                                                             											                                                                                	                                            	 <li class="img package-photo"><a href="image.cfm?type=img&name=invirase-03.jpg&setid=c00d1607-ac36-457b-a34b-75ad74f9cf0a" class="thumbnail" title="Package Photo" data-photo-type="package" data-slideorder="1">                                                 	<img id="zoom_2" title="Package Photo" alt="Package Photo"                                                     data-zoom-image="image.cfm?type=img&name=invirase-03.jpg&setid=c00d1607-ac36-457b-a34b-75ad74f9cf0a" src="image.cfm?type=img&name=invirase-03.jpg&setid=c00d1607-ac36-457b-a34b-75ad74f9cf0a" data-photo-type="package">                                                 	<span class="enlarge"></span>                                                    </a></li>                                                                                             											                                                                                </ul>                                    </li>                                </ul>								                                </div>            								                                                                                            </div>                            <div class="mod-wrap">                                <div class="mod blue-list page-jump">                                    <h2><a href="#drug-information">Drug Label Info</a></h2>                                </div>                                                                <div class="mod blue-list orange">                                                                                                                                                                                                                                                                                                                                                                                                                                                    <h2><a href="#">Safety</a></h2>                                    <ul>                                                                                                                                                                    <li>                                                <a href="/www.accessdata.fda.gov/scripts/medwatch/ " target="_blank">Report Adverse Events</a>                                            </li>                                            <li><a href="http://www.fda.gov/Safety/Recalls/" target="_blank">FDA Safety Recalls</a></li>                                            <li>                                                <a href="http://toxnet.nlm.nih.gov/cgi-bin/sis/search2/r?dbs+lactmed:@or+%28@na+%22saquinavir%22+%29" target="_blank">Presence in Breast Milk</a>                                            </li>                                                                            </ul>                                </div>                                <div class="mod blue-list">                                    <h2><a href="#">Related Resources</a></h2>                                    <ul>                                                                                                                            <li>                                                <a href="/vsearch.nlm.nih.gov/vivisimo/cgi-bin/query-meta?v:project=medlineplus&query=saquinavir" target="_blank">Medline Plus</a>                                            </li>                                                                                <li>                                            <a href="/www.clinicaltrials.gov/ct/search?submit=Search&term=saquinavir" target="blank">Clinical Trials</a>                                        </li>                                                                                    <li>                                                                                                <a href="#" id="pubmed-menu">PubMed</a>                                            	    											                                                                                                <ul>                                                    <li>                                                        <a href="/www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=saquinavir[All Fields]" title="Link opens new window for All Citations" target="pubmed">All Citations</a>                                                    </li>                                					<li>                                                        <a href="/www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=saquinavir/AE" title="Link opens new window for Adverse Effects" target="pubmed">Adverse Effects</a>                                                    </li>                                					<li>                                                        <a href="/www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=saquinavir/TU"  title="Link opens new window for Therapeutic Use" target="pubmed">Therapeutic Use</a>                                                    </li>                                					<li>                                                        <a href="/www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=saquinavir/PD" title="Link opens new window for Pharmacology" target="pubmed">Pharmacology</a>                                                    </li>                                					<li>                                                        <a href="/www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=saquinavir[All Fields] AND Clinical Trial[ptyp]" title="Link opens new window for Clinical Trials" target="pubmed">Clinical Trials</a>                                                    </li>                                                </ul>                                            </li>                                            <li>                                                <a href="http://www.drugbank.ca/search?utf8=%E2%9C%93&query=APRD00623&search_type=drugs&button=" target="_blank">Biochemical Data Summary</a>                                            </li>                                                                            </ul>                                </div>                                <div class="mod blue-list">                                    <h2><a href="#">More Info For This Drug</a></h2>                                    <ul>                                    	                                        <li><a href="#modal-label-archives" class="modal-open">View Label Archives</a></li>                                        <li><a href="#modal-rx-norm" class="modal-open">RxNorm</a></li>                                                                                <li><a href="#modal-label-rss" class="modal-open">Get Label RSS Feed</a></li>                                    </ul>                                </div>                                                            </div>                        </article>                    </section>                </div>                               <div class="content-wide">                        <article>                            <ul class="drug-information">                            	                                                                <li>                                <strong><a class="tip" rel="tooltip" title="NDC (National Drug Code) - Each drug product is assigned this unique number which can be found on the drug's outer packaging." href="#">NDC Code(s):</a></strong> <span id="item-code-s">                                                                                                	                                    0004-0244-51,                                                                                                                                        	                                    0004-0245-15                                                                                                                                                                        								</li>                                <li>                                                                                                                                                                <li><strong>Packager: </strong>Genentech, Inc.</li>                                						    	    																																			    																	    	    	                             		       	                                                                                                                                                                   </ul>                                                        <ul class="drug-information">                            	                                <li><strong>Category:</strong>                                 	                                    	<span id="category" class="orangetext">                                                                            	HUMAN PRESCRIPTION DRUG LABEL</span></li>                                                                    <li><strong>DEA Schedule:</strong> <span id="dea-schedule">                                                                        	None                                                                        </span></li>                                                                    <li><strong>Marketing Status:</strong> <span id="marketing-status">New Drug Application</span></li>								                            </ul>							                                                                                            <div id="drug-information" class="toggle">                                                                                    <h2><a id="druglabel"></a>Drug Label Information</h2>                                                 <p class="date">Updated                                                  	                                                    	04/15                                                                                                     </p>                                                                                                                                                     <p class="orangetext">If you are a consumer or patient please visit <a class="audience-context-switch consumer" href="dailymed/drugInfo.cfm?setid=c00d1607-ac36-457b-a34b-75ad74f9cf0a&audience=consumer">this version.</a></p>                                                                                                   <ul class="tools">                                                    <li class="download">Download DRUG LABEL INFO: <a download class="pdf" href="dailymed/getFile.cfm?setid=c00d1607-ac36-457b-a34b-75ad74f9cf0a&amp;type=pdf&amp;name=c00d1607-ac36-457b-a34b-75ad74f9cf0a" target="_blank">PDF</a>                                                    	<a download class="xml" href="dailymed/getFile.cfm?setid=c00d1607-ac36-457b-a34b-75ad74f9cf0a&amp;type=zip&amp;name=INVIRASE" target="_blank">XML</a>                                                    </li>                                                                                                                                                            <li class="medguide">Medication Guide:                                                         <a href="dailymed/medguide.cfm?setid=c00d1607-ac36-457b-a34b-75ad74f9cf0a" target="_blank">HTML</a>                                                                                                            </li>                                                                                                        <li class="print">                                                        <a href="dailymed/fda/fdaDrugXsl.cfm?setid=c00d1607-ac36-457b-a34b-75ad74f9cf0a&amp;type=display" target="_blank">Print Drug Label Info</a>                                                    </li>                                                                                                    </ul>                                                                                                  <div class="drug-label-sections">                                                   <div class="control-nav show-js">                                            <a class="open-all" href="#">View All Sections</a><a class="close-all" href="#">Close All Sections</a>                                        </div>                                                                        <ul>                                                                                        	                                                <li><a href="#">HIGHLIGHTS OF PRESCRIBING INFORMATION</a> <div id="Highlights" class=" Highlights toggle-content closed">    <div class="HighlightsDisclaimer">   These highlights do not include all the information needed to use INVIRASE safely and effectively. See full prescribing information for INVIRASE.    <br />    <br />INVIRASE   <span class="Sup">&reg;</span> (saquinavir mesylate) capsules and tablets, for oral use    <br />Initial U.S. Approval: 1995   </div>   <div class="HighlightSection">    <h1 class="Highlights"> <span>RECENT MAJOR CHANGES</span> </h1>    <div>     <table class="Noautorules" width="100%">      <colgroup>      <col align="left" valign="top" width="80%" />       <col align="right" valign="top" width="20%" />      </colgroup>     <tbody class="Headless">       <tr>        <td align="left">Warnings and Precautions</td>       <td align="right"></td>       </tr>       <tr>        <td align="left">Risk of Serious Adverse Reactions Due to Drug Interactions (<a href="#S5.1">5.1</a>)</td>       <td align="right">03/2015</td>       </tr>      </tbody>     </table>    </div>   </div>   <div></div>   <div></div>   <div class="HighlightSection">    <h1 class="Highlights"> <span>INDICATIONS AND USAGE</span> </h1>    <div>     <p class="Highlighta">INVIRASE is an HIV-1 protease inhibitor indicated for the treatment of HIV-1 infection in combination with ritonavir and other antiretroviral agents in adults (over the age of 16 years). (<a href="#s1">1</a>) </p>    </div>   </div>   <div class="HighlightSection">    <h1 class="Highlights"> <span>DOSAGE AND ADMINISTRATION</span> </h1>    <div>     <ul class="Disc">      <li> <span class="Bold">INVIRASE must be administered in combination with ritonavir.</span> (<a href="#s2">2</a>)</li>      <li> Adults (over the age of 16 years ): INVIRASE 1000 mg twice daily (5 &times; 200 mg capsules or 2 &times; 500 mg tablets) in combination with ritonavir 100 mg twice daily. (<a href="#s2.1">2.1</a>)</li>      <li> INVIRASE and ritonavir should be taken within 2 hours after a meal. (<a href="#s2.1">2.1</a>)</li>     </ul>    </div>    <div></div>    <div></div>   </div>   <div class="HighlightSection">    <h1 class="Highlights"> <span>DOSAGE FORMS AND STRENGTHS</span> </h1>    <div>     <p class="Highlighta">200 mg capsules and 500 mg film-coated tablets (<a href="#s3">3</a>) </p>    </div>   </div>   <div class="HighlightSection">    <h1 class="Highlights"> <span>CONTRAINDICATIONS</span> </h1>    <div>     <ul class="Disc">      <li> Patients with congenital or documented acquired QT prolongation, patients with refractory hypokalemia or hypomagnesemia, or those on concomitant therapy with other drugs that prolong the QT interval. (<a href="#s4">4</a>)</li>      <li> INVIRASE is contraindicated in patients with complete atrioventricular (AV) block without implanted pacemakers, or patients who are at high risk of complete AV block. (<a href="#s4">4</a>)</li>      <li> INVIRASE is contraindicated in patients with clinically significant hypersensitivity (e.g., anaphylactic reaction, Stevens-Johnson syndrome) to saquinavir, saquinavir mesylate, or any of its ingredients. (<a href="#s4">4</a>)</li>      <li> INVIRASE when administered with ritonavir is contraindicated in patients with severe hepatic impairment. (<a href="#s4">4</a>)</li>      <li> Coadministration of INVIRASE/ritonavir with CYP3A substrates for which increased plasma levels may result in serious or life-threatening reactions. (<a href="#s4">4</a>)</li>      <li> Coadministration of INVIRASE/ritonavir with rifampin due to the risk of severe hepatotoxicity. (<a href="#s4">4</a>)</li>     </ul>    </div>   </div>   <div class="HighlightSection">    <h1 class="Highlights"> <span>WARNINGS AND PRECAUTIONS</span> </h1>    <div>     <ul class="Disc">      <li>The concomitant use of INVIRASE/ritonavir and certain other drugs may result in known or potentially significant drug interactions. Consult the full prescribing information prior to and during treatment for potential drug interactions (<a href="#S5.1">5.1</a>, <a href="#S7.3">7.3</a>)</li>      <li> QT and PR interval prolongations have been observed in a healthy volunteer study. Use with caution in patients with preexisting conduction system abnormalities and certain heart diseases. (<a href="#s5.2">5.2</a>, <a href="#s5.3">5.3</a>, <a href="#s12.2">12.2</a>)</li>      <li> Patients on INVIRASE therapy may develop new onset or exacerbations of diabetes mellitus (<a href="#s5.4">5.4</a>), hyperglycemia (<a href="#s5.4">5.4</a>), elevated cholesterol and/or triglyceride concentrations (<a href="#s5.7">5.7</a>), redistribution/accumulation of body fat (<a href="#s5.9">5.9</a>), and immune reconstitution syndrome (<a href="#s5.10">5.10</a>). Monitor cholesterol and triglycerides prior to therapy and periodically thereafter. (<a href="#s5.7">5.7</a>)</li>      <li> In patients with underlying hepatitis B or C, cirrhosis, chronic alcoholism and/or other underlying liver abnormalities there have been reports of worsening liver disease. (<a href="#s5.5">5.5</a>)</li>      <li> Hemophilia: Spontaneous bleeding may occur and additional factor VII may be required. (<a href="#s5.6">5.6</a>)</li>      <li> Various degrees of cross-resistance have been observed. (<a href="#s5.11">5.11</a>)</li>     </ul>    </div>    <div></div>    <div></div>    <div>     <div></div>     <div></div>    </div>    <div></div>    <div></div>    <div></div>    <div></div>    <div></div>    <div></div>    <div></div>    <div></div>   </div>   <div class="HighlightSection">    <h1 class="Highlights"> <span>ADVERSE REACTIONS</span> </h1>    <div>     <p class="Highlighta">The most common adverse reactions are nausea, vomiting, diarrhea, fatigue, pneumonia, lipodystrophy and abdominal pain. (<a href="#s6.1">6.1</a>)<br /> <br /> <span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Genentech at 1-800-835-2555 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</span> </p>    </div>    <div>     <div></div>    </div>    <div></div>    <div></div>   </div>   <div class="HighlightSection">    <h1 class="Highlights"> <span>DRUG INTERACTIONS</span> </h1>    <div>     <ul class="Disc">      <li> INVIRASE/ritonavir is a potent inhibitor of CYP3A, significantly increasing the exposure of drugs primarily metabolized by CYP3A. (<a href="#s7.1">7.1</a>)</li>      <li> Coadministration of INVIRASE/ritonavir with drugs that induce CYP3A may result in decreased plasma concentrations of saquinavir and reduced efficacy. (<a href="#s7.2">7.2</a>)</li>      <li> Certain drugs or drug classes should not be coadministered with INVIRASE/ritonavir based on drug interaction studies or predicted drug interactions. (<a href="#s5.1">5.1</a>, <a href="#s7.2">7.2</a>, <a href="#s7.3">7.3</a>)</li>     </ul>    </div>    <div></div>    <div></div>    <div></div>   </div>   <div class="HighlightSection">    <h1 class="Highlights"> <span>USE IN SPECIFIC POPULATIONS</span> </h1>    <div>     <ul class="Disc">      <li> Pregnancy: Use during pregnancy only if the potential benefit justifies the potential risk to the fetus. (<a href="#s8.1">8.1</a>)</li>      <li> Nursing Mothers: Do not breastfeed if HIV-1-infected mothers are receiving INVIRASE therapy. (<a href="#s8.3">8.3</a>)</li>      <li> Pediatric Use: Pediatric dose recommendations that are both reliably effective and below thresholds of concern with respect to QT and PR prolongation could not be determined (<a href="#s8.4">8.4</a>)</li>      <li> Geriatric Use: Caution should be exercised due to greater frequency of decreased hepatic, renal or cardiac function in elderly population. (<a href="#s8.5">8.5</a>)</li>      <li> Impaired Renal Function: No initial dose adjustment is necessary for patients with renal impairment. (<a href="#s8.6">8.6</a>)</li>      <li> Impaired Hepatic Function: No dose adjustment is necessary for patients with mild or moderate hepatic impairment. (<a href="#s8.7">8.7</a>)</li>     </ul>    </div>    <div>     <div>      <div></div>     </div>    </div>    <div></div>    <div></div>    <div></div>    <div></div>   </div>   <div></div>   <div></div>   <div>    <div></div>    <div></div>    <div>     <div>      <div>       <div></div>       <div></div>       <div></div>       <div>        <div></div>        <div></div>        <div></div>        <div></div>       </div>       <div></div>      </div>     </div>    </div>   </div>   <div>    <div>     <div></div>     <div></div>     <div></div>    </div>   </div>   <div>    <div></div>   </div>   <div>    <div></div>   </div>   <div>    <div></div>    <div></div>    <div></div>    <div></div>    <div></div>   </div>   <div></div>   <div></div>   <div></div>   <p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.</p>   <p class="HighlightsRevision">Revised: 4/2015</p>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">FULL PRESCRIBING INFORMATION: CONTENTS*</a> <div id="Index" class=" Index toggle-content closed">    <h1> <a href="#section-2" class="toc">1 INDICATIONS AND USAGE</a> </h1>   <h1> <a href="#section-3" class="toc">2 DOSAGE AND ADMINISTRATION</a> </h1>   <h2> <a href="#section-3.1" class="toc">2.1 Recommended Dose</a> </h2>   <h2> <a href="#section-3.2" class="toc">2.2 Administration for Patients Unable to Swallow Capsules</a> </h2>   <h1> <a href="#section-4" class="toc">3 DOSAGE FORMS AND STRENGTHS</a> </h1>   <h1> <a href="#section-5" class="toc">4 CONTRAINDICATIONS</a> </h1>   <h1> <a href="#section-6" class="toc">5 WARNINGS AND PRECAUTIONS</a> </h1>   <h2> <a href="#section-6.1" class="toc">5.1 Risk of Serious Adverse Reactions Due to Drug Interactions</a> </h2>   <h2> <a href="#section-6.2" class="toc">5.2 PR Interval Prolongation</a> </h2>   <h2> <a href="#section-6.3" class="toc">5.3 QT Interval Prolongation</a> </h2>   <h2> <a href="#section-6.4" class="toc">5.4 Diabetes Mellitus / Hyperglycemia</a> </h2>   <h2> <a href="#section-6.5" class="toc">5.5 Hepatotoxicity</a> </h2>   <h2> <a href="#section-6.6" class="toc">5.6 Hemophilia</a> </h2>   <h2> <a href="#section-6.7" class="toc">5.7 Hyperlipidemia</a> </h2>   <h2> <a href="#section-6.8" class="toc">5.8 Lactose Intolerance</a> </h2>   <h2> <a href="#section-6.9" class="toc">5.9 Fat Redistribution</a> </h2>   <h2> <a href="#section-6.10" class="toc">5.10 Immune Reconstitution Syndrome</a> </h2>   <h2> <a href="#section-6.11" class="toc">5.11 Resistance/Cross-resistance</a> </h2>   <h1> <a href="#section-7" class="toc">6 ADVERSE REACTIONS</a> </h1>   <h2> <a href="#section-7.1" class="toc">6.1 Clinical Trial Experience in Adult Subjects</a> </h2>   <h2> <a href="#section-7.2" class="toc">6.2 Clinical Trial Experience in Pediatric Subjects</a> </h2>   <h2> <a href="#section-7.3" class="toc">6.3 Postmarketing Experience</a> </h2>   <h1> <a href="#section-8" class="toc">7 DRUG INTERACTIONS</a> </h1>   <h2> <a href="#section-8.1" class="toc">7.1 Potential for INVIRASE to Affect Other Drugs</a> </h2>   <h2> <a href="#section-8.2" class="toc">7.2 Potential for Other Drugs to Affect INVIRASE</a> </h2>   <h2> <a href="#section-8.3" class="toc"> 7.3 Established and Other Potentially Significant Drug Interactions</a> </h2>   <h1> <a href="#section-9" class="toc">8 USE IN SPECIFIC POPULATIONS</a> </h1>   <h2> <a href="#section-9.1" class="toc">8.1 Pregnancy</a> </h2>   <h2> <a href="#section-9.2" class="toc">8.3 Nursing Mothers</a> </h2>   <h2> <a href="#section-9.3" class="toc">8.4 Pediatric Use</a> </h2>   <h2> <a href="#section-9.4" class="toc">8.5 Geriatric Use</a> </h2>   <h2> <a href="#section-9.5" class="toc">8.6 Impaired Renal Function</a> </h2>   <h2> <a href="#section-9.6" class="toc">8.7 Impaired Hepatic Function</a> </h2>   <h1> <a href="#section-10" class="toc">10 OVERDOSAGE</a> </h1>   <h1> <a href="#section-11" class="toc">11 DESCRIPTION</a> </h1>   <h1> <a href="#section-12" class="toc">12 CLINICAL PHARMACOLOGY</a> </h1>   <h2> <a href="#section-12.1" class="toc">12.1 Mechanism of Action</a> </h2>   <h2> <a href="#section-12.2" class="toc">12.2 Pharmacodynamics</a> </h2>   <h2> <a href="#section-12.3" class="toc">12.3 Pharmacokinetics</a> </h2>   <h2> <a href="#section-12.4" class="toc">12.4 Microbiology</a> </h2>   <h1> <a href="#section-13" class="toc">13 NONCLINICAL TOXICOLOGY</a> </h1>   <h2> <a href="#section-13.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a> </h2>   <h1> <a href="#section-14" class="toc">14 CLINICAL STUDIES</a> </h1>   <h2> <a href="#section-14.1" class="toc">14.1 Description of Clinical Studies in Adults</a> </h2>   <h1> <a href="#section-15" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a> </h1>   <h1> <a href="#section-16" class="toc">17 PATIENT COUNSELING INFORMATION</a> </h1>   <dl class="Footnote">    <dt>     <a name="footnote-content" href="#footnote-reference-content">*</a>    </dt>    <dd>    Sections or subsections omitted from the full prescribing information are not listed.   </dd>   </dl>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">SPL UNCLASSIFIED SECTION</a> <div class="Section toggle-content closed" data-sectioncode="42229-5">   <a name="section-1"></a>   <p></p>   <p class="First"> <span class="Bold">Product identification in this document includes: INVIRASE in reference to saquinavir mesylate; saquinavir 200 mg soft gel capsule formulation<a class="Sup" href="#footnote-1" name="footnote-reference-1">1</a> in reference to saquinavir active base.</span> </p>   <hr class="Footnoterule" />   <dl class="Footnote">    <dt>     <a href="#footnote-reference-1" name="footnote-1">1</a>    </dt>    <dd>    The term &quot;saquinavir soft gel capsules&quot; used in this label refers to the drug product formerly marketed as &quot;Fortovase&quot; (saquinavir 200 mg soft gel capsule formulation). This formulation has been withdrawn from the market.   </dd>   </dl>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">1 INDICATIONS AND USAGE</a> <div class="Section toggle-content closed" data-sectioncode="34067-9">   <a name="S1"></a>  <a name="section-2"></a>   <p></p>    <p class="First">INVIRASE in combination with ritonavir and other antiretroviral agents is indicated for the treatment of HIV-1 infection in adults (over the age of 16 years).</p>   <p>The following points should be considered when initiating therapy with INVIRASE:</p>   <dl>    <dt>    –   </dt>    <dd>     The twice daily administration of INVIRASE in combination with ritonavir is supported by safety data from the MaxCmin 1 trial     <span class="Italics">[see <a href="#s6.1">Adverse Reactions (6.1)</a>]</span> and pharmacokinetic data     <span class="Italics">[see <a href="#s12.3">Clinical Pharmacology (12.3)</a>]</span>.   </dd>    <dt>    –   </dt>    <dd>     The efficacy of INVIRASE with ritonavir has not been compared against the efficacy of antiretroviral regimens currently considered standard of care.   </dd>    <dt>    –   </dt>    <dd>     The number of baseline primary protease inhibitor mutations affects the virologic response to INVIRASE/ritonavir.   </dd>   </dl>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">2 DOSAGE AND ADMINISTRATION</a> <div class="Section toggle-content closed" data-sectioncode="34068-7">   <a name="S2"></a>  <a name="section-3"></a>   <p></p>    <p class="First"> <span class="Bold">INVIRASE must be used in combination with ritonavir because ritonavir significantly inhibits saquinavir's metabolism to provide increased plasma saquinavir levels.</span> </p>   <div class="Section" data-sectioncode="42229-5">    <a name="S2.1"></a>   <a name="section-3.1"></a>    <p></p>    <h2>2.1 Recommended Dose</h2>    <ul class="Disc">     <li>INVIRASE 1000-mg twice daily (5 &times; 200-mg capsules or 2 &times; 500-mg tablets) in combination with ritonavir 100-mg twice daily.</li>     <li>Ritonavir should be taken at the same time as INVIRASE.</li>     <li>INVIRASE and ritonavir should be taken within 2 hours after a meal.</li>     <li>No additional ritonavir is recommended when INVIRASE is administered with lopinavir/ritonavir 400/100 mg twice daily.</li>     <li>Pediatric dose recommendations that are both reliably effective and below thresholds of concern for QT and PR interval prolongation could not be determined.</li>    </ul>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="S2.2"></a>   <a name="section-3.2"></a>    <p></p>    <h2>2.2 Administration for Patients Unable to Swallow Capsules</h2>    <p class="First">Open the INVIRASE capsules and place the contents into an empty container. Add 15 mL of either sugar syrup or sorbitol syrup (for patients with Type 1 diabetes or glucose intolerance) <span class="Bold">OR </span>3 teaspoons of jam to the contents of INVIRASE capsules that are in the container. Stir with a spoon for 30 to 60 seconds. Administer the full amount prepared for each dose. Suspensions should be at room temperature before administering.</p>   </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">3 DOSAGE FORMS AND STRENGTHS</a> <div class="Section toggle-content closed" data-sectioncode="43678-2">   <a name="S3"></a>  <a name="section-4"></a>   <p></p>    <p class="First">Capsules: 200 mg<br />Film-coated tablets: 500 mg</p>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">4 CONTRAINDICATIONS</a> <div class="Section toggle-content closed" data-sectioncode="34070-3">   <a name="S4"></a>  <a name="section-5"></a>   <p></p>    <p class="First">QT interval prolongation and torsades de pointes have been reported rarely with INVIRASE/ritonavir use. Do not use in patients with congenital long QT syndrome, those with refractory hypokalemia or hypomagnesemia, and in combination with drugs that both increase saquinavir plasma concentrations and prolong the QT interval <span class="Italics">[see <a href="#s5.3">Warnings and Precautions (5.3)</a> and <a href="#s12.2">Clinical Pharmacology (12.2)</a>]</span>.</p>   <p>INVIRASE is contraindicated in patients with complete atrioventricular (AV) block without implanted pacemakers, or patients who are at high risk of complete AV block <span class="Italics">[see <a href="#s5.2">Warnings and Precautions (5.2)</a>]</span>.</p>   <p>INVIRASE is contraindicated in patients with clinically significant hypersensitivity (e.g., anaphylactic reaction, Stevens-Johnson syndrome) to saquinavir, saquinavir mesylate, or any of its ingredients.</p>   <p>INVIRASE when administered with ritonavir is contraindicated in patients with severe hepatic impairment.</p>   <p>Coadministration of INVIRASE/ritonavir is contraindicated with drugs that are CYP3A substrates for which increased plasma levels may result in serious or life-threatening reactions. These drugs and potentially related adverse events are listed in <span class="Bold"><a href="#table1">Table 1</a></span>.</p>   <a name="table1"></a>   <div class="scrollingtable">   <table width="100%">     <caption>      <span>Table 1 Drugs That Are Contraindicated With INVIRASE/ritonavir</span>     </caption>     <colgroup>     <col align="left" valign="top" width="20%" />      <col align="left" valign="top" width="35%" />      <col align="left" valign="top" width="45%" />     </colgroup>    <thead>      <tr class="First Last">       <th class="Lrule Rrule" align="left">Drug Class</th>      <th class="Rrule" align="left">Drugs Within Class That Are Contraindicated With INVIRASE/ritonavir</th>      <th class="Rrule" align="center">Clinical Comment</th>      </tr>     </thead>     <tbody>      <tr class="Botrule First">       <td class="Lrule Rrule" align="left">Alpha 1-adrenoreceptor antagonist</td>      <td class="Rrule" align="left">Alfuzosin</td>      <td class="Rrule" align="left">Potentially increased alfuzosin concentrations can result in hypotension.</td>      </tr>      <tr class="Botrule">       <td class="Lrule Rrule" align="left">Antiarrhythmics</td>      <td class="Rrule" align="left">Amiodarone, bepridil, dofetilide, flecainide, lidocaine (systemic), propafenone, quinidine</td>      <td class="Rrule" align="left">Potential for serious and/or life-threatening cardiac arrhythmia.</td>      </tr>      <tr class="Botrule">       <td class="Lrule Rrule" align="left">Antidepressant</td>      <td class="Rrule" align="left">Trazodone</td>      <td class="Rrule" align="left">Increased trazodone concentrations can result in potentially life threatening cardiac arrhythmia.</td>      </tr>      <tr class="Botrule">       <td class="Lrule Rrule" align="left">Antimycobacterial Agents</td>      <td class="Rrule" align="left">Rifampin</td>      <td class="Rrule" align="left">Rifampin should not be administered in patients taking ritonavir-boosted INVIRASE part of an ART regimen due to the risk of severe hepatocellular toxicity.</td>      </tr>      <tr class="Botrule">       <td class="Lrule Rrule" align="left">Ergot Derivatives</td>      <td class="Rrule" align="left">Dihydroergotamine, ergonovine, ergotamine, methylergonovine</td>      <td class="Rrule" align="left">Potential for serious and life threatening reactions such as ergot toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues.</td>      </tr>      <tr class="Botrule">       <td class="Lrule Rrule" align="left">GI Motility Agent</td>      <td class="Rrule" align="left">Cisapride</td>      <td class="Rrule" align="left">Potential for serious and/or life threatening reactions such as cardiac arrhythmias.</td>      </tr>      <tr class="Botrule">       <td class="Lrule Rrule" align="left">HMG-CoA Reductase Inhibitors</td>      <td class="Rrule" align="left">Lovastatin, Simvastatin</td>      <td class="Rrule" align="left">Potential for myopathy including rhabdomyolysis.</td>      </tr>      <tr class="Botrule">       <td class="Lrule Rrule" align="left">Neuroleptics</td>      <td class="Rrule" align="left">Pimozide</td>      <td class="Rrule" align="left">Potential for serious and/or life threatening reactions such as cardiac arrhythmias.</td>      </tr>      <tr class="Botrule">       <td class="Lrule Rrule" align="left">PDE5 Inhibitors</td>      <td class="Rrule" align="left">Sildenafil (Revatio<span class="Sup">&reg;</span>)[for treatment of pulmonary arterial hypertension]</td>      <td class="Rrule" align="left">Increased potential for sildenafil-associated adverse events (which include visual disturbances, hypotension, prolonged erection, and syncope). A safe and effective dose has not been established when used with INVIRASE/ritonavir.</td>      </tr>      <tr class="Last">       <td class="Lrule Rrule" align="left">Sedative/Hypnotics</td>      <td class="Rrule" align="left">Triazolam, orally administered midazolam</td>      <td class="Rrule" align="left">Potential for serious and/or life threatening reactions such as prolonged or increased sedation or respiratory depression.<br /> <br />Triazolam and orally administered midazolam are extensively metabolized by CYP3A4. Coadministration of triazolam or orally administered midazolam with INVIRASE/ritonavir may cause large increases in the concentration of these benzodiazepines.</td>      </tr>     </tbody>    </table>  </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">5 WARNINGS AND PRECAUTIONS</a> <div class="Section toggle-content closed" data-sectioncode="43685-7">   <a name="S5"></a>  <a name="section-6"></a>   <p></p>    <p class="First"> <span class="Bold">INVIRASE must be used in combination with ritonavir. </span>Please refer to the ritonavir full prescribing information for additional precautionary measures.</p>   <p>If a serious or severe toxicity occurs during treatment with INVIRASE, INVIRASE should be interrupted until the etiology of the event is identified or the toxicity resolves. At that time, resumption of treatment with full-dose INVIRASE may be considered. For antiretroviral agents used in combination with INVIRASE, physicians should refer to the complete product information for these drugs for dose adjustment recommendations and for information regarding drug-associated adverse reactions.</p>   <div class="Section" data-sectioncode="42229-5">    <a name="S5.1"></a>   <a name="section-6.1"></a>    <p></p>    <h2>5.1 Risk of Serious Adverse Reactions Due to Drug Interactions</h2>    <p class="First" style="border-left:1px solid;"> <span class="XmChange">Initiation of INVIRASE/ritonavir, a CYP3A inhibitor, in patients receiving medications metabolized by CYP3A or initiation of medications metabolized by CYP3A in patients already receiving INVIRASE/ritonavir, may increase plasma concentrations of medications metabolized by CYP3A. Initiation of medications that inhibit or induce CYP3A may increase or decrease concentrations of INVIRASE/ritonavir, respectively. These interactions may lead to:</span> </p>    <ul>     <li style="border-left:1px solid;"> <span class="XmChange">Clinically significant adverse reactions potentially leading to severe, life threatening, or fatal events from greater exposures of concomitant medications.</span> </li>     <li style="border-left:1px solid;"> <span class="XmChange">Clinically significant adverse reactions from greater exposures of INVIRASE/ritonavir.</span> </li>     <li style="border-left:1px solid;"> <span class="XmChange">Loss of therapeutic effect of INVIRASE/ritonavir and possible development of resistance.</span> </li>    </ul>    <p>See <span class="Bold"><a href="#table3">Table 3</a></span> for steps to prevent or manage these possible and known significant drug interactions, including dosing recommendations <span class="Italics">[see <a href="#S7">Drug Interactions (7)</a>]</span>. Consider the potential for drug interactions prior to and during INVIRASE/ritonavir therapy; review concomitant medications during INVIRASE/ritonavir therapy; and monitor for adverse reactions associated with concomitant medications <span class="Italics">[see <a href="#S4">Contraindications (4)</a> and <a href="#S7">Drug Interactions (7)</a>].</span> </p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="S5.2"></a>   <a name="section-6.2"></a>    <p></p>    <h2>5.2 PR Interval Prolongation</h2>    <p class="First">Saquinavir/ritonavir prolongs the PR interval in a dose-dependent fashion. Cases of second or third degree atrioventricular block have been reported rarely. Patients with underlying structural heart disease, pre-existing conduction system abnormalities, cardiomyopathies and ischemic heart disease may be at increased risk for developing cardiac conduction abnormalities. ECG monitoring is recommended in these patients <span class="Italics">[see <a href="#s5.3">Warnings and Precautions (5.3)</a>]</span>.</p>    <p>The impact on the PR interval of co-administration of saquinavir/ritonavir with other drugs that prolong the PR interval (including calcium channel blockers, beta-adrenergic blockers, digoxin and atazanavir) has not been evaluated. As a result, co-administration of saquinavir/ritonavir with these drugs should be undertaken with caution, particularly with those drugs metabolized by CYP3A, and clinical monitoring is recommended <span class="Italics">[see <a href="#s12.2">Clinical Pharmacology (12.2)</a>]</span>.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="S5.3"></a>   <a name="section-6.3"></a>    <p></p>    <h2>5.3 QT Interval Prolongation</h2>    <p class="First">Saquinavir/ritonavir causes dose-dependent QT prolongation. Torsades de pointes has been reported rarely post-marketing. Avoid saquinavir/ritonavir in patients with long QT syndrome. ECG monitoring is recommended if therapy is initiated in patients with congestive heart failure, bradyarrhythmias, hepatic impairment and electrolyte abnormalities. Correct hypokalemia or hypomagnesemia prior to initiating saquinavir/ritonavir and monitor these electrolytes periodically during therapy. Do not use in combination with drugs that both increase saquinavir plasma concentrations and prolong the QT interval (see <span class="Bold"><a href="#table1">Tables 1</a></span> and <span class="Bold"><a href="#table3">3</a></span>) <span class="Italics">[see <a href="#s12.2">Clinical Pharmacology (12.2)</a>]</span>.</p>    <div class="Section" data-sectioncode="42229-5">     <a name="section-6.3.1"></a>     <p></p>     <p class="First"> <span class="Italics">Patients initiating therapy with ritonavir-boosted INVIRASE:</span> </p>     <p>An ECG should be performed prior to initiation of treatment. Patients with a QT interval &gt; 450 msec should not receive ritonavir-boosted INVIRASE. For patients with a QT interval &lt; 450 msec, an on-treatment ECG is suggested after approximately 3 to 4 days of therapy; patients with a QT interval &gt; 480 msec or prolongation over pre-treatment by &gt; 20 msec should discontinue ritonavir-boosted INVIRASE.</p>    </div>    <div class="Section" data-sectioncode="42229-5">     <a name="section-6.3.2"></a>     <p></p>     <p class="First"> <span class="Italics">Patients requiring treatment with medications with the potential to increase the QT interval and concomitant ritonavir-boosted INVIRASE:</span> </p>     <p>Such combinations should only be used where no alternative therapy is available and the potential benefits outweigh the potential risks. An ECG should be performed prior to initiation of the concomitant therapy, and patients with a QT interval &gt; 450 msec should not initiate the concomitant therapy. If baseline QT interval &lt; 450 msec, an on-treatment ECG should be performed after 3-4 days of therapy. For patients demonstrating a subsequent increase in QT interval to &gt; 480 msec or increase by &gt; 20 msec after commencing concomitant therapy, the physician should use best clinical judgment to discontinue either ritonavir-boosted INVIRASE or the concomitant therapy or both.</p>     <p>A cardiology consult is recommended if drug discontinuation or interruption is being considered on the basis of ECG assessment.</p>    </div>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="S5.4"></a>   <a name="section-6.4"></a>    <p></p>    <h2>5.4 Diabetes Mellitus / Hyperglycemia</h2>    <p class="First">New onset diabetes mellitus, exacerbation of preexisting diabetes mellitus and hyperglycemia have been reported during postmarketing surveillance in HIV-1-infected patients receiving protease-inhibitor therapy. Some patients required either initiation or dose adjustments of insulin or oral hypoglycemic agents for the treatment of these events. In some cases diabetic ketoacidosis has occurred. In those patients who discontinued protease-inhibitor therapy, hyperglycemia persisted in some cases. Because these events have been reported voluntarily during clinical practice, estimates of frequency cannot be made and a causal relationship between protease-inhibitor therapy and these events has not been established.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="S5.5"></a>   <a name="section-6.5"></a>    <p></p>    <h2>5.5 Hepatotoxicity</h2>    <p class="First">In patients with underlying hepatitis B or C, cirrhosis, chronic alcoholism and/or other underlying liver abnormalities, there have been reports of worsening liver disease.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="S5.6"></a>   <a name="section-6.6"></a>    <p></p>    <h2>5.6 Hemophilia</h2>    <p class="First">There have been reports of spontaneous bleeding in patients with hemophilia A and B treated with protease inhibitors. In some patients additional factor VIII was required. In the majority of reported cases treatment with protease inhibitors was continued or restarted. A causal relationship between protease inhibitor therapy and these episodes has not been established.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="S5.7"></a>   <a name="section-6.7"></a>    <p></p>    <h2>5.7 Hyperlipidemia</h2>    <p class="First">Elevated cholesterol and/or triglyceride levels have been observed in some patients taking saquinavir in combination with ritonavir. Marked elevation in triglyceride levels is a risk factor for development of pancreatitis. Cholesterol and triglyceride levels should be monitored prior to initiating combination dosing regimen of INVIRASE with ritonavir, and at periodic intervals while on such therapy. In these patients, lipid disorders should be managed as clinically appropriate.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="S5.8"></a>   <a name="section-6.8"></a>    <p></p>    <h2>5.8 Lactose Intolerance</h2>    <p class="First">Each capsule contains lactose (anhydrous) 63.3 mg. This quantity should not induce specific symptoms of intolerance.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="S5.9"></a>   <a name="section-6.9"></a>    <p></p>    <h2>5.9 Fat Redistribution</h2>    <p class="First">Redistribution/accumulation of body fat including central obesity, dorsocervical fat enlargement (buffalo hump), facial wasting, peripheral wasting, breast enlargement, and &quot;cushingoid appearance&quot; have been observed in patients receiving antiretroviral therapy. The mechanism and long-term consequences of these events are currently unknown. A causal relationship has not been established.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="S5.10"></a>   <a name="section-6.10"></a>    <p></p>    <h2>5.10 Immune Reconstitution Syndrome</h2>    <p class="First">Immune reconstitution syndrome has been reported in patients treated with combination antiretroviral therapy, including INVIRASE. During the initial phase of combination antiretroviral treatment, patients whose immune system responds may develop an inflammatory response to indolent or residual opportunistic infections (such as <span class="Italics">Mycobacterium avium</span> infection, cytomegalovirus, <span class="Italics">Pneumocystis jiroveci</span> pneumonia [PCP], or tuberculosis), which may necessitate further evaluation and treatment.</p>    <p>Autoimmune disorders (such as Graves' disease, polymyositis, and Guillain-Barr&eacute; syndrome) have also been reported to occur in the setting of immune reconstitution; however, the time to onset is more variable, and can occur many months after initiation of treatment.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="S5.11"></a>   <a name="section-6.11"></a>    <p></p>    <h2>5.11 Resistance/Cross-resistance</h2>    <p class="First">Varying degrees of cross-resistance among HIV-1 protease inhibitors have been observed. Continued administration of INVIRASE therapy following loss of viral suppression may increase the likelihood of cross resistance to other protease inhibitors <span class="Italics">[see <a href="#s12.4">Microbiology (12.4)</a>]</span>.</p>   </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">6 ADVERSE REACTIONS</a> <div class="Section toggle-content closed" data-sectioncode="34084-4">   <a name="S6"></a>  <a name="section-7"></a>   <p></p>    <p class="First">The following adverse reactions are discussed in greater detail in other sections of the labeling:</p>   <ul class="Disc">    <li>PR Interval Prolongation <span class="Italics">[see <a href="#s5.2">Warnings and Precautions (5.2)</a>]</span> </li>    <li>QT Interval Prolongation <span class="Italics">[see <a href="#s5.3">Warnings and Precautions (5.3)</a>]</span> </li>   </ul>   <div class="Section" data-sectioncode="42229-5">    <a name="S6.1"></a>   <a name="section-7.1"></a>    <p></p>    <h2>6.1 Clinical Trial Experience in Adult Subjects</h2>    <p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.</p>    <p>The original INVIRASE safety database consisted of a total of 574 adult subjects who received saquinavir 600 mg alone or in combination with ZDV or ddC. Combination dosing with ritonavir is based on 352 HIV-1 infected subjects and 166 healthy subjects who received various combinations of either saquinavir (hard gel or soft-gel capsules) with ritonavir.</p>    <p>The recommended dose of INVIRASE is 1000 mg twice daily co-administered with ritonavir 100 mg twice daily, in combination with other antiretroviral agents. <span class="Bold"><a href="#table2">Table 2</a></span> lists grade 2, 3 and 4 adverse events that occurred in ≥2% of subjects receiving saquinavir soft gel capsules with ritonavir (1000/100 mg bid).</p>    <a name="table2"></a>    <div class="scrollingtable">    <table width="100%">      <caption>       <span>Table 2 Grade 2, 3 and 4 Adverse Events (All Causality<a class="Sup" href="#footnote-2" name="footnote-reference-2">*</a>) Reported in ≥2% of Adult Subjects in the MaxCmin 1 Study of Saquinavir Soft Gel Capsules in Combination with Ritonavir 1000/100 mg twice a day</span>      </caption>      <colgroup>      <col align="left" valign="top" width="50%" />       <col align="center" valign="top" width="50%" />      </colgroup>     <thead>       <tr class="First Last">        <th class="Lrule Rrule" align="left">Adverse Events</th>       <th class="Rrule" align="center">Saquinavir soft gel capsules 1000 mg plus Ritonavir 100 mg bid (48 weeks)<br />N=148<br />n (%=n/N)</th>       </tr>      </thead>      <tfoot>       <tr>        <td align="left" colspan="2">         <dl class="Footnote">          <dt>           <a href="#footnote-reference-2" name="footnote-2">*</a>          </dt>          <dd>          Includes events with unknown relationship to study drug         </dd>         </dl> </td>       </tr>      </tfoot>      <tbody>       <tr class="Botrule First">        <td class="Lrule Rrule" align="left"><span class="Bold">Endocrine Disorders</span></td>       <td class="Rrule" align="center"></td>       </tr>       <tr class="Botrule">        <td class="Lrule Rrule" align="left">&nbsp;&nbsp;Diabetes mellitus/hyperglycemia</td>       <td class="Rrule" align="center">4 (3)</td>       </tr>       <tr class="Botrule">        <td class="Lrule Rrule" align="left">&nbsp;&nbsp;Lipodystrophy</td>       <td class="Rrule" align="center">8 (5)</td>       </tr>       <tr class="Botrule">        <td class="Lrule Rrule" align="left"><span class="Bold">Gastrointestinal Disorders</span></td>       <td class="Rrule" align="center"></td>       </tr>       <tr class="Botrule">        <td class="Lrule Rrule" align="left">&nbsp;&nbsp;Nausea</td>       <td class="Rrule" align="center">16 (11)</td>       </tr>       <tr class="Botrule">        <td class="Lrule Rrule" align="left">&nbsp;&nbsp;Vomiting</td>       <td class="Rrule" align="center">11 (7)</td>       </tr>       <tr class="Botrule">        <td class="Lrule Rrule" align="left">&nbsp;&nbsp;Diarrhea</td>       <td class="Rrule" align="center">12 (8)</td>       </tr>       <tr class="Botrule">        <td class="Lrule Rrule" align="left">&nbsp;&nbsp;Abdominal Pain</td>       <td class="Rrule" align="center">9 (6)</td>       </tr>       <tr class="Botrule">        <td class="Lrule Rrule" align="left">&nbsp;&nbsp;Constipation</td>       <td class="Rrule" align="center">3 (2)</td>       </tr>       <tr class="Botrule">        <td class="Lrule Rrule" align="left"><span class="Bold">General Disorders and Administration Site Conditions</span></td>       <td class="Rrule" align="center"></td>       </tr>       <tr class="Botrule">        <td class="Lrule Rrule" align="left">&nbsp;&nbsp;Fatigue</td>       <td class="Rrule" align="center">9 (6)</td>       </tr>       <tr class="Botrule">        <td class="Lrule Rrule" align="left">&nbsp;&nbsp;Fever</td>       <td class="Rrule" align="center">5 (3)</td>       </tr>       <tr class="Botrule">        <td class="Lrule Rrule" align="left"><span class="Bold">Musculoskeletal Disorders</span></td>       <td class="Rrule" align="center"></td>       </tr>       <tr class="Botrule">        <td class="Lrule Rrule" align="left">&nbsp;&nbsp;Back Pain</td>       <td class="Rrule" align="center">3 (2)</td>       </tr>       <tr class="Botrule">        <td class="Lrule Rrule" align="left"><span class="Bold">Respiratory Disorders</span></td>       <td class="Rrule" align="center"></td>       </tr>       <tr class="Botrule">        <td class="Lrule Rrule" align="left">&nbsp;&nbsp;Pneumonia</td>       <td class="Rrule" align="center">8 (5)</td>       </tr>       <tr class="Botrule">        <td class="Lrule Rrule" align="left">&nbsp;&nbsp;Bronchitis</td>       <td class="Rrule" align="center">4 (3)</td>       </tr>       <tr class="Botrule">        <td class="Lrule Rrule" align="left">&nbsp;&nbsp;Influenza</td>       <td class="Rrule" align="center">4 (3)</td>       </tr>       <tr class="Botrule">        <td class="Lrule Rrule" align="left">&nbsp;&nbsp;Sinusitis</td>       <td class="Rrule" align="center">4 (3)</td>       </tr>       <tr class="Botrule">        <td class="Lrule Rrule" align="left"><span class="Bold">Dermatological Disorders</span></td>       <td class="Rrule" align="center"></td>       </tr>       <tr class="Botrule">        <td class="Lrule Rrule" align="left">&nbsp;&nbsp;Rash</td>       <td class="Rrule" align="center">5 (3)</td>       </tr>       <tr class="Botrule">        <td class="Lrule Rrule" align="left">&nbsp;&nbsp;Pruritus</td>       <td class="Rrule" align="center">5 (3)</td>       </tr>       <tr class="Botrule">        <td class="Lrule Rrule" align="left">&nbsp;&nbsp;Dry lips/skin</td>       <td class="Rrule" align="center">3 (2)</td>       </tr>       <tr class="Last">        <td class="Lrule Rrule" align="left">&nbsp;&nbsp;Eczema</td>       <td class="Rrule" align="center">3 (2)</td>       </tr>      </tbody>     </table>   </div>    <p>Limited experience is available from three trials investigating the pharmacokinetics of the INVIRASE 500 mg film-coated tablet compared to the INVIRASE 200 mg capsule in healthy volunteers (n=140). In two of these trials saquinavir was boosted with ritonavir; in the other trial, saquinavir was administered as single drug. The INVIRASE tablet and the capsule formulations were similarly tolerated. The most common adverse events were gastrointestinal disorders (such as nausea, vomiting, and diarrhea). Similar bioavailability was demonstrated and no clinically significant differences in saquinavir exposures were seen. Thus, similar safety profiles are expected between the two INVIRASE formulations.</p>    <p>A study investigating the drug-drug interaction of rifampin 600 mg/day daily and INVIRASE 1000 mg/ritonavir 100 mg twice daily enrolled 28 healthy volunteers. Eleven of 17 healthy volunteers (65%) exposed concomitantly to rifampin and ritonavir-boosted INVIRASE developed severe hepatocellular toxicity which presented as increased hepatic transaminases. In some subjects, transaminases increased up to &gt;20-fold the upper limit of normal and were associated with gastrointestinal symptoms, including abdominal pain, gastritis, nausea, and vomiting. Following discontinuation of all three drugs, clinical symptoms abated and the increased hepatic transaminases normalized <span class="Italics">[see <a href="#s4">Contraindications (4)</a>]</span>.</p>    <div class="Section" data-sectioncode="42229-5">     <a name="section-7.1.1"></a>     <p></p>     <p class="First"> <span class="Underline">Additional Adverse Reactions Reported During Clinical Trials with Saquinavir</span> </p>     <p> <span class="Bold">Blood and lymphatic system disorders: </span>anemia, hemolytic anemia, leukopenia, lymphadenopathy, neutropenia, pancytopenia, thrombocytopenia</p>     <p> <span class="Bold">Cardiac disorders: </span>heart murmur, syncope</p>     <p> <span class="Bold">Ear and labyrinth disorders:</span> tinnitus</p>     <p> <span class="Bold">Eye disorders:</span> visual impairment</p>     <p> <span class="Bold">Gastrointestinal disorders: </span>abdominal discomfort, ascites, dyspepsia, dysphagia, eructation, flatulence, gastritis, gastrointestinal hemorrhage, intestinal obstruction, mouth dry, mucosal ulceration, pancreatitis</p>     <p> <span class="Bold">General disorders and administration site conditions: </span>anorexia, asthenia, chest pain, edema, lethargy, wasting syndrome, weight increased</p>     <p> <span class="Bold">Hepatobiliary disorders: </span>chronic active hepatitis, hepatitis, hepatomegaly, hyperbilirubinemia, jaundice, portal hypertension</p>     <p> <span class="Bold">Immune system disorders:</span> allergic reaction</p>     <p> <span class="Bold">Investigations: </span>ALT increase, AST increase, blood creatine phosphokinase increased, increased alkaline phosphatase, GGT increase, raised amylase, raised LDH</p>     <p> <span class="Bold">Metabolism and nutrition disorders: </span>increased or decreased appetite, dehydration, hypertriglyceridemia</p>     <p> <span class="Bold">Musculoskeletal and connective tissue disorders: </span>arthralgia, muscle spasms, myalgia, polyarthritis</p>     <p> <span class="Bold">Neoplasms benign, malignant and unspecified (incl cysts and polyps): </span>acute myeloid leukemia, papillomatosis</p>     <p> <span class="Bold">Nervous system disorders: </span>confusion, convulsions, coordination abnormal, dizziness, dysgeusia, headache, hypoaesthesia, intracranial hemorrhage leading to death, loss of consciousness, paresthesia, peripheral neuropathy, somnolence, tremor</p>     <p> <span class="Bold">Psychiatric disorders: </span>anxiety, depression, insomnia, libido disorder, psychotic disorder, sleep disorder, suicide attempt</p>     <p> <span class="Bold">Renal and urinary disorders:</span> nephrolithiasis</p>     <p> <span class="Bold">Respiratory, thoracic and mediastinal disorders: </span>cough, dyspnea</p>     <p> <span class="Bold">Skin and subcutaneous tissue disorders:</span> acne, alopecia, dermatitis bullous, drug eruption, erythema, severe cutaneous reaction associated with increased liver function tests, Stevens-Johnson syndrome, sweating increased, urticaria</p>     <p> <span class="Bold">Vascular disorders: </span>hypertension, hypotension, thrombophlebitis, peripheral vasoconstriction</p>    </div>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="S6.2"></a>   <a name="section-7.2"></a>    <p></p>    <h2>6.2 Clinical Trial Experience in Pediatric Subjects</h2>    <p class="First">Limited safety data are available from two pediatric clinical trials of saquinavir hard gel capsules (approximately 50 mg per kg twice daily) used in combination with either low dose ritonavir or lopinavir/ritonavir. These trials enrolled pediatric subjects aged 4 months to 16 years old. In the HIVNAT 017 study (INVIRASE + lopinavir/ritonavir), adverse events were reported in 90% of the 50 subjects enrolled. The most commonly reported adverse events considered related to study treatment were diarrhea (18%) and vomiting (10%). In the NV20911 study (INVIRASE + ritonavir), 4 subjects (22% of 18 enrolled) experienced adverse events that were considered related to INVIRASE + ritonavir. These events (n) were vomiting (3), abdominal pain (1) and diarrhea (1). All reported adverse events were mild or moderate in intensity. The adverse reaction profile of INVIRASE in the pediatric trials is similar to that observed in adult trials.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="s6.3"></a>   <a name="section-7.3"></a>    <p></p>    <h2>6.3 Postmarketing Experience</h2>    <p class="First">Additional adverse events identified during postmarketing use are similar to those observed in clinical trials with INVIRASE and saquinavir soft gel capsules alone or in combination with ritonavir. Because these events are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to INVIRASE exposure. In addition, torsades de pointes has been reported rarely [<span class="Italics">see <a href="#s5.3">Warnings and Precautions (5.3)</a></span>].</p>   </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">7 DRUG INTERACTIONS</a> <div class="Section toggle-content closed" data-sectioncode="34073-7">   <a name="S7"></a>  <a name="section-8"></a>   <p></p>    <p class="First"> <span class="Bold">Drug interaction studies have been completed with both INVIRASE and saquinavir soft gel capsules. Observations from drug interaction studies with saquinavir soft gel capsules may not be predictive for INVIRASE/ritonavir.</span> Because ritonavir is coadministered with INVIRASE, prescribers should also refer to the prescribing information for ritonavir regarding drug interactions associated with this agent.</p>   <div class="Section" data-sectioncode="42229-5">    <a name="S7.1"></a>   <a name="section-8.1"></a>    <p></p>    <h2>7.1 Potential for INVIRASE to Affect Other Drugs</h2>    <p class="First">The combination INVIRASE/ritonavir is a potent inhibitor of CYP3A and may significantly increase the exposure of drugs primarily metabolized by CYP3A. Drugs that are contraindicated specifically due to the observed or expected magnitude of interaction and potential for serious or life-threatening adverse events are listed in <span class="Bold"><a href="#table1">Table 1</a></span><span class="Italics"> [see <a href="#s4">Contraindications (4)</a>]</span>. Coadministration with other CYP3A substrates may require a dose adjustment or additional monitoring (see <span class="Bold"><a href="#table3">Table 3</a></span>).</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="S7.2"></a>   <a name="section-8.2"></a>    <p></p>    <h2>7.2 Potential for Other Drugs to Affect INVIRASE</h2>    <p class="First">The metabolism of saquinavir is mediated primarily by CYP3A. Additionally, saquinavir is a substrate for P-glycoprotein (P-gp). Therefore, drugs that affect CYP3A and/or P-gp may modify the pharmacokinetics of saquinavir. Coadministration with drugs that are potent inducers of CYP3A (e.g., phenobarbital, phenytoin, carbamazepine) may result in decreased plasma concentrations of saquinavir and reduced therapeutic effect.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="S7.3"></a>   <a name="section-8.3"></a>    <p></p>    <h2> 7.3 Established and Other Potentially Significant Drug Interactions</h2>    <p class="First">Based on the finding of dose-dependent prolongations of QT and PR intervals in healthy volunteers receiving INVIRASE/ritonavir, additive effects on QT and/or PR interval prolongation may occur with certain members of the following drug classes: antiarrhythmics class IA or class III, neuroleptics, antidepressive agents, PDE5 inhibitors (when used for pulmonary arterial hypertension), antimicrobials, antihistaminics and others. This effect might lead to an increased risk of ventricular arrhythmias, notably torsades de pointes. Therefore, concurrent administration of these agents with INVIRASE/ritonavir is contraindicated <span class="Italics">[see <a href="#s4">Contraindications (4)</a>]</span>.</p>    <p> <span class="Bold"><a href="#table3">Table 3</a></span> provides a listing of established or potentially clinically significant drug interactions. Alteration in dose or avoidance of the combination may be recommended depending on the interaction.</p>    <a name="table3"></a>    <div class="scrollingtable">    <table width="100%">      <caption>       <span>Table 3 Established and Other Potentially Significant Drug Interactions: Alteration in Dose or Regimen May Be Recommended Based on Drug Interaction Studies or on Predicted Interaction with INVIRASE/ritonavir</span>      </caption>      <colgroup>      <col align="left" valign="top" width="25%" />       <col align="left" valign="top" width="25%" />       <col align="left" valign="top" width="50%" />      </colgroup>     <thead>       <tr class="First Last">        <th class="Lrule Rrule" align="center">Concomitant Drug Class:<br /> Drug Name </th>       <th class="Rrule" align="center">Effect on Concentration of Saquinavir or Concomitant Drug</th>       <th class="Rrule" align="center">Clinical Comment</th>       </tr>      </thead>      <tfoot>       <tr>        <td align="left" colspan="3">         <dl class="Footnote">          <dt>           <a href="#footnote-reference-3" name="footnote-3">*</a>          </dt>          <dd>          INVIRASE/ritonavir interaction has not been evaluated.         </dd>          <dt>           <a href="#footnote-reference-4" name="footnote-4">†</a>          </dt>          <dd>          See           <span class="Bold"><a href="#S7">Drug Interactions (7)</a></span>,           <span class="Bold"><a href="#table5">Table 5</a></span> and           <span class="Bold"><a href="#table6">Table 6</a></span> for magnitude of interactions.         </dd>         </dl> </td>       </tr>      </tfoot>      <tbody>       <tr class="Botrule First">        <td class="Lrule Rrule" align="center" colspan="3"><span class="Bold">HIV-1 Antiviral Agents</span></td>       </tr>       <tr class="Botrule">        <td class="Lrule Rrule" align="left"><span class="Bold">Non-nucleoside reverse transcriptase inhibitor:</span> <br />Delavirdine<a class="Sup" href="#footnote-3" name="footnote-reference-3">*</a> <br /> </td>       <td class="Rrule" align="left">↑ Saquinavir<br /> <br />Effect on delavirdine is not well established</td>       <td class="Rrule" align="left">Appropriate doses of the combination with respect to safety and efficacy have not been established.</td>       </tr>       <tr class="Botrule">        <td class="Lrule Rrule" align="left"><span class="Bold">Non-nucleoside reverse transcriptase inhibitor:</span> <br />Efavirenz<a class="Sup" href="#footnote-4" name="footnote-reference-4">†</a>,<br />nevirapine<a class="Sup" href="#footnote-3">*</a></td>       <td class="Rrule" align="left">↓ Saquinavir<br />↔ Efavirenz<br /> <br /> <br /> </td>       <td class="Rrule" align="left">Appropriate doses of the combination of efavirenz or nevirapine and INVIRASE/ritonavir with respect to safety and efficacy have not been established.</td>       </tr>       <tr class="Botrule">        <td class="Lrule Rrule" align="left"><span class="Bold">HIV-1 protease inhibitor:</span> <br />Atazanavir<a class="Sup" href="#footnote-4">†</a></td>       <td class="Rrule" align="left"><span class="Bold">INVIRASE/ritonavir</span> <br />↑ Saquinavir<br />↑ Ritonavir<br />↔ Atazanavir</td>       <td class="Rrule" align="left">Atazanavir in combination with INVIRASE/ritonavir should be used with caution. Additive effects on PR interval prolongation may occur with INVIRASE/ritonavir <span class="Italics">[see <a href="#S5.2">Warnings and Precautions (5.2)</a>]</span>.<br /> </td>       </tr>       <tr class="Botrule">        <td class="Lrule Rrule" align="left"><span class="Bold">HIV-1 protease inhibitor:</span> <br />Indinavir<a class="Sup" href="#footnote-3">*</a></td>       <td class="Rrule" align="left">↑ Saquinavir<br /> <br />Effect on indinavir is not well established<br /> </td>       <td class="Rrule" align="left">Appropriate doses of the combination of indinavir and INVIRASE/ritonavir with respect to safety and efficacy have not been established.</td>       </tr>       <tr class="Botrule">        <td class="Lrule Rrule" align="left"><span class="Bold">HIV-1 protease inhibitor:</span> <br />Lopinavir/ritonavir<a class="Sup" href="#footnote-4">†</a> (coformulated tablet)</td>       <td class="Rrule" align="left">↔ Saquinavir<br />↔ Lopinavir<br />↓ Ritonavir<br /> </td>       <td class="Rrule" align="left">Evidence from several clinical trials indicates that saquinavir concentrations achieved with the saquinavir and lopinavir/ritonavir combination are similar to those achieved following saquinavir/ritonavir 1000/100 mg. The recommended dose for this combination is saquinavir 1000 mg plus lopinavir/ritonavir 400/100 mg bid.<br /> <br />Lopinavir/ritonavir in combination with INVIRASE should be used with caution. Additive effects on QT and/or PR interval prolongation may occur with INVIRASE <span class="Italics">[see <a href="#S5.2">Warnings and Precautions (5.2,</a><a href="#S5.3"> 5.3)</a>]. </span> <br /> </td>       </tr>       <tr class="Botrule">        <td class="Lrule Rrule" align="left"><span class="Bold">HIV-1 protease inhibitor:</span> <br />Tipranavir/ritonavir<a class="Sup" href="#footnote-4">†</a></td>       <td class="Rrule" align="left">↓ Saquinavir<br /> </td>       <td class="Rrule" align="left">Combining saquinavir with tipranavir/ritonavir is not recommended.<br /> <br /> </td>       </tr>       <tr class="Botrule">        <td class="Lrule Rrule" align="left"><span class="Bold">HIV-1 fusion inhibitor:</span> <br />Enfuvirtide<a class="Sup" href="#footnote-4">†</a></td>       <td class="Rrule" align="left">Saquinavir soft gel capsules/ritonavir<br />↔ enfuvirtide<br /> </td>       <td class="Rrule" align="left">No clinically significant interaction was noted from a study in 12 HIV-1 subjects who received enfuvirtide concomitantly with saquinavir soft gel capsules/ritonavir 1000/100 mg bid. No dose adjustments are required.<br /> </td>       </tr>       <tr class="Botrule">        <td class="Lrule Rrule" align="left"><span class="Bold">HIV-1 CCR5 antagonist:</span> <br />Maraviroc</td>       <td class="Rrule" align="left">↑ Maraviroc</td>       <td class="Rrule" align="left">Maraviroc dose should be 150 mg twice daily when coadministered with INVIRASE/ritonavir. For further details see complete prescribing information for Selzentry<span class="Sup">&reg;</span> (maraviroc).<br /> </td>       </tr>       <tr class="Botrule">        <td class="Lrule Rrule" align="center" colspan="3"><span class="Bold">Other Agents</span></td>       </tr>       <tr class="Botrule">        <td class="Lrule Rrule" align="left">Ibutilide<br />Sotalol</td>       <td class="Rrule" align="left"></td>       <td class="Rrule" align="left">Use with caution. Additive effects on QT and/or PR interval prolongation may occur with INVIRASE/ritonavir <span class="Italics">[see <a href="#S4">Contraindications (4)</a> and <a href="#S5.2">Warnings and Precautions (5.2,</a><a href="#S5.3"> 5.3)</a>]</span>.<br /> </td>       </tr>       <tr class="Botrule">        <td class="Lrule Rrule" align="left"><span class="Bold">Anticoagulant:</span> <br />Warfarin<a class="Sup" href="#footnote-3">*</a></td>       <td class="Rrule" align="left">↑ Warfarin</td>       <td class="Rrule" align="left">Concentrations of warfarin may be affected. It is recommended that INR (international normalized ratio) be monitored.<br /> </td>       </tr>       <tr class="Botrule">        <td class="Lrule Rrule" align="left"><span class="Bold">Anticonvulsants:</span> <br />Carbamazepine<a class="Sup" href="#footnote-3">*</a>, phenobarbital<a class="Sup" href="#footnote-3">*</a>, phenytoin<a class="Sup" href="#footnote-3">*</a></td>       <td class="Rrule" align="left">↓ Saquinavir<br /> <br />Effect on carbamazepine, phenobarbital, and phenytoin is not well established<br /> </td>       <td class="Rrule" align="left">Use with caution. Saquinavir may be less effective due to decreased saquinavir plasma concentrations in patients taking these agents concomitantly.</td>       </tr>       <tr class="Botrule">        <td class="Lrule Rrule" align="left"><span class="Bold">Anti-gout:</span> <br />Colchicine</td>       <td class="Rrule" align="left">↑ Colchicine</td>       <td class="Rrule" align="left"><span class="Underline">Treatment of gout flares-coadministration of colchicine in patients on INVIRASE/ritonavir:</span> <br /> <br />0.6 mg (1 tablet) &times; 1 dose, followed by 0.3 mg (half tablet) 1 hour later. Dose to be repeated no earlier than 3 days.<br /> <br /> <span class="Underline">Treatment of familial Mediterranean fever (FMF) coadministration of colchicine in patients on INVIRASE/ritonavir:</span> <br /> <br />Maximum daily dose of 0.6 mg (may be given as 0.3 mg twice a day).<br /> <br /> <span class="Underline">Prophylaxis of gout-flares-co-administration of colchicine in patients on INVIRASE/ritonavir:</span> <br /> <br />If the original colchicine regimen was 0.6 mg twice a day, the regimen should be adjusted to 0.3 mg once a day.<br /> <br />If the original colchicine regimen was 0.6 mg once a day, the regimen should be adjusted to 0.3 mg once every other day.<br /> <br />Patients with renal or hepatic impairment should not be given colchicine with INVIRASE/ritonavir.<br /> </td>       </tr>       <tr class="Botrule">        <td class="Lrule Rrule" align="left"><span class="Bold">Anti-infective:</span> <br />Clarithromycin<a class="Sup" href="#footnote-4">†</a></td>       <td class="Rrule" align="left">↑ Saquinavir<br />↑ Clarithromycin<br /> </td>       <td class="Rrule" align="left">Due to the known effect of ritonavir on clarithromycin concentrations, the following dose adjustments are recommended for patients with renal impairment:         <ul>          <li>For patients with CL<span class="Sub">CR</span> 30 to 60 mL/min the dose of clarithromycin should be reduced by 50%.</li>          <li>For patients with CL<span class="Sub">CR</span> &lt;30 mL/min the dose of clarithromycin should be decreased by 75%.</li>         </ul>No dose adjustment for patients with normal renal function is necessary.</td>       </tr>       <tr class="Botrule">        <td class="Lrule Rrule" align="left">Erythromycin<br />Halofantrine<br />Pentamidine</td>       <td class="Rrule" align="left"></td>       <td class="Rrule" align="left">Use with caution. Additive effects on QT and/or PR interval prolongation may occur with INVIRASE/ritonavir <span class="Italics">[see <a href="#S4">Contraindications (4)</a> and <a href="#S5.2">Warnings and Precautions (5.2,</a><a href="#S5.3"> 5.3</a>)]</span>.<br /> </td>       </tr>       <tr class="Botrule">        <td class="Lrule Rrule" align="left">Fusidic acid</td>       <td class="Rrule" align="left">↑ Saquinavir <br />↑ Fusidic Acid <br />↑ Ritonavir</td>       <td class="Rrule" align="left">Concomitant use of fusidic acid and saquinavir/ritonavir is not recommended due to potential for increased mutual toxicities. <br /> &nbsp; <br />The interaction between INVIRASE/ritonavir and fusidic acid has not been formally evaluated. Co-administration of fusidic acid and INVIRASE/ritonavir can cause increased plasma concentrations of fusidic acid, saquinavir and ritonavir.</td>       </tr>       <tr class="Botrule">        <td class="Lrule Rrule" align="left"><span class="Bold">Antifungal:</span> <br />Ketoconazole<a class="Sup" href="#footnote-4">†</a>, <br />itraconazole<a class="Sup" href="#footnote-3">*</a></td>       <td class="Rrule" align="left">↔ Saquinavir<br />↔ Ritonavir<br />↑ Ketoconazole</td>       <td class="Rrule" align="left">When INVIRASE/ritonavir and ketoconazole are coadministered, plasma concentrations of ketoconazole are increased (see <span class="Bold"><a href="#table3">Table 3</a></span>). Hence, doses of ketoconazole or itraconazole &gt;200 mg/day are not recommended.<br /> </td>       </tr>       <tr class="Botrule">        <td class="Lrule Rrule" align="left"><span class="Bold">Antimycobacterial:</span> <br />Rifabutin<a class="Sup" href="#footnote-4">†</a></td>       <td class="Rrule" align="left">↔ Saquinavir<br />↑ Rifabutin<br />↔ Ritonavir<br /> <br /> </td>       <td class="Rrule" align="left">No dose adjustment of INVIRASE/ritonavir (1000/100 mg bid) is required if ritonavir-boosted INVIRASE is administered in combination with rifabutin.<br /> <br />Dosage reduction of rifabutin by at least 75% of the usual dose of 300 mg/day is recommended (i.e., a maximum dose of 150 mg every other day or three times per week). Increased monitoring for adverse events is warranted in patients receiving the combination.<br /> <br />Consider monitoring rifabutin concentrations to ensure adequate exposure.<br /> </td>       </tr>       <tr class="Botrule">        <td class="Lrule Rrule" align="left"><span class="Bold">Antipsychotic:</span> <br />Quetiapine</td>       <td class="Rrule" align="left">↑ Quetiapine</td>       <td class="Rrule" align="left"><span class="Underline">Initiation of INVIRASE with ritonavir in patients taking quetiapine:</span> <br />Consider alternative antiretroviral therapy to avoid increases in quetiapine drug exposures. If coadministration is necessary, reduce the quetiapine dose to 1/6 of the current dose and monitor for quetiapine-associated adverse reactions. Refer to the quetiapine prescribing information for recommendations on adverse reaction monitoring.<br /> <br /> <span class="Underline">Initiation of quetiapine in patients taking INVIRASE with ritonavir:</span> <br />Refer to the quetiapine prescribing information for initial dosing and titration of quetiapine.</td>       </tr>       <tr class="Botrule">        <td class="Lrule Rrule" align="left"><span class="Bold">Benzodiazepines</span><a class="Sup" href="#footnote-3">*</a><span class="Bold">:</span> <br />Alprazolam, clorazepate, diazepam, flurazepam<br /> </td>       <td class="Rrule" align="left">↑ Benzodiazepines</td>       <td class="Rrule" align="left">Clinical significance is unknown; however, a decrease in benzodiazepine dose may be needed.<br /> </td>       </tr>       <tr class="Botrule">        <td class="Lrule Rrule" align="left"><span class="Bold">Benzodiazepine</span><a class="Sup" href="#footnote-3">*</a><span class="Bold">:</span> <br />Intravenously administered Midazolam</td>       <td class="Rrule" align="left">↑ Midazolam</td>       <td class="Rrule" align="left">Midazolam is extensively metabolized by CYP3A4. Increases in the concentration of midazolam are expected to be significantly higher with oral than parenteral administration. Therefore, INVIRASE should not be given with orally administered midazolam <span class="Italics">[see <a href="#S4">Contraindications (4)</a>]</span>. If INVIRASE is coadministered with parenteral midazolam, close clinical monitoring for respiratory depression and/or prolonged sedation should be exercised and dosage adjustment should be considered.<br /> </td>       </tr>       <tr class="Botrule">        <td class="Lrule Rrule" align="left"><span class="Bold">Calcium channel blockers</span><a class="Sup" href="#footnote-3">*</a><span class="Bold">:</span> <br />Diltiazem, felodipine, nifedipine, nicardipine, nimodipine, verapamil, amlodipine, nisoldipine, isradipine<br /> </td>       <td class="Rrule" align="left">↑ Calcium channel blockers</td>       <td class="Rrule" align="left">Caution is warranted and clinical monitoring of patients is recommended.</td>       </tr>       <tr class="Botrule">        <td class="Lrule Rrule" align="left"><span class="Bold">Corticosteroid:</span> <br />Dexamethasone<a class="Sup" href="#footnote-3">*</a></td>       <td class="Rrule" align="left">↓ Saquinavir<br /> </td>       <td class="Rrule" align="left">Use with caution. Saquinavir may be less effective due to decreased saquinavir plasma concentrations.<br /> </td>       </tr>       <tr class="Botrule">        <td class="Lrule Rrule" align="left"><span class="Bold">Digitalis Glycosides: </span>Digoxin<a class="Sup" href="#footnote-4">†</a></td>       <td class="Rrule" align="left">↑ Digoxin<br /> <br />Increases in serum digoxin concentration were greater in female subjects as compared to male subjects when digoxin was coadministered with INVIRASE/ritonavir.<br /> </td>       <td class="Rrule" align="left">Concomitant use of INVIRASE/ritonavir with digoxin results in a significant increase in serum concentrations of digoxin. Caution should be exercised when INVIRASE/ritonavir and digoxin are coadministered; serum digoxin concentrations should be monitored and the dose of digoxin may need to be reduced when coadministered with INVIRASE/ritonavir.<br /> </td>       </tr>       <tr class="Botrule">        <td class="Lrule Rrule" align="left"><span class="Bold">Endothelin receptor antagonists:</span> <br />Bosentan</td>       <td class="Rrule" align="left">↑ Bosentan</td>       <td class="Rrule" align="left"><span class="Underline">Coadministration of bosentan in patients on INVIRASE/ritonavir:</span> <br /> <br />In patients who have been receiving INVIRASE/ritonavir for at least 10 days, start bosentan at 62.5 mg once daily or every other day based upon individual tolerability.<br /> <br /> <span class="Underline">Coadministration of INVIRASE/ritonavir in patients on bosentan:</span> <br /> <br />Discontinue use of bosentan at least 36 hours prior to initiation of INVIRASE/ritonavir.<br /> <br />After at least 10 days following the initiation of INVIRASE/ritonavir, resume bosentan at 62.5 mg once daily or every other day based upon individual tolerability.<br /> </td>       </tr>       <tr class="Botrule">        <td class="Lrule Rrule" align="left"><span class="Bold">Inhaled beta agonist:</span> <br />Salmeterol</td>       <td class="Rrule" align="left">↑ Salmeterol</td>       <td class="Rrule" align="left">Concurrent administration of salmeterol with INVIRASE/ritonavir is not recommended. The combination may result in increased risk of cardiovascular adverse events associated with salmeterol, including QT prolongation, palpitations and sinus tachycardia.<br /> </td>       </tr>       <tr class="Botrule">        <td class="Lrule Rrule" align="left"><span class="Bold">Inhaled/nasal steroid:</span> <br />Fluticasone<a class="Sup" href="#footnote-3">*</a></td>       <td class="Rrule" align="left"><span class="Bold">INVIRASE/ritonavir</span> <br />↑ Fluticasone</td>       <td class="Rrule" align="left">Concomitant use of fluticasone propionate and INVIRASE/ritonavir may increase plasma concentrations of fluticasone propionate, resulting in significantly reduced serum cortisol concentrations. Coadministration of fluticasone propionate and INVIRASE/ritonavir is not recommended unless the potential benefit to the patient outweighs the risk of systemic corticosteroid side effects.<br /> </td>       </tr>       <tr class="Botrule">        <td class="Lrule Rrule" align="left"><span class="Bold">HMG-CoA reductase inhibitors</span><a class="Sup" href="#footnote-3">*</a><span class="Bold">:</span> <br />Atorvastatin</td>       <td class="Rrule" align="left">↑ Atorvastatin<br /> </td>       <td class="Rrule" align="left">Titrate atorvastatin dose carefully and use the lowest dose necessary; do not exceed atorvastatin 20 mg/day.<br /> </td>       </tr>       <tr class="Botrule">        <td class="Lrule Rrule" align="left"><span class="Bold">Immunosuppressants</span><a class="Sup" href="#footnote-3">*</a><span class="Bold">:</span> <br />Cyclosporine, tacrolimus, rapamycin</td>       <td class="Rrule" align="left">↑ Immunosuppressants</td>       <td class="Rrule" align="left">Therapeutic concentration monitoring is recommended for immunosuppressant agents when coadministered with INVIRASE/ritonavir.<br /> </td>       </tr>       <tr class="Botrule">        <td class="Lrule Rrule" align="left"><span class="Bold">Narcotic analgesic:</span> <br />Methadone<a class="Sup" href="#footnote-4">†</a></td>       <td class="Rrule" align="left">↓ Methadone</td>       <td class="Rrule" align="left">Dosage of methadone may need to be increased when coadministered with INVIRASE/ritonavir.<br /> <br />Use with caution. Additive effects on QT and/or PR interval prolongation may occur with INVIRASE/ritonavir <span class="Italics">[see <a href="#S4">Contraindications (4)</a> and <a href="#S5.2">Warnings and Precautions (5.2,</a><a href="#S5.3"> 5.3)</a>]</span>.<br /> </td>       </tr>       <tr class="Botrule">        <td class="Lrule Rrule" align="left"><span class="Bold">Neuroleptics:</span> <br />Clozapine<br />Haloperidol<br />Mesoridazine<br />Phenothiazines<br />Thioridazine<br />Ziprasidone<br /> </td>       <td class="Rrule" align="left"></td>       <td class="Rrule" align="left">Use with caution. Additive effects on QT and/or PR interval prolongation may occur with INVIRASE/ritonavir <span class="Italics">[see <a href="#S4">Contraindications (4)</a> and <a href="#S5.2">Warnings and Precautions (5.2,</a><a href="#S5.3"> 5.3)</a>]</span>.<br /> </td>       </tr>       <tr class="Botrule">        <td class="Lrule Rrule" align="left"><span class="Bold">Oral contraceptives:</span> <br />Ethinyl estradiol<a class="Sup" href="#footnote-3">*</a></td>       <td class="Rrule" align="left">↓ Ethinyl estradiol</td>       <td class="Rrule" align="left">Alternative or additional contraceptive measures should be used when estrogen-based oral contraceptives and INVIRASE/ritonavir are coadministered.<br /> </td>       </tr>       <tr class="Botrule">        <td class="Lrule Rrule" align="left"><span class="Bold">PDE5 inhibitors (phosphodiesterase type 5 inhibitors):</span> <br />Sildenafil<a class="Sup" href="#footnote-4">†</a>, vardenafil<a class="Sup" href="#footnote-3">*</a>, tadalafil<a class="Sup" href="#footnote-3">*</a></td>       <td class="Rrule" align="left">↑ Sildenafil<br />↔ Saquinavir<br /> <br />↑ Vardenafil<br />↑ Tadalafil<br /> <br />Only the combination of sildenafil with saquinavir soft gelatin capsules has been studied at doses used for treatment of erectile dysfunction.<br /> </td>       <td class="Rrule" align="left">May result in an increase in PDE5 inhibitor-associated adverse events, including hypotension, syncope, visual disturbances, and priapism.<br /> <br /> <span class="Underline">Use of PDE-5 inhibitors for pulmonary arterial hypertension (PAH):</span>         <ul>          <li>Use of sildenafil (Revatio) is contraindicated when used for the treatment of pulmonary arterial hypertension (PAH) <span class="Italics">[see <a href="#S4">Contraindications (4)</a>]</span>.</li>         </ul> The following dose adjustments are recommended for use of tadalafil (Adcirca<span class="Sup">&reg;</span>) with INVIRASE/ritonavir:<br /> <br /> <span class="Underline">Coadministration of Adcirca in patients on INVIRASE/ritonavir:</span> <br /> <br />In patients receiving INVIRASE/ritonavir for at least one week, start Adcirca at 20 mg once daily. Increase to 40 mg once daily based upon individual tolerability.<br /> <br /> <span class="Underline">Coadministration of INVIRASE/ritonavir in patients on Adcirca:</span> <br /> <br />Avoid use of Adcirca during the initiation of INVIRASE/ritonavir. Stop Adcirca at least 24 hours prior to starting INVIRASE/ritonavir. After at least one week following the initiation of INVIRASE/ritonavir, resume Adcirca at 20 mg once daily. Increase to 40 mg once daily based upon individual tolerability.<br /> <br /> <span class="Underline">Use of PDE5 inhibitors for erectile dysfunction:</span> <br /> <br />Use sildenafil with caution at reduced doses of 25 mg every 48 hours with increased monitoring of adverse events when administered concomitantly with INVIRASE/ritonavir.<br /> <br />Use vardenafil with caution at reduced doses of no more than 2.5 mg every 72 hours with increased monitoring of adverse events when administered concomitantly with INVIRASE/ritonavir.<br /> <br />Use tadalafil with caution at reduced doses of no more than 10 mg every 72 hours with increased monitoring of adverse events when administered concomitantly with INVIRASE/ritonavir.<br /> </td>       </tr>       <tr class="Botrule">        <td class="Lrule Rrule" align="left"><span class="Bold">Tricyclic antidepressants</span><a class="Sup" href="#footnote-3">*</a><span class="Bold">: </span>Amitriptyline, imipramine<br /> </td>       <td class="Rrule" align="left">↑ Tricyclics</td>       <td class="Rrule" align="left">Therapeutic concentration monitoring is recommended for tricyclic antidepressants when coadministered with INVIRASE/ritonavir.<br /> </td>       </tr>       <tr class="Botrule">        <td class="Lrule Rrule" align="left"><span class="Bold">Proton pump inhibitors: </span>Omeprazole<a class="Sup" href="#footnote-4">†</a></td>       <td class="Rrule" align="left">↑ Saquinavir</td>       <td class="Rrule" align="left">When INVIRASE/ritonavir is co-administered with omeprazole, saquinavir concentrations are increased significantly. If omeprazole or another proton pump inhibitor is taken concomitantly with INVIRASE/ritonavir, caution is advised and monitoring for potential saquinavir toxicities is recommended, particularly gastrointestinal symptoms, increased triglycerides, deep vein thrombosis, and QT prolongation.<br /> </td>       </tr>       <tr class="Botrule">        <td class="Lrule Rrule" align="left"><span class="Bold">Herbal Products:</span> <br />St. John's wort<a class="Sup" href="#footnote-3">*</a> (hypericum perforatum)</td>       <td class="Rrule" align="left">↓ Saquinavir</td>       <td class="Rrule" align="left">Coadministration may lead to loss of virologic response and possible resistance to INVIRASE or to the class of protease inhibitors.<br /> </td>       </tr>       <tr class="Last">        <td class="Lrule Rrule" align="left">Garlic Capsules<a class="Sup" href="#footnote-3">*</a></td>       <td class="Rrule" align="left">↓ Saquinavir</td>       <td class="Rrule" align="left">Coadministration of garlic capsules and saquinavir is not recommended due to the potential for garlic capsules to induce the metabolism of saquinavir which may result in sub-therapeutic saquinavir concentrations.<br /> </td>       </tr>      </tbody>     </table>   </div>   </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">8 USE IN SPECIFIC POPULATIONS</a> <div class="Section toggle-content closed" data-sectioncode="43684-0">   <a name="S8"></a>  <a name="section-9"></a>   <p></p>    <div class="Section" data-sectioncode="42228-7">    <a name="S8.1"></a>   <a name="section-9.1"></a>    <p></p>    <h2>8.1 Pregnancy</h2>    <div class="Section" data-sectioncode="34077-8">     <a name="section-9.1.1"></a>     <p></p>     <p class="First"> <span class="Italics">Pregnancy Category B</span> </p>     <p>Reproduction studies conducted with saquinavir have shown no embryotoxicity or teratogenicity in both rats and rabbits. Because of limited bioavailability of saquinavir in animals and/or dosing limitations, the plasma exposures (AUC values) in the respective species were approximately 29% (using rat) and 21% (using rabbit) of those obtained in humans at the recommended clinical dose boosted with ritonavir. Clinical experience in pregnant women is limited. Saquinavir should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>     <div class="Section" data-sectioncode="42229-5">      <a name="section-9.1.1.1"></a>      <p></p>      <p class="First"> <span class="Italics">Antiretroviral Pregnancy Registry</span> </p>      <p>To monitor maternal-fetal outcomes of pregnant women exposed to antiretroviral medications, including INVIRASE, an Antiretroviral Pregnancy Registry has been established. Physicians are encouraged to register patients by calling 1-800-258-4263.</p>     </div>    </div>   </div>   <div class="Section" data-sectioncode="34080-2">    <a name="S8.3"></a>   <a name="section-9.2"></a>    <p></p>    <h2>8.3 Nursing Mothers</h2>    <p class="First"> <span class="Bold">The Centers for Disease Control and Prevention recommend that HIV</span>-<span class="Bold">infected mothers not breastfeed their infants to avoid risking postnatal transmission of HIV-1.</span> </p>    <p>It is not known whether saquinavir is excreted in human milk. Because of both the potential for HIV-1 transmission and the potential for serious adverse reactions in nursing infants, <span class="Bold">mothers should be instructed not to breastfeed if they are receiving INVIRASE.</span> </p>   </div>   <div class="Section" data-sectioncode="34081-0">    <a name="S8.4"></a>   <a name="section-9.3"></a>    <p></p>    <h2>8.4 Pediatric Use</h2>    <p class="First">The safety and activity of saquinavir have been evaluated in 68 pediatric subjects 4 months to less than 16 years of age treated with INVIRASE boosted with either ritonavir or with lopinavir/ritonavir in two clinical trials. Data from the NV20911 trial demonstrated that saquinavir boosted with low dose ritonavir provided plasma levels of saquinavir that were significantly higher than those historically observed in adults at the approved dose [<span class="Italics">see <a href="#s12.3">Clinical Pharmacology (12.3)</a></span>]. The HIVNAT 017 trial provided long term 96-week activity and safety data; however, pharmacokinetic data from this study could not be validated.</p>    <p>HIVNAT 017 was an open-label, single-arm trial at two centers in Thailand that evaluated the use of INVIRASE (50 mg per kg twice daily given as 200 mg capsules) with lopinavir/ritonavir (230/57.5 mg/m<span class="Sup">2</span> twice daily) for 96 weeks. Fifty subjects 4 years to less than 16 years of age were enrolled. In this trial population, treatment resulted in HIV-1 RNA &lt;400 copies/mL at week 96 in 78% of subjects (HIV-1 RNA &lt;50 copies per mL at week 96 in 66%). Mean CD4 lymphocyte percentage increased from 8% at screening to 22% at week 96.</p>    <p>NV20911 was an open label, multinational trial that evaluated the pharmacokinetics, safety, and activity of INVIRASE (50 mg per kg twice daily as 200 mg capsules, up to the adult dose of 1000 mg twice daily) and ritonavir oral solution plus ≥ 2 background ARVs. Eighteen subjects 4 months to less than 6 years of age were enrolled. Treatment with INVIRASE/ritonavir resulted in HIV-1 RNA &lt;400 copies per mL at week 48 in 72% of subjects (HIV-1 RNA &lt;50 copies per mL at week 48 in 61%). The percentage of subjects with HIV-1 RNA &lt;50 copies per mL at week 48 was 61%. Mean CD4 lymphocyte percentage increased from 29% at screening to 34% at week 48.</p>    <p>Steady state saquinavir exposures observed in pediatric trials were substantially higher than historical data in adults where dose- and exposure-dependent QTc and PR prolongation were observed [<span class="Italics">see <a href="#s5.3">Warnings and Precautions (5.3)</a>, <a href="#s12.2">Clinical Pharmacology (12.2</a>, <a href="#s12.3">12.3)</a></span>]. Although electrocardiogram abnormalities were not reported in these pediatric trials, the trials were small and not designed to evaluate QT or PR intervals. Modeling and simulation assessment of pharmacokinetic/pharmacodynamic relationships in pediatric subjects suggest that reducing the INVIRASE dose to minimize risk of QT prolongation is likely to reduce antiviral efficacy. In addition, no clinical efficacy data are available at INVIRASE doses less than 50 mg per kg in pediatric subjects. Therefore, pediatric dose recommendations that are both reliably effective and below thresholds of concern with respect to QT and PR prolongation could not be determined.</p>   </div>   <div class="Section" data-sectioncode="34082-8">    <a name="S8.5"></a>   <a name="section-9.4"></a>    <p></p>    <h2>8.5 Geriatric Use</h2>    <p class="First">Clinical trials of INVIRASE did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. In general, dosing INVIRASE in elderly patients should be undertaken with caution keeping in mind the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="S8.6"></a>   <a name="section-9.5"></a>    <p></p>    <h2>8.6 Impaired Renal Function</h2>    <p class="First">Renal clearance is a minor elimination pathway; the principal route of excretion for saquinavir is by hepatic metabolism. Therefore, no initial dose adjustment is necessary for patients with renal impairment. However, patients with severe renal impairment or end-stage renal disease (ESRD) have not been studied, and caution should be exercised when prescribing INVIRASE in this population.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="S8.7"></a>   <a name="section-9.6"></a>    <p></p>    <h2>8.7 Impaired Hepatic Function</h2>    <p class="First">No dosage adjustment is necessary for HIV-1-infected patients with mild or moderate hepatic impairment based on limited data. In patients with underlying hepatitis B or C, cirrhosis, chronic alcoholism and/or other underlying liver abnormalities, there have been reports of worsening liver disease <span class="Italics">[see <a href="#s12.3">Clinical Pharmacology (12.3)</a>]</span>. INVIRASE when administered with ritonavir is contraindicated in patients with severe hepatic impairment <span class="Italics">[see <a href="#s4">Contraindications (4)</a>].</span> </p>   </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">10 OVERDOSAGE</a> <div class="Section toggle-content closed" data-sectioncode="34088-5">   <a name="S10"></a>  <a name="section-10"></a>   <p></p>    <p class="First">There is limited experience of overdose with saquinavir.</p>   <p>No acute toxicities or sequelae were noted in 1 subject who ingested 8 grams of INVIRASE as a single dose. The subject was treated with induction of emesis within 2 to 4 hours after ingestion. A second subject ingested 2.4 grams of INVIRASE in combination with 600 mg of ritonavir and experienced pain in the throat that lasted for 6 hours and then resolved. In an exploratory Phase II study of oral dosing with INVIRASE at 7200 mg per day (1200 mg q4h), there were no serious toxicities reported through the first 25 weeks of treatment.</p>   <p>Treatment of overdose with saquinavir should consist of general supportive measures including monitoring of vital signs and ECG and observations of the patient's clinical status. Since saquinavir is highly protein bound, dialysis is unlikely to be beneficial in significant removal of the active substance.</p>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">11 DESCRIPTION</a> <div class="Section toggle-content closed" data-sectioncode="34089-3">   <a name="S11"></a>  <a name="section-11"></a>   <p></p>    <p class="First">INVIRASE brand of saquinavir mesylate is an inhibitor of the human immunodeficiency virus type 1 (HIV-1) protease.</p>   <p>The chemical name for saquinavir mesylate is N-tert-butyl-decahydro-2-[2(R)-hydroxy-4-phenyl-3(S)-[[N-(2-quinolylcarbonyl)-L-asparaginyl]amino]butyl]-(4aS,8aS)-isoquinoline-3(S)-carboxamide methanesulfonate with a molecular formula C<span class="Sub">38</span>H<span class="Sub">50</span>N<span class="Sub">6</span>O<span class="Sub">5</span>∙CH<span class="Sub">4</span>O<span class="Sub">3</span>S and a molecular weight of 766.96. The molecular weight of the free base is 670.86. Saquinavir mesylate has the following structural formula:</p>   <div class="Figure">    <img src="image.cfm?setid=c00d1607-ac36-457b-a34b-75ad74f9cf0a&name=invirase%2D01%2Ejpg" alt="Chemical Structure" />  </div>   <p>Saquinavir mesylate is a white to off-white, very fine powder with an aqueous solubility of 2.22 mg per mL at 25&deg;C.</p>   <p>INVIRASE is available as light brown and green, opaque hard gelatin capsules for oral administration in a 200-mg strength (as saquinavir free base). Each capsule also contains the inactive ingredients lactose, microcrystalline cellulose, povidone K30, sodium starch glycolate, talc, and magnesium stearate. Each capsule shell contains gelatin and water with the following dye systems: red iron oxide, yellow iron oxide, black iron oxide, FD&amp;C Blue #2, and titanium dioxide.</p>   <p>INVIRASE is also available as a light orange to greyish- or brownish-orange, oval cylindrical, biconvex film-coated tablet for oral administration in 500-mg strength (as saquinavir free base). Each tablet also contains the inactive ingredients lactose, microcrystalline cellulose, povidone K30, croscarmellose sodium, and magnesium stearate. Each film coat contains hypromellose, titanium dioxide, talc, iron oxide yellow, iron oxide red, and triacetin.</p>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">12 CLINICAL PHARMACOLOGY</a> <div class="Section toggle-content closed" data-sectioncode="34090-1">   <a name="S12"></a>  <a name="section-12"></a>   <p></p>    <div class="Section" data-sectioncode="43679-0">    <a name="S12.1"></a>   <a name="section-12.1"></a>    <p></p>    <h2>12.1 Mechanism of Action</h2>    <p class="First">INVIRASE is an antiviral agent <span class="Italics">[see <a href="#S12.4">Microbiology (12.4)</a>]</span> </p>   </div>   <div class="Section" data-sectioncode="43681-6">    <a name="S12.2"></a>   <a name="section-12.2"></a>    <p></p>    <h2>12.2 Pharmacodynamics</h2>    <p class="First">QTcS interval was evaluated in a randomized, placebo and active (moxifloxacin 400 mg once daily) controlled crossover study in 59 healthy adults, with ECG measurements on Day 3. The maximum mean (95% upper confidence bound) differences in QTcS interval from placebo after baseline-correction were 18.9 (22.0) and 30.2 (33.4) ms for 1000/100 mg twice daily and supratherapeutic 1500/100 mg twice daily of INVIRASE/ritonavir, respectively. There is a delayed effect between QTc interval change and drug concentrations, with the maximum placebo-adjusted baseline-corrected QTcS observed at about 12-20 h post-dose. INVIRASE/ritonavir 1500/100 mg twice daily resulted in a Day 3 mean C<span class="Sub">max</span> of INVIRASE approximately 1.4-fold higher than the mean C<span class="Sub">max</span> observed on Day 3 with the approved therapeutic dose in healthy volunteers (within the same study). QTcS in this study was QT/RR<span class="Sup">0.319</span> for males and QT/RR<span class="Sup">0.337</span> for females, which are similar to Fridericia's correction (QTcF=QT/RR<span class="Sup">0.3333</span>).</p>    <p>PR and QRS interval prolongations were also noted in subjects receiving INVIRASE/ritonavir in the same study on Day 3. The maximum mean (95% upper confidence bound) difference from placebo in the PR interval after baseline-correction were 28.6 (31.6) and 38.4 (41.4) ms for 1000/100 mg twice daily and supratherapeutic 1500/100 mg twice daily saquinavir/ritonavir respectively. The maximum mean (95% upper confidence bound) difference from placebo in QRS interval after baseline correction were 2.9 (3.9) and 4.4 (5.3) ms for 1000/100 mg twice daily and supratherapeutic 1500/100 mg twice daily INVIRASE/ritonavir respectively. In this study using healthy subjects, PR interval prolongation of &gt;200 ms was also observed in 40% and 47% of subjects receiving INVIRASE/ritonavir 1000/100 mg bid and 1500/100 mg bid, respectively, on Day 3. Three (3%) of subjects in the active control moxifloxacin arm and 5% in the placebo arm experienced PR prolongation of &gt;200 ms.</p>   </div>   <div class="Section" data-sectioncode="43682-4">    <a name="S12.3"></a>   <a name="section-12.3"></a>    <p></p>    <h2>12.3 Pharmacokinetics</h2>    <p class="First">The pharmacokinetics of INVIRASE/ritonavir 1000/100 mg twice daily have been evaluated in HIV-1-infected subjects and healthy subjects. Steady-state saquinavir AUC, C<span class="Sub">max</span>, and C<span class="Sub">min</span> in healthy subjects are approximately 50% higher than observed in HIV-1-infected subjects.</p>    <div class="Section" data-sectioncode="42229-5">     <a name="section-12.3.1"></a>     <p></p>     <p class="First"> <span class="Italics">Adults</span> </p>     <div class="Section" data-sectioncode="42229-5">      <a name="section-12.3.1.1"></a>      <p></p>      <p class="First"> <span class="Underline">Absorption and Bioavailability in Adults</span> </p>      <p>Similar bioavailability was demonstrated when INVIRASE 500 mg film-coated tablet (2 &times; 500 mg) and INVIRASE 200 mg capsule (5 &times; 200 mg) were administered with low-dose ritonavir (100 mg) under fed conditions. The ratio of mean exposures (90% confidence intervals) of tablets vs capsules was 1.10 (1.04-1.16) for AUC<span class="Sub">0-</span><span class="Sub">∞</span> and 1.19 (1.14-1.25) for C<span class="Sub">max</span>.</p>      <p>Absolute bioavailability of saquinavir administered as INVIRASE averaged 4% (CV 73%, range: 1% to 9%) in 8 healthy volunteers who received a single 600-mg dose (3 &times; 200 mg) of saquinavir mesylate following a high-fat breakfast (48 g protein, 60 g carbohydrate, 57 g fat; 1006 kcal). The low bioavailability is thought to be due to a combination of incomplete absorption and extensive first-pass metabolism.</p>      <p>INVIRASE in combination with ritonavir at a dose of 1000/100 mg twice daily provides saquinavir systemic exposures over a 24-hour period that are similar to those achieved with saquinavir soft gel capsules with ritonavir 1000/100 mg twice daily and greater than that achieved with saquinavir soft gel capsules 1200 mg three times daily (see <span class="Bold"><a href="#table4">Table 4</a></span>).</p>      <a name="table4"></a>      <div class="scrollingtable">      <table width="100%">        <caption>         <span>Table 4 Pharmacokinetic Parameters of Saquinavir at Steady-State After Administration of Different Regimens in HIV-1-Infected Subjects</span>        </caption>        <colgroup>        <col align="left" valign="top" width="45%" />         <col align="center" valign="top" width="10%" />         <col align="center" valign="top" width="15%" />         <col align="center" valign="top" width="15%" />         <col align="center" valign="top" width="15%" />        </colgroup>       <thead>         <tr class="First Last">          <th class="Lrule Rrule" align="left">Dosing Regimen</th>         <th class="Rrule" align="center">N</th>         <th class="Rrule" align="center">AUC<span class="Sub">τ</span> <br />(ng∙h/mL)</th>         <th class="Rrule" align="center">AUC<span class="Sub">24h</span> <br />(ng∙h/mL)</th>         <th class="Rrule" align="center">C<span class="Sub">min</span> <br />(ng/mL)</th>         </tr>        </thead>        <tfoot>         <tr class="First Last">          <td align="left" colspan="5">τ is the dosing interval (i.e., 8h if three times daily and 12h if twice daily)</td>         </tr>        </tfoot>        <tbody>         <tr class="Botrule First">          <td class="Lrule Rrule" align="left">INVIRASE 600 mg tid (arithmetic mean, %CV)</td>         <td class="Rrule" align="center">10</td>         <td class="Rrule" align="center">866 (62)</td>         <td class="Rrule" align="center">2598</td>         <td class="Rrule" align="center">79</td>         </tr>         <tr class="Botrule">          <td class="Lrule Rrule" align="left">Saquinavir soft gel capsules 1200 mg tid (arithmetic mean)</td>         <td class="Rrule" align="center">31</td>         <td class="Rrule" align="center">7249</td>         <td class="Rrule" align="center">21747</td>         <td class="Rrule" align="center">216</td>         </tr>         <tr class="Botrule">          <td class="Lrule Rrule" align="left">INVIRASE 1000 mg bid + ritonavir 100 mg bid (geometric mean and 95% CI)</td>         <td class="Rrule" align="center">24</td>         <td class="Rrule" align="center">14607<br />(10218-20882)</td>         <td class="Rrule" align="center">29214</td>         <td class="Rrule" align="center">371<br />(245-561)</td>         </tr>         <tr class="Last">          <td class="Lrule Rrule" align="left">Saquinavir soft gel capsules 1000 mg bid + ritonavir 100 mg bid (geometric mean and 95% CI)</td>         <td class="Rrule" align="center">24</td>         <td class="Rrule" align="center">19085<br />(13943-26124)</td>         <td class="Rrule" align="center">38170</td>         <td class="Rrule" align="center">433<br />(301-622)</td>         </tr>        </tbody>       </table>     </div>      <div class="Section" data-sectioncode="42229-5">       <a name="section-12.3.1.1.1"></a>       <p></p>       <p class="First"> <span class="Underline">Food Effect</span> </p>       <p>The mean 24-hour AUC after a single 600-mg oral dose (6 &times; 100 mg) in healthy volunteers (n=6) was increased from 24 ng∙h/mL (CV 33%), under fasting conditions, to 161 ng∙h/mL (CV 35%) when INVIRASE was given following a high-fat breakfast (48 g protein, 60 g carbohydrate, 57 g fat; 1006 kcal). Saquinavir 24-hour AUC and C<span class="Sub">max</span> (n=6) following the administration of a higher calorie meal (943 kcal, 54 g fat) were on average 2 times higher than after a lower calorie, lower fat meal (355 kcal, 8 g fat). The effect of food has been shown to persist for up to 2 hours.</p>       <p>INVIRASE/ritonavir should be taken within 2 hours after a meal.</p>      </div>      <div class="Section" data-sectioncode="42229-5">       <a name="section-12.3.1.1.2"></a>       <p></p>       <p class="First"> <span class="Underline">Distribution</span> </p>       <p>The mean steady-state volume of distribution following intravenous administration of a 12-mg dose of saquinavir (n=8) was 700 L (CV 39%), suggesting saquinavir partitions into tissues. Saquinavir was approximately 98% bound to plasma proteins over a concentration range of 15 to 700 ng/mL. In 2 subjects receiving saquinavir mesylate 600 mg three times daily, cerebrospinal fluid concentrations were negligible when compared to concentrations from matching plasma samples.</p>      </div>      <div class="Section" data-sectioncode="42229-5">       <a name="section-12.3.1.1.3"></a>       <p></p>       <p class="First"> <span class="Underline">Metabolism and Elimination</span> </p>       <p>In vitro studies using human liver microsomes have shown that the metabolism of saquinavir is cytochrome P450 mediated with the specific isoenzyme, CYP3A4, responsible for more than 90% of the hepatic metabolism. Based on in vitro studies, saquinavir is rapidly metabolized to a range of mono- and di-hydroxylated inactive compounds. In a mass balance study using 600 mg <span class="Sup">14</span>C-saquinavir mesylate (n=8), 88% and 1% of the orally administered radioactivity was recovered in feces and urine, respectively, within 5 days of dosing. In an additional 4 subjects administered 10.5 mg <span class="Sup">14</span>C-saquinavir intravenously, 81% and 3% of the intravenously administered radioactivity was recovered in feces and urine, respectively, within 5 days of dosing. In mass balance studies, 13% of circulating radioactivity in plasma was attributed to unchanged drug after oral administration and the remainder attributed to saquinavir metabolites. Following intravenous administration, 66% of circulating radioactivity was attributed to unchanged drug and the remainder attributed to saquinavir metabolites, suggesting that saquinavir undergoes extensive first-pass metabolism.</p>       <p>Systemic clearance of saquinavir was rapid, 1.14 L/h/kg (CV 12%) after intravenous doses of 6, 36, and 72 mg. The mean residence time of saquinavir was 7 hours (n=8).</p>      </div>      <div class="Section" data-sectioncode="42229-5">       <a name="section-12.3.1.1.4"></a>       <p></p>       <p class="First"> <span class="Italics">Special Populations</span> </p>       <div class="Section" data-sectioncode="42229-5">        <a name="section-12.3.1.1.4.1"></a>        <p></p>        <p class="First"> <span class="Underline">Renal Impairment</span> </p>        <p>Saquinavir pharmacokinetics in patients with renal impairment has not been investigated. Only 1% of saquinavir is excreted in the urine, so the impact of renal impairment on saquinavir elimination would likely be minimal. However, subjects with severe renal impairment or end-stage renal disease (ESRD) have not been studied, and concentrations of saquinavir may be elevated in these populations.</p>       </div>       <div class="Section" data-sectioncode="42229-5">        <a name="section-12.3.1.1.4.2"></a>        <p></p>        <p class="First"> <span class="Underline">Hepatic Impairment</span> </p>        <p>The effect of hepatic impairment on the steady state pharmacokinetics of INVIRASE/ritonavir (1000/100 mg bid for 14 days) was investigated in 7 HIV-1-infected subjects with moderate liver impairment (6 with Child-Pugh score of 7 and 1 with Child-Pugh score of 9). The study included a control group consisting of 7 HIV-1-infected subjects with normal hepatic function matched with hepatically impaired subjects for age, gender, weight and tobacco use. The mean (% coefficient of variation in parentheses) values for INVIRASE AUC<span class="Sub">0-12</span> and C<span class="Sub">max</span> were 24.3 (102%) &micro;g∙hr/mL and 3.6 (83%) &micro;g/mL, respectively, for HIV-1-infected subjects with moderate hepatic impairment. The corresponding values in the control group were 28.5 (71%) &micro;g∙hr/mL and 4.3 (68%) &micro;g/mL. The geometic mean ratio (ratio of pharmacokinetic parameters in hepatically impaired subjects to subjects with normal liver function) (90% confidence interval) was 0.7 (0.3 to 1.6) for both AUC<span class="Sub">0-12</span> and C<span class="Sub">max</span>, which suggests approximately 30% reduction in saquinavir exposure in subjects with moderate hepatic impairment. No dose adjustment is warranted for INVIRASE in HIV-1-infected patients with mild or moderate hepatic impairment <span class="Italics">[see <a href="#S5.5">Warnings and Precautions (5.5)</a>]</span>.</p>       </div>       <div class="Section" data-sectioncode="42229-5">        <a name="section-12.3.1.1.4.3"></a>        <p></p>        <p class="First"> <span class="Underline">Gender, Race, and Age</span> </p>        <p>A gender difference was observed, with females showing higher saquinavir exposure than males (mean AUC 56% higher, mean C<span class="Sub">max </span>26% higher), in the relative bioavailability study comparing INVIRASE 500 mg film-coated tablets to the INVIRASE 200 mg capsules in combination with ritonavir. There was no evidence that age and body weight explained the gender difference in this study. A clinically significant difference in safety and efficacy between men and women has not been reported with the approved dosage regimen (saquinavir 1000-mg/ritonavir 100-mg twice daily).</p>        <p>The effect of race on the pharmacokinetics of saquinavir has not been investigated.</p>        <p>The pharmacokinetics of saquinavir have not been evaluated in the elderly.</p>       </div>       <div class="Section" data-sectioncode="42229-5">        <a name="section-12.3.1.1.4.4"></a>        <p></p>        <p class="First"> <span class="Underline">Pediatric Subjects</span> </p>        <p>Steady-state pharmacokinetic information is available from HIV-1 infected pediatric subjects from study NV20911. In this study, 5 subjects less than 2 years of age and 13 subjects between 2 and less than 6 years of age received 50 mg per kg saquinavir twice daily (not to exceed 1000 mg twice daily) boosted with ritonavir at 3 mg/kg for subjects with body weight ranging from 5 to &lt;15 kg or 2.5 mg per kg for subjects with body weight ranging from 15 to 40 kg (not to exceed 100 mg twice daily). For subjects unable to swallow the INVIRASE capsules, the contents of INVIRASE 200 mg capsules were mixed with sugar syrup, or sorbitol syrup (for subjects with Type I diabetes or glucose intolerance), jam, or baby formula. The mean steady state saquinavir PK parameters for pediatric subjects 2 to less than 6 years of age were: AUC<span class="Sub">0-12h</span> 37269 &plusmn; 18232 ng∙h/mL; C<span class="Sub">trough</span> 1811 &plusmn; 998 ng/mL; C<span class="Sub">max </span>5464 &plusmn; 2782 ng/mL, and day 3 exposures may be within the range of exposure associated with QT and PR prolongation [<span class="Italics">see <a href="#s12.2">Clinical Pharmacology: Pharmacodynamics (12.2)</a></span>]. The subject number was too low and the pharmacokinetic data too variable in the subjects less than 2 years to establish an appropriate dosing recommendation for this age group. Pharmacokinetic data for subjects ages 6 to 16 years were not available for comparisons with observations from NV20911 [<span class="Italics">see <a href="#s8.4">Use in Specific Populations: Pediatric Use (8.4)</a>]</span> as the data from HIVNAT 017 could not be validated.</p>       </div>      </div>      <div class="Section" data-sectioncode="42229-5">       <a name="section-12.3.1.1.5"></a>       <p></p>       <p class="First"> <span class="Italics">Drug Interactions</span> </p>       <p> <span class="Bold"><a href="#table5">Table 5</a></span> summarizes the effect of saquinavir soft gel capsules and INVIRASE with and without ritonavir on the geometric mean AUC and C<span class="Sub">max</span> of coadministered drugs. <span class="Bold"><a href="#table6">Table 6</a></span> summarizes the effect of coadministered drugs on the geometric mean AUC and C<span class="Sub">max</span> of saquinavir.</p>       <a name="table5"></a>       <div class="scrollingtable">       <table width="100%">         <caption>          <span>Table 5 Effect of Saquinavir (+/- Ritonavir) on the Pharmacokinetics of Coadministered Drugs</span>         </caption>         <colgroup>         <col align="left" valign="top" width="36%" />          <col align="left" valign="top" width="25%" />          <col align="center" valign="top" width="5%" />          <col align="center" valign="top" width="17%" />          <col align="center" valign="top" width="17%" />         </colgroup>        <thead>          <tr class="First">           <th class="Lrule Rrule" align="left">Coadministered Drug</th>          <th class="Rrule" align="center">Saquinavir soft gel capsules or saquinavir soft gel capsules/<br />ritonavir</th>          <th class="Rrule" align="center">N</th>          <th class="Botrule Rrule" align="center" colspan="2">% Change for Coadministered Drug</th>          </tr>          <tr class="Botrule Last">           <th class="Lrule Rrule" align="left"></th>          <th class="Rrule" align="center">Dose</th>          <th class="Rrule" align="center"></th>          <th class="Rrule" align="center">AUC (95% CI)</th>          <th class="Rrule" align="center">C<span class="Sub">max</span> (95% CI)</th>          </tr>         </thead>         <tfoot>          <tr class="First">           <td align="left" colspan="5">↑ Denotes an average increase in exposure by the percentage indicated.</td>          </tr>          <tr>           <td align="left" colspan="5">↓ Denotes an average decrease in exposure by the percentage indicated.</td>          </tr>          <tr>           <td align="left" colspan="5">↔ Denotes no statistically significant change in exposure was observed.</td>          </tr>          <tr>           <td align="left" colspan="5">S Subjects</td>          </tr>          <tr>           <td align="left" colspan="5">V Healthy Volunteers</td>          </tr>          <tr>           <td align="left" colspan="5">M Methadone-dependent, HIV negative subjects</td>          </tr>          <tr class="Last">           <td align="left" colspan="5">NA Not Available </td>          </tr>          <tr>           <td align="left" colspan="5">            <dl class="Footnote">             <dt>              <a href="#footnote-reference-5" name="footnote-5">*</a>             </dt>             <dd>             90% Confidence Interval             </dd>             <dt>              <a href="#footnote-reference-6" name="footnote-6">†</a>             </dt>             <dd>             AUC             <span class="Sub">0-96hr</span> and C             <span class="Sub">max</span> of the active moiety (rifabutin + 25-O-desacetyl rifabutin)            </dd>             <dt>              <a href="#footnote-reference-7" name="footnote-7">‡</a>             </dt>             <dd>             Compared to rifabutin 150 mg QD             </dd>             <dt>              <a href="#footnote-reference-8" name="footnote-8">&sect;</a>             </dt>             <dd>             AUC             <span class="Sub">0-96hr</span> and C             <span class="Sub">max</span> for rifabutin only            </dd>            </dl> </td>          </tr>         </tfoot>         <tbody>          <tr class="First">           <td class="Lrule Rrule Toprule" align="left">Clarithromycin 500 mg bid &times; 7 days<br />&nbsp;&nbsp;Clarithromycin<br />&nbsp;&nbsp;14-OH clarithromycin metabolite</td>          <td class="Rrule Toprule" align="left">1200 mg tid &times; 7 days</td>          <td class="Rrule Toprule" align="center">12V</td>          <td class="Rrule Toprule" align="center">↑45% (17-81%)<br />↓24% (5-40%)</td>          <td class="Rrule Toprule" align="center">↑39% (10-76%)<br />↓34% (14-50%)</td>          </tr>          <tr>           <td class="Lrule Rrule Toprule" align="left">Enfuvirtide 90 mg SC q12h (bid) for 7 days</td>          <td class="Rrule Toprule" align="left">1000/100 mg bid</td>          <td class="Botrule Rrule Toprule" align="center">12S</td>          <td class="Rrule Toprule" align="center">↔</td>          <td class="Botrule Rrule Toprule" align="center">↔</td>          </tr>          <tr class="Botrule">           <td class="Lrule Rrule Toprule" align="left">Sildenafil 100-mg single dose</td>          <td class="Rrule Toprule" align="left">1200 mg tid &times; 8 days</td>          <td class="Rrule" align="center">27V</td>          <td class="Rrule Toprule" align="center">↑210% (150-300%)</td>          <td class="Rrule" align="center">↑140% (80-230%)</td>          </tr>          <tr class="Botrule">           <td class="Lrule Rrule" align="left">Efavirenz 600 mg qd</td>          <td class="Rrule" align="left">1200 mg tid</td>          <td class="Rrule" align="center">13V</td>          <td class="Rrule" align="center">↓12%</td>          <td class="Rrule" align="center">↓13%</td>          </tr>          <tr class="Botrule">           <td class="Lrule Rrule" align="left"></td>          <td class="Rrule" align="center"><span class="Bold">INVIRASE/ritonavir<br />Dose</span></td>          <td class="Rrule" align="center"></td>          <td class="Rrule" align="center"></td>          <td class="Rrule" align="center"></td>          </tr>          <tr class="Botrule">           <td class="Lrule Rrule" align="left">Digoxin 0.5 mg single dose</td>          <td class="Rrule" align="left">1000/100 mg bid &times; 16 days</td>          <td class="Rrule" align="center">16V</td>          <td class="Rrule" align="center">↑49% (32-69%)<a class="Sup" href="#footnote-5" name="footnote-reference-5">*</a></td>          <td class="Rrule" align="center">↑27% (5-54%)<a class="Sup" href="#footnote-5">*</a></td>          </tr>          <tr class="Botrule">           <td class="Lrule Rrule" align="left">R-Methadone 60-120 mg qd</td>          <td class="Rrule" align="left">1000/100 mg bid &times; 14 days</td>          <td class="Rrule" align="center">12M</td>          <td class="Rrule" align="center">↓19% (9-29%)<a class="Sup" href="#footnote-5">*</a></td>          <td class="Rrule" align="center">NA</td>          </tr>          <tr class="Botrule">           <td class="Lrule Rrule" align="left">Ketoconazole 200 mg/day</td>          <td class="Rrule" align="left">1000/100 mg bid</td>          <td class="Rrule" align="center">12V</td>          <td class="Rrule" align="center">↑168% (146-193%)<a class="Sup" href="#footnote-5">*</a></td>          <td class="Rrule" align="center">↑45% (32-59%)<a class="Sup" href="#footnote-5">*</a></td>          </tr>          <tr class="Botrule">           <td class="Lrule Rrule" align="left">Midazolam 7.5 mg oral single dose</td>          <td class="Rrule" align="left">1000/100 mg bid</td>          <td class="Rrule" align="center">16V</td>          <td class="Rrule" align="center">↑1144% (975-1339%)<a class="Sup" href="#footnote-5">*</a></td>          <td class="Rrule" align="center">↑327% (264 -402%)<a class="Sup" href="#footnote-5">*</a></td>          </tr>          <tr class="Last">           <td class="Lrule Rrule" align="left">Rifabutin 150 mg q4d</td>          <td class="Rrule" align="left">1000/100 mg bid</td>          <td class="Rrule" align="center">11V</td>          <td class="Rrule" align="center">↑60%<a class="Sup" href="#footnote-6" name="footnote-reference-6">†</a><a class="Sup" href="#footnote-7" name="footnote-reference-7">‡</a> <br />(43-79%)<a class="Sup" href="#footnote-5">*</a> <br />↔<a class="Sup" href="#footnote-8" name="footnote-reference-8">&sect;</a> (-10 to 13%)<a class="Sup" href="#footnote-5">*</a></td>          <td class="Rrule" align="center">↑111%<a class="Sup" href="#footnote-6">†</a><a class="Sup" href="#footnote-7">‡</a> <br />(75-153%)<a class="Sup" href="#footnote-5">*</a> <br />↑68%<a class="Sup" href="#footnote-8">&sect;</a> (38-105%)<a class="Sup" href="#footnote-5">*</a></td>          </tr>         </tbody>        </table>      </div>       <a name="table6"></a>       <div class="scrollingtable">       <table width="100%">         <caption>          <span>Table 6 Effect of Coadministered Drugs on Saquinavir Pharmacokinetics</span>         </caption>         <colgroup>         <col align="left" valign="top" width="35%" />          <col align="left" valign="top" width="20%" />          <col align="center" valign="top" width="5%" />          <col align="center" valign="top" width="20%" />          <col align="center" valign="top" width="20%" />         </colgroup>        <tfoot>          <tr class="First">           <td align="left" colspan="5">↑ Denotes an average increase in exposure by the percentage indicated.</td>          </tr>          <tr>           <td align="left" colspan="5">↓ Denotes an average decrease in exposure by the percentage indicated.</td>          </tr>          <tr>           <td align="left" colspan="5">↔ Mean change &lt;10%</td>          </tr>          <tr>           <td align="left" colspan="5">S Subjects</td>          </tr>          <tr class="Last">           <td align="left" colspan="5">V Healthy Volunteers</td>          </tr>          <tr>           <td align="left" colspan="5">            <dl class="Footnote">             <dt>              <a href="#footnote-reference-9" name="footnote-9">*</a>             </dt>             <dd>             Compared to saquinavir soft gel capsules 1200 mg tid regimen (n=33).            </dd>             <dt>              <a href="#footnote-reference-10" name="footnote-10">†</a>             </dt>             <dd>             Did not reach statistical significance.            </dd>             <dt>              <a href="#footnote-reference-11" name="footnote-11">‡</a>             </dt>             <dd>             Compared to INVIRASE 600 mg tid regimen (n=114).            </dd>             <dt>              <a href="#footnote-reference-12" name="footnote-12">&sect;</a>             </dt>             <dd>             90% Confidence Interval            </dd>            </dl> </td>          </tr>         </tfoot>         <tbody class="Headless">          <tr class="First">           <td class="Lrule Rrule" align="left"><span class="Bold">Coadministered Drug</span></td>          <td class="Rrule" align="center"><span class="Bold">Saquinavir soft gel capsules</span></td>          <td class="Rrule" align="center"><span class="Bold">N</span></td>          <td class="Rrule" align="center" colspan="2"><span class="Bold">% Change for Saquinavir</span></td>          </tr>          <tr class="Toprule">           <td class="Lrule Rrule" align="left"></td>          <td class="Rrule" align="center"><span class="Bold">Dose</span></td>          <td class="Rrule" align="center"></td>          <td class="Rrule Toprule" align="center"><span class="Bold">AUC (95% CI)</span></td>          <td class="Rrule Toprule" align="center"><span class="Bold">C<span class="Sub">max</span> (95% CI)</span></td>          </tr>          <tr>           <td class="Lrule Rrule Toprule" align="left">Clarithromycin 500 mg bid &times; 7 days</td>          <td class="Rrule Toprule" align="left">1200 mg tid &times; 7 days</td>          <td class="Rrule Toprule" align="center">12V</td>          <td class="Rrule Toprule" align="center">↑177% (108-269%)</td>          <td class="Rrule Toprule" align="center">↑187% (105-300%)</td>          </tr>          <tr>           <td class="Lrule Rrule Toprule" align="left">Efavirenz 600 mg qd</td>          <td class="Rrule Toprule" align="left">1200 mg tid</td>          <td class="Botrule Rrule Toprule" align="center">13V</td>          <td class="Rrule Toprule" align="center">↓62%</td>          <td class="Botrule Rrule Toprule" align="center">↓50%</td>          </tr>          <tr>           <td class="Lrule Rrule Toprule" align="left">Indinavir 800 mg q8h &times; 2 days</td>          <td class="Rrule Toprule" align="left">1200 mg single dose</td>          <td class="Botrule Rrule" align="center">6V</td>          <td class="Rrule Toprule" align="center">↑364% (190-644%)</td>          <td class="Botrule Rrule" align="center">↑299% (138-568%)</td>          </tr>          <tr class="Botrule">           <td class="Lrule Rrule Toprule" align="left">Ritonavir 400 mg bid &times; 14 days</td>          <td class="Rrule Toprule" align="left">400 mg bid &times; 14 days<a class="Sup" href="#footnote-9" name="footnote-reference-9">*</a></td>          <td class="Rrule" align="center">8V</td>          <td class="Rrule Toprule" align="center">↑121% (7-359%)</td>          <td class="Rrule" align="center">↑64%<a class="Sup" href="#footnote-10" name="footnote-reference-10">†</a></td>          </tr>          <tr class="Botrule">           <td class="Lrule Rrule" align="left" colspan="5">Lopinavir/ritonavir<br />Evidence from several clinical trials indicates that saquinavir concentrations achieved with saquinavir 1000 mg + lopinavir/ritonavir 400/100 mg BID are similar to those achieved following saquinavir/ritonavir 1000/100 mg BID.</td>          </tr>          <tr>           <td class="Lrule Rrule" align="left"><span class="Bold">Coadministered Drug</span></td>          <td class="Rrule" align="center"><span class="Bold">INVIRASE or INVIRASE/ritonavir</span></td>          <td class="Rrule" align="center"><span class="Bold">N</span></td>          <td class="Rrule" align="center" colspan="2"><span class="Bold">% Change for Saquinavir</span></td>          </tr>          <tr>           <td class="Botrule Lrule Rrule" align="left"></td>          <td class="Botrule Rrule" align="center"><span class="Bold">Dose</span></td>          <td class="Botrule Rrule" align="center"></td>          <td class="Rrule Toprule" align="center"><span class="Bold">AUC (95% CI)</span></td>          <td class="Rrule Toprule" align="center"><span class="Bold">C<span class="Sub">max</span> (95% CI)</span></td>          </tr>          <tr>           <td class="Botrule Lrule Rrule" align="left">Atazanavir 300 mg qd</td>          <td class="Botrule Rrule" align="left">1600/100 mg qd</td>          <td class="Botrule Rrule" align="center">18S</td>          <td class="Rrule Toprule" align="center">↑60%<br />(16-122%)</td>          <td class="Rrule Toprule" align="center">↑42%<br />(10-84%)</td>          </tr>          <tr>           <td class="Botrule Lrule Rrule" align="left">Fosamprenavir 700 mg bid</td>          <td class="Botrule Rrule" align="left">1000 mg bid/100 mg bid</td>          <td class="Botrule Rrule" align="center">18S</td>          <td class="Rrule Toprule" align="center">↓15%<br />(-33% to 9%)</td>          <td class="Rrule Toprule" align="center">↔<br /> </td>          </tr>          <tr class="Botrule">           <td class="Lrule Rrule" align="left">Ritonavir 100 mg bid</td>          <td class="Rrule" align="left">1000 mg bid<a class="Sup" href="#footnote-11" name="footnote-reference-11">‡</a></td>          <td class="Rrule" align="center">24S</td>          <td class="Rrule Toprule" align="center">↑1124%</td>          <td class="Rrule Toprule" align="center">↑1325%</td>          </tr>          <tr class="Botrule">           <td class="Lrule Rrule" align="left">Tenofovir 300 mg qd</td>          <td class="Rrule" align="left">1000 mg bid/100 mg bid</td>          <td class="Rrule" align="center">18S</td>          <td class="Rrule" align="center">↔<br /> </td>          <td class="Rrule" align="center">↔<br /> </td>          </tr>          <tr class="Botrule">           <td class="Lrule Rrule" align="left">Tipranavir 500 mg + ritonavir 200 mg bid</td>          <td class="Rrule" align="left">600 mg bid/100 mg bid</td>          <td class="Rrule" align="center">20S</td>          <td class="Rrule" align="center">↓76%<br />(68-81%)<a class="Sup" href="#footnote-12" name="footnote-reference-12">&sect;</a></td>          <td class="Rrule" align="center">↓70%<br />(60-77%)<a class="Sup" href="#footnote-12">&sect;</a></td>          </tr>          <tr class="Botrule">           <td class="Lrule Rrule" align="left">Omeprazole 40 mg qd &times; 5 days</td>          <td class="Rrule" align="left">1000/100 mg bid &times; 15 days</td>          <td class="Rrule" align="center">19V</td>          <td class="Rrule" align="center">↑82%<br />(37-234%)<a class="Sup" href="#footnote-12">&sect;</a></td>          <td class="Rrule" align="center">↑ 75%<br />(31-234%)<a class="Sup" href="#footnote-12">&sect;</a></td>          </tr>          <tr class="Botrule">           <td class="Lrule Rrule" align="left">Ketoconazole 200 mg/day</td>          <td class="Rrule" align="left">1000 mg bid/100 mg bid</td>          <td class="Rrule" align="center">20V</td>          <td class="Rrule" align="center">↔<a class="Sup" href="#footnote-12">&sect;</a></td>          <td class="Rrule" align="center">↔</td>          </tr>          <tr class="Last">           <td class="Lrule Rrule" align="left">Rifabutin 150 mg q3d</td>          <td class="Rrule" align="left">1000 mg bid/100 mg bid</td>          <td class="Rrule" align="center">19V</td>          <td class="Rrule" align="center">↓13%<br />(-31% to 9%)<a class="Sup" href="#footnote-12">&sect;</a></td>          <td class="Rrule" align="center">↓15%<br />(-32% to 7%)<a class="Sup" href="#footnote-12">&sect;</a></td>          </tr>         </tbody>        </table>      </div>      </div>     </div>    </div>   </div>   <div class="Section" data-sectioncode="49489-8">    <a name="S12.4"></a>   <a name="section-12.4"></a>    <p></p>    <h2>12.4 Microbiology</h2>    <div class="Section" data-sectioncode="42229-5">     <a name="section-12.4.1"></a>     <p></p>     <p class="First"> <span class="Italics">Mechanism of Action</span> </p>     <p>Saquinavir is an inhibitor of HIV-1 protease. HIV-1 protease is an enzyme required for the proteolytic cleavage of viral polyprotein precursors into individual functional proteins found in HIV-1 particles. Saquinavir is a peptide-like substrate analogue that binds to the protease active site and inhibits the activity of the enzyme. Saquinavir inhibition prevents cleavage of the viral polyproteins resulting in the formation of immature noninfectious viral particles.</p>    </div>    <div class="Section" data-sectioncode="42229-5">     <a name="section-12.4.2"></a>     <p></p>     <p class="First"> <span class="Italics">Antiviral Activity</span> </p>     <p>The antiviral activity of saquinavir was assessed in lymphoblastoid and monocytic cell lines and in peripheral blood lymphocytes in cell culture. Saquinavir inhibited HIV-1 activity in both acutely and chronically infected cells. EC<span class="Sub">50</span> and EC<span class="Sub">90</span> values (50% and 90% inhibitory concentrations) ranged from 1 to 30 nM and 5 to 80 nM, respectively. In the presence of 40% human serum, the mean EC<span class="Sub">50</span> of saquinavir against laboratory strain HIV-1 RF in MT4 cells was 37.7&plusmn; 5 nM representing a 4-fold increase in the EC<span class="Sub">50</span> value. In cell culture, saquinavir demonstrated additive to synergistic effects against HIV-1 in combination with reverse transcriptase inhibitors (didanosine, lamivudine, nevirapine, stavudine and zidovudine) without enhanced cytotoxicity. Saquinavir in combination with the protease inhibitors amprenavir, atazanavir, or lopinavir resulted in synergistic antiviral activity. Saquinavir displayed antiviral activity in cell culture against HIV-1 clades A-H (EC<span class="Sub">50</span> values ranged from 0.9 to 2.5 nM). The EC<span class="Sub">50 and</span> EC<span class="Sub">90</span> values of saquinavir against HIV-2 isolates in cell culture ranged from 0.25 nM to 14.6 nM and 4.65 nM to 28.6 nM, respectively.</p>    </div>    <div class="Section" data-sectioncode="42229-5">     <a name="section-12.4.3"></a>     <p></p>     <p class="First"> <span class="Italics">Resistance</span> </p>     <p>HIV-1 isolates with reduced susceptibility to saquinavir have been selected during passage in cell culture. Genotypic analyses of these isolates showed several amino acid substitutions in the HIV-1 protease. Only the G48V and L90M substitutions were associated with reduced susceptibility to saquinavir, and conferred an increase in the EC<span class="Sub">50</span> value of 8- and 3-fold, respectively.</p>     <p>HIV-1 isolates with reduced susceptibility (≥4-fold increase in the EC<span class="Sub">50</span> value) to saquinavir emerged in some subjects treated with INVIRASE. Genotypic analysis of these isolates identified resistance conferring primary amino acid substitutions in the protease G48V and L90M, and secondary substitutions L10I/R/V, I54V/L, A71V/T, G73S, V77I, V82A and I84V that contributed additional resistance to saquinavir. Forty-one isolates from 37 subjects failing therapy with INVIRASE had a median decrease in susceptibility to saquinavir of 4.3-fold.</p>     <p>The degree of reduction in cell culture susceptibility to saquinavir of clinical isolates bearing substitutions G48V and L90M depends on the number of secondary substitutions present. In general, higher levels of resistance are associated with greater number of substitutions only in association with either or both of the primary substitutions G48V and L90M. No data are currently available to address the development of resistance in patients receiving saquinavir/ritonavir.</p>    </div>    <div class="Section" data-sectioncode="42229-5">     <a name="section-12.4.4"></a>     <p></p>     <p class="First"> <span class="Italics">Cross-resistance</span> </p>     <p>Among protease inhibitors, variable cross-resistance has been observed. In one clinical study, 22 HIV-1 isolates with reduced susceptibility (&gt;4-fold increase in the EC<span class="Sub">50</span> value) to saquinavir following therapy with INVIRASE were evaluated for cross-resistance to amprenavir, indinavir, nelfinavir and ritonavir. Six of the 22 isolates (27%) remained susceptible to all 4 protease inhibitors, 12 of the 22 isolates (55%) retained susceptibility to at least one of the protease inhibitors and 4 out of the 22 isolates (18%) displayed broad cross-resistance to all protease inhibitors. Sixteen (73%) and 11 (50%) of the 22 isolates remained susceptible (&lt;4-fold) to amprenavir and indinavir, respectively. Four of 16 (25%) and nine of 21 (43%) with available data remained susceptible to nelfinavir and ritonavir, respectively.</p>     <p>After treatment failure with amprenavir, cross-resistance to saquinavir was evaluated. HIV-1 isolates from 22/22 subjects failing treatment with amprenavir and containing one or more substitutions M46L/I, I50V, I54L, V32I, I47V, and I84V were susceptible to saquinavir.</p>    </div>   </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">13 NONCLINICAL TOXICOLOGY</a> <div class="Section toggle-content closed" data-sectioncode="43680-8">   <a name="S13"></a>  <a name="section-13"></a>   <p></p>    <div class="Section" data-sectioncode="34083-6">    <a name="S13.1"></a>   <a name="section-13.1"></a>    <p></p>    <h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>    <div class="Section" data-sectioncode="42229-5">     <a name="section-13.1.1"></a>     <p></p>     <p class="First"> <span class="Italics">Carcinogenesis</span> </p>     <p>Carcinogenicity studies found no indication of carcinogenic activity in rats and mice administered saquinavir for approximately 2 years. Because of limited bioavailability of saquinavir in animals, the plasma exposures (AUC values<span class="Italics">)</span> in the respective species were approximately 29% (using rat) and 65% (using mouse) of those obtained in humans at the recommended clinical dose boosted with ritonavir.</p>    </div>    <div class="Section" data-sectioncode="42229-5">     <a name="section-13.1.2"></a>     <p></p>     <p class="First"> <span class="Italics">Mutagenesis</span> </p>     <p>Mutagenicity and genotoxicity studies, with and without metabolic activation where appropriate, have shown that saquinavir has no mutagenic activity in vitro in either bacterial (Ames test) or mammalian cells (Chinese hamster lung V79/HPRT test). Saquinavir does not induce chromosomal damage in vivo in the mouse micronucleus assay or in vitro in human peripheral blood lymphocytes, and does not induce primary DNA damage in vitro in the unscheduled DNA synthesis test.</p>    </div>    <div class="Section" data-sectioncode="42229-5">     <a name="section-13.1.3"></a>     <p></p>     <p class="First"> <span class="Italics">Impairment of Fertility</span> </p>     <p>No adverse effects were reported in fertility and reproductive performance study conducted in rats. Because of limited bioavailability of saquinavir in animals, the maximal plasma exposures achieved in rats were approximately 26% of those obtained in humans at the recommended clinical dose boosted with ritonavir.</p>    </div>   </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">14 CLINICAL STUDIES</a> <div class="Section toggle-content closed" data-sectioncode="34092-7">   <a name="S14"></a>  <a name="section-14"></a>   <p></p>    <div class="Section" data-sectioncode="42229-5">    <a name="S14.1"></a>   <a name="section-14.1"></a>    <p></p>    <h2>14.1 Description of Clinical Studies in Adults</h2>    <p class="First">In a randomized, double-blind clinical study NV14256 in zidovudine-experienced, HIV-1-infected adult subjects, INVIRASE in combination with zalcitabine<a class="Sup" href="#footnote-13" name="footnote-reference-13">2</a> was shown to be superior to either INVIRASE or zalcitabine monotherapy in decreasing the cumulative incidence of clinical disease progression to AIDS-defining events or death. In another randomized study ACTG229/NV14255, subjects with advanced HIV-1 infection with history of prolonged zidovudine treatment were administered INVIRASE 600 mg (three times daily) + zidovudine + zalcitabine. Subjects receiving this regimen experienced greater increases in CD4<span class="Sup">+ </span>cell counts as compared to those who received INVIRASE + zidovudine or zalcitabine + zidovudine. It should be noted the HIV treatment regimens that were used in these clinical trials are no longer considered standard of care.</p>    <p>In the MaxCmin1 trial, saquinavir gel capsule 1000 mg twice daily coadministered with ritonavir 100 mg twice daily was evaluated in a heterogeneous population of 148 HIV-1-infected subjects. A total of 42 subjects enrolled were treatment na&iuml;ve, and 106 subjects were treatment experienced (of which 52 subjects had HIV-1 RNA &lt; 400 copies/mL at baseline). Results showed that 91/148 (61%) subjects achieved and/or sustained an HIV-1 RNA &lt;400 copies per mL at the completion of 48 weeks treatment.</p>    <hr class="Footnoterule" />    <dl class="Footnote">     <dt>      <a href="#footnote-reference-13" name="footnote-13">2</a>     </dt>     <dd>     No longer available in the US.    </dd>    </dl>   </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">16 HOW SUPPLIED/STORAGE AND HANDLING</a> <div class="Section toggle-content closed" data-sectioncode="34069-5">   <a name="S16"></a>  <a name="section-15"></a>   <p></p>    <p class="First">INVIRASE 200-mg capsules are light brown and green opaque capsules with ROCHE and 0245 imprinted on the capsule shell—bottles of 270 (NDC 0004-0245-15).</p>   <p>INVIRASE 500-mg film-coated tablets are light orange to greyish- or brownish-orange, oval cylindrical, biconvex tablets with ROCHE and SQV 500 imprinted on the tablet face—bottles of 120 (NDC 0004-0244-51).</p>   <div class="Section" data-sectioncode="44425-7">    <a name="section-15.1"></a>    <p></p>    <p class="First">The capsules and tablets should be stored at 25&deg;C (77&deg;F); excursions permitted to 15&deg; to 30&deg;C (59&deg; to 86&deg;F) [see USP Controlled Room Temperature] in tightly closed bottles.</p>   </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">17 PATIENT COUNSELING INFORMATION</a> <div class="Section toggle-content closed" data-sectioncode="34076-0">   <a name="S17"></a>  <a name="section-16"></a>   <p></p>    <ul class="Disc">    <li>Advise the patient to read the FDA-approved patient labeling (Medication Guide).</li>   </ul>   <p class="First">A statement to patients and health care providers is included on the product's bottle label: <span class="Bold">ALERT: Find out about medicines that should NOT be taken with INVIRASE.</span> </p>   <p>INVIRASE is not a cure for HIV-1 infection and patients may continue to experience illnesses associated with HIV-1 infection, including opportunistic infections. Patients should remain under the care of a physician when using INVIRASE.</p>   <p>Patients should be advised to avoid doing things that can spread HIV-1 infection to others.</p>   <ul class="Disc">    <li> <span class="Bold">Do not share needles or other injection equipment.</span> </li>    <li> <span class="Bold">Do not share personal items that can have blood or body fluids on them, like toothbrushes and razor blades.</span> </li>    <li> <span class="Bold">Do not have any kind of sex without protection. </span>Always practice safe sex by using a latex or polyurethane condom to lower the chance of sexual contact with semen, vaginal secretions, or blood.</li>    <li> <span class="Bold">Do not breastfeed. </span>We do not know if INVIRASE can be passed to your baby in your breast milk and whether it could harm your baby. Also, mothers with HIV-1 should not breastfeed because HIV-1 can be passed to the baby in the breast milk.</li>   </ul>   <div class="Section" data-sectioncode="42229-5">    <a name="section-16.1"></a>    <p></p>    <p class="First"> <span class="Bold">Pregnancy</span> </p>    <p>An Antiretroviral Pregnancy Registry has been established. See <span class="Italics"><a href="#S8.1">Pregnancy (8.1)</a></span> for information on how to enroll.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="section-16.2"></a>    <p></p>    <p class="First"> <span class="Bold">Drug Interactions</span> </p>    <p>INVIRASE may interact with some drugs; therefore, advise patients to report to their doctor the use of any other prescription, nonprescription medication, or herbal products, particularly St. John's wort.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="section-16.3"></a>    <p></p>    <p class="First"> <span class="Bold">PR and QT Interval Prolongation</span> </p>    <p>Inform patients that INVIRASE may produce changes in the electrocardiogram (PR interval or QT interval prolongation). Patients should consult their health care provider if they are experiencing symptoms such as dizziness, lightheadedness, or palpitations.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="section-16.4"></a>    <p></p>    <p class="First"> <span class="Bold">Fat Redistribution</span> </p>    <p>Inform patients that redistribution or accumulation of body fat may occur in patients receiving protease inhibitors and that the cause and long-term health effects of these conditions are not known at this time.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="section-16.5"></a>    <p></p>    <p class="First"> <span class="Bold">Dosing Instructions</span> </p>    <p>Advise patients that <span class="Bold">INVIRASE must be used in combination with ritonavir, which significantly inhibits saquinavir's metabolism to provide increased plasma saquinavir levels.</span> </p>    <p>Advise patients that INVIRASE administered with ritonavir should be taken within 2 hours after a full meal <span class="Italics">[see <a href="#S12.3">Clinical Pharmacology (12.3)</a>]</span>. When INVIRASE is taken without food, concentrations of saquinavir in the blood are substantially reduced and may result in no antiviral activity. Advise patients of the importance of taking their medication every day, as prescribed, to achieve maximum benefit. Patients should not alter the dose or discontinue therapy without consulting their physician. If a dose is missed, patients should take the next dose as soon as possible. However, the patient should not double the next dose.</p>   </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">MEDICATION GUIDE</a> <div class="Section toggle-content closed" data-sectioncode="42231-1">   <a name="medguide"></a>  <a name="section-17"></a>   <p></p>   <p class="First"> <span class="Bold">Medication Guide</span> </p>   <p> <span class="Bold">INVIRASE<span class="Sup">&reg;</span> (in-ver-ase)</span> </p>   <p> <span class="Bold">(saquinavir mesylate)</span> </p>   <p> <span class="Bold">Capsules and Tablets</span> </p>   <p>Read this Medication Guide before you start taking INVIRASE and each time you get a refill. There may be new information. This Medication Guide does not take the place of talking to your healthcare provider about your medical condition or treatment. You and your healthcare provider should talk about your treatment with INVIRASE before you start taking it and at regular checkups. You should stay under a healthcare provider's care when taking INVIRASE.</p>   <p> <span class="Bold">Also read the Medication Guide for ritonavir (Norvir).</span> </p>   <p> <a name="important_info"></a><span class="Bold">What is the most important information I should know about INVIRASE?</span> </p>   <ul>    <li> <span class="Bold">INVIRASE must be taken along with ritonavir (Norvir).</span> </li>   </ul>   <p> <span class="Bold">INVIRASE may cause serious side effects including: </span> </p>   <ul>    <li> <span class="Bold">Interactions with other medicines. </span>It is important to know the medicines that should not be taken with INVIRASE. Read the section &quot;<a href="#healthcare">What should I tell my healthcare provider before taking INVIRASE?</a>&quot;</li>    <li> <span class="Bold">Changes in your heart rhythm and the electrical activity of your heart. </span>These changes may be seen on an EKG (electrocardiogram) and can lead to serious heart problems. Your risk for these problems may be higher if you:    <ul class="Disc">      <li>already have a history of abnormal heart rhythm, including Congenital Long QT Syndrome, or other types of heart disease.</li>      <li>take other medicines that can affect your heart rhythm while you take INVIRASE.</li>     </ul> </li>   </ul>   <p>Tell your healthcare provider right away if you have any of these symptoms while taking INVIRASE:</p>   <ul>    <li>dizziness</li>    <li>lightheadedness</li>    <li>fainting</li>    <li>sensation of abnormal heartbeats</li>   </ul>   <p> <span class="Bold">See the section below &quot;<a href="#possible_side">What are the possible side effects of INVIRASE?</a>&quot; for more information about serious side effects. </span> </p>   <p> <span class="Bold">What is INVIRASE?</span> </p>   <p>INVIRASE is a prescription anti-HIV medicine used in people over 16 years of age. HIV-1 is the virus that causes AIDS (Acquired Immune Deficiency Syndrome). INVIRASE is a type of HIV-1 medicine called a protease inhibitor. INVIRASE is used with ritonavir and other anti-HIV medicines to treat people with human immunodeficiency virus (HIV-1) infection.</p>   <p>When used with other HIV-1 medicines, INVIRASE may help to reduce the amount of HIV-1 in your blood (called &quot;viral load&quot;). INVIRASE may also help to increase the number of white blood cells called CD4 (T) cell which help fight off other infections. Reducing the amount of HIV-1 and increasing the CD4 (T) cell count may improve your immune system. This may reduce your risk of death or infections (opportunistic infections) that can happen when your immune system is weak.</p>   <p>In children, INVIRASE doses that are both effective and safe could not be determined.</p>   <p> <span class="Bold">INVIRASE does not cure HIV-1 infection or AIDS. </span>People taking INVIRASE may develop infections or other conditions associated with HIV-1 infection, including opportunistic infections (for example, pneumonia and herpes virus infections).</p>   <p>Avoid doing things that can spread HIV-1 infection to others:</p>   <ul>    <li> <span class="Bold">Do not share needles or other injection equipment. </span> </li>    <li> <span class="Bold">Do not share personal items that can have blood or body fluids on them, like toothbrushes and razor blades. </span> </li>    <li> <span class="Bold">Do not have any kind of sex without protection. </span>Always practice safe sex by using a latex or polyurethane condom to lower the chance of sexual contact with semen, vaginal secretions, or blood.</li>   </ul>   <p> <span class="Bold">Who should not take INVIRASE?</span> </p>   <p> <span class="Bold">Do not take INVIRASE if you take any of the following medicines or have the following conditions:</span> </p>   <ul>    <li>your healthcare provider has told you that you have a condition called Congenital Long QT Syndrome.</li>    <li>your healthcare provider has told you that you have complete AV (atrioventricular) block and you do not have a pacemaker or you are at risk for complete AV block.</li>    <li>your healthcare provider has told you that you have low potassium or low magnesium in your blood.</li>    <li>you have severe liver problems.</li>    <li>you have had a severe allergic reaction to saquinavir mesylate or any of the ingredients in INVIRASE. See the end of this Medication Guide for a complete list of ingredients in INVIRASE.</li>   </ul>   <p> <span class="Bold">Talk to your healthcare provider before taking INVIRASE if you have any of the conditions listed above.</span> </p>   <p> <span class="Bold">Taking INVIRASE with certain other medicines can cause serious problems or life threatening reactions. </span> </p>   <p> <span class="Bold"><span class="Underline">Do not take INVIRASE/ritonavir (Norvir) if you take any of the following medicines: </span></span> </p>   <ul class="Disc">    <li>alfuzosin (Uroxatral<span class="Sup">&reg;</span>)</li>    <li>amiodarone (Cordarone<span class="Sup">&reg;</span>, Pacerone<span class="Sup">&reg;</span>)</li>    <li>bepridil</li>    <li>cisapride</li>    <li>dofetilide (Tikosyn<span class="Sup">&reg;</span>)</li>    <li>Ergot containing medicines, including:    <ul class="Disc">      <li>dihydroergotamine mesylate (D.H.E. 45, Embolex, Migranal )</li>      <li>ergonovine, ergonovine and methylergonovine (Ergotrate, Methergine), ergotamine and methylergonovine</li>      <li>ergotamine tartrate (Cafergot, Migergot, Ergomar, Ergostate Medhaler Ergotamine, Wigraine Wigrettes)</li>     </ul> </li>    <li>flecainide (Tambocor<span class="Sup">&reg;</span>)</li>    <li>lidocaine</li>    <li>lovastatin (Advicor<span class="Sup">&reg;</span>, Altoprev<span class="Sup">&reg;</span>, Mevacor<span class="Sup">&reg;</span>)</li>    <li>midazolam hydrochloride oral syrup</li>    <li>pimozide (Orap<span class="Sup">&reg;</span>)</li>    <li>propafenone (Rhythmol<span class="Sup">&reg;</span>)</li>    <li>quinidine</li>    <li>rifampin (Rifadin<span class="Sup">&reg;</span>, Rifamate<span class="Sup">&reg;</span>, Rifater<span class="Sup">&reg;</span>, Rimactane<span class="Sup">&reg;</span>)</li>    <li>sildenafil (Revatio<span class="Sup">&reg;</span>)</li>    <li>simvastatin (Simcor<span class="Sup">&reg;</span>, Vytorin<span class="Sup">&reg;</span>, Zocor<span class="Sup">&reg;</span>)</li>    <li>trazodone (Oleptro<span class="Sup">&reg;</span>)</li>    <li>triazolam (Halcion<span class="Sup">&reg;</span>)</li>   </ul>   <p> <span class="Bold"><span class="Underline">Talk to your healthcare provider before taking INVIRASE if you take any of the medications listed above.</span></span> </p>   <p> <a name="healthcare"></a><span class="Bold">What should I tell my healthcare provider before taking INVIRASE?</span> </p>   <p>INVIRASE may not be right for you. Before you take INVIRASE, tell your healthcare provider if you:</p>   <ul class="Disc">    <li>have any heart problems, including a condition called Congenital Long QT Syndrome.</li>    <li>have diabetes.</li>    <li>have liver problems, including Hepatitis B or Hepatitis C.</li>    <li>have hemophilia. People who take INVIRASE may have increased bleeding.</li>    <li>are pregnant or plan to become pregnant. It is not known if INVIRASE will harm your unborn baby.<p class="First"> <span class="Bold">Antiretroviral Pregnancy Registry</span>. If you take INVIRASE during pregnancy, talk with your healthcare provider about how you can take part in an antiretroviral pregnancy registry. The purpose of the pregnancy registry is to collect information about the health of you and your baby.</p> </li>    <li>are breastfeeding or plan to breastfeed<span class="Bold">. Do not breastfeed. </span>We do not know if INVIRASE can be passed to your baby in your breast milk and whether it could harm your baby. Also, mothers with HIV-1 should not breastfeed because HIV-1 can be passed to the baby in the breast milk.</li>   </ul>   <p> <span class="Bold">Tell your healthcare provider about all the medicines you take, </span>including prescriptions and non-prescriptions medicines, vitamins and herbal supplements. INVIRASE may affect the way other medicines work, and other medicines may affect how INVIRASE works. Do not start taking a new medicine without talking with your healthcare provider or pharmacist. Your healthcare provider can tell you if it is safe to take INVIRASE with other medicines.</p>   <p> <span class="Bold">Especially tell your healthcare provider if you take:</span> </p>   <ul class="Disc">    <li>medicines to lower cholesterol</li>    <li>medicines to treat depression</li>    <li>medicines to prevent organ transplant rejection</li>    <li>oral contraceptives containing ethinyl estradiol used for preventing pregnancy</li>    <li>any of the following medicines:    <ul class="Circle">      <li>alprazolam (Xanax<span class="Sup">&reg;</span>)</li>      <li>amlodipine-containing medications (such as Caduet<span class="Sup">&reg;</span>, Norvasc<span class="Sup">&reg;</span>)</li>      <li>amitriptyline (Elavil<span class="Sup">&reg;</span>)</li>      <li>atazanavir (Reyataz<span class="Sup">&reg;</span>)</li>      <li>atorvastatin (Lipitor<span class="Sup">&reg;</span>)</li>      <li>bosentan (Tracleer<span class="Sup">&reg;</span>)</li>      <li>carbamazepine (Carbatrol<span class="Sup">&reg;</span>, Tegretol<span class="Sup">&reg;</span>)</li>      <li>clarithromycin (Biaxin<span class="Sup">&reg;</span>)</li>      <li>clorazepate (Tranxene<span class="Sup">&reg;</span>)</li>      <li>colchicine (Colcrys<span class="Sup">&reg;</span>)</li>      <li>cyclosporine (Sandimmune<span class="Sup">&reg;</span>), (Neoral<span class="Sup">&reg;</span>)</li>      <li>diazepam (Valium<span class="Sup">&reg;</span>)</li>      <li>delavirdine (Rescriptor<span class="Sup">&reg;</span>)</li>      <li>dexamethasone</li>      <li>diltiazem (Cardizem<span class="Sup">&reg;</span>, Cartia XT<span class="Sup">&reg;</span>, Dilacor XR<span class="Sup">&reg;</span>, Diltzac<span class="Sup">&reg;</span>, Taztia XT<span class="Sup">&reg;</span>, Tiazac<span class="Sup">&reg;</span>)</li>      <li>digoxin (Lanoxin<span class="Sup">&reg;</span>)</li>      <li>efavirenz (Sustiva<span class="Sup">&reg;</span>)</li>      <li>ethinyl estradiol</li>      <li>felodipine (Plendil<span class="Sup">&reg;</span>)</li>      <li>flurazepam (Dalmane<span class="Sup">&reg;</span>)</li>      <li>fluticasone propionate (Flonase<span class="Sup">&reg;</span>, Flovent<span class="Sup">&reg;</span>, Advair<span class="Sup">&reg;</span>), given by nose or inhaled to treat allergic symptoms or asthma</li>      <li>fusidic acid</li>      <li>Garlic capsules, an herbal product sold as a dietary supplement</li>      <li>imipramine (Tofranil<span class="Sup">&reg;</span>) </li>      <li>indinavir (Crixivan<span class="Sup">&reg;</span>)</li>      <li>isradipine (Dynacirc<span class="Sup">&reg;</span>)</li>      <li>itraconazole (Sporanox<span class="Sup">&reg;</span>) </li>      <li>ketoconazole (Nizoral<span class="Sup">&reg;</span>)</li>      <li>methadone</li>      <li>nevirapine (Viramune<span class="Sup">&reg;</span>)</li>      <li>nicardipine (Cardene<span class="Sup">&reg;</span>)</li>      <li>nifedipine (Procardia<span class="Sup">&reg;</span>)</li>      <li>nimodipine (Nimotop<span class="Sup">&reg;</span>)</li>      <li>nisoldipine (Sular<span class="Sup">&reg;</span>)</li>      <li>omeprazole (Prilosec<span class="Sup">&reg;</span>)</li>      <li>phenobarbital</li>      <li>phenytoin (Dilantin<span class="Sup">&reg;</span>)</li>      <li>quetiapine (Seroquel<span class="Sup">&reg;</span>)</li>      <li>rapamycin</li>      <li>rifabutin (Mycobutin<span class="Sup">&reg;</span>)</li>      <li>ritonavir (Norvir<span class="Sup">&reg;</span>)</li>      <li>rosuvastatin (Crestor<span class="Sup">&reg;</span>)</li>      <li>sirolimus (Rapamune<span class="Sup">&reg;</span>)</li>      <li>St. John's wort (Hypericum perforatum) or herbal supplement products containing St. John's wort</li>      <li>tacrolimus (Prograf<span class="Sup">&reg;</span>)</li>      <li>tadalafil (Adcirca<span class="Sup">&reg;</span>) used to treat pulmonary arterial hypertension</li>      <li>tadalafil (Cialis<span class="Sup">&reg;</span>), sildenafil citrate (Viagra<span class="Sup">&reg;</span>), or vardenafil (Levitra<span class="Sup">&reg;</span>), for the treatment of erectile dysfunction</li>      <li>tipranavir (Aptivus<span class="Sup">&reg;</span>) </li>      <li>trazodone (Desyrel<span class="Sup">&reg;</span>)</li>      <li>verapamil-containing medications (such as Calan<span class="Sup">&reg;</span>, Verelan<span class="Sup">&reg;</span>)</li>      <li>warfarin (Coumadin<span class="Sup">&reg;</span>, Jantoven<span class="Sup">&reg;</span>)</li>     </ul> </li>   </ul>   <p> <span class="Bold">Ask your healthcare provider or pharmacist for a list of these medicines, if you are not sure. </span> </p>   <p>Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.</p>   <p> <span class="Bold">How should I take INVIRASE?</span> </p>   <ul>    <li>Take INVIRASE exactly as your healthcare provider tells you.</li>    <li>INVIRASE comes as a 500 mg tablet or a 200 mg capsule.</li>    <li>Do not change your dose of INVIRASE or stop treatment without first talking with your healthcare provider.</li>    <li>INVIRASE must be used along with ritonavir (Norvir).</li>    <li>Take INVIRASE up to 2 hours after a meal.</li>    <li>Do not miss a dose of INVIRASE. It is very important to take your medicine every day. If you skip doses or take less than the prescribed dose the medicine will not work as well, and the virus may become harder to treat.</li>    <li>If you miss a dose of INVIRASE, you should take the next dose as soon as possible. Do not double your dose.</li>    <li>If you take more than your prescribed dose of INVIRASE, call your healthcare provider or go to the nearest hospital emergency room right away.</li>    <li> If you are unable to swallow INVIRASE capsules whole, you may open the capsule and mix the contents with sugar syrup or jam. People with type 1 diabetes or glucose intolerance should use sorbitol syrup.    <ul class="Disc">      <li>Use a medicine cup to measure 15 mL of the syrup or jam into a container. You can ask your pharmacist for a medicine cup if you do not have one.</li>      <li>Open the capsule and pour the contents into the container with the syrup or jam.</li>      <li>Mix with a spoon for 30 to 60 seconds.</li>      <li>Let the mixture come to room temperature.</li>      <li>Eat the entire mixture. Be sure to take the full dose.</li>     </ul> </li>   </ul>   <p> <a name="possible_side"></a><span class="Bold">What are the possible side effects of INVIRASE?</span> </p>   <p> <span class="Bold">INVIRASE can cause serious side effects. </span> </p>   <ul>    <li>See <span class="Bold">&quot;<a href="#important_info">What is the most important information I should know about INVIRASE?</a>&quot;</span> </li>    <li> <span class="Bold">Diabetes and high blood sugar. </span>Some people who take protease inhibitors including INVIRASE get new or more serious diabetes, or high blood sugar. Tell your healthcare provider if you notice an increase in thirst or urinate more often than normal while taking INVIRASE.</li>    <li> <span class="Bold">Liver problems. </span>People with liver problems such as Hepatitis B or C, cirrhosis or have a history of alcoholism may have worsening liver problems.<p class="First">Tell your healthcare provider right away if you have any of these signs and symptoms of liver problems:</p>     <ul class="Disc">      <li>loss of appetite</li>      <li>yellowing of your skin or whites of your eyes (jaundice)</li>      <li>dark-colored urine</li>      <li>pale colored stools</li>      <li>itchy skin</li>      <li>stomach area (abdominal) pain</li>     </ul> </li>    <li> <span class="Bold">Increased bleeding in people with hemophilia. </span>Some people with hemophilia have increased bleeding with protease inhibitors including INVIRASE.</li>    <li> <span class="Bold">Increase in certain fat (cholesterol and triglycerides) levels in your blood. </span>Your healthcare provider will check your blood for high levels of cholesterol and triglycerides before you start INVIRASE and during treatment with INVIRASE.</li>    <li> <span class="Bold">Changes in body fat can happen in people who take HIV-1 medicine. </span>These changes may include increased amount of fat in the upper back and neck (&quot;buffalo hump&quot;), breasts, and around the middle of your body (trunk). Loss of fat from the legs, arms and face may also happen. The cause and long-term health effects of these conditions are not known at this time.</li>    <li> <span class="Bold">Immune System Changes (Immune Reconstitution Syndrome) </span>can happen when you start taking HIV medicines. Your immune system may get stronger and begin to fight infections that have been hidden in your body for a long time. Tell your healthcare provider if you start having new or worse symptoms of infection after starting your HIV-1 medicine.</li>   </ul>   <p> <span class="Bold">Common side effects of INVIRASE include:</span> </p>   <ul>    <li>nausea</li>    <li>vomiting</li>    <li>diarrhea</li>    <li>stomach area (abdominal) pain</li>    <li>tiredness</li>    <li>pneumonia</li>    <li>changes in body fat </li>   </ul>   <p>Tell your healthcare provider if you have any side effect that bothers you or that does not go away.</p>   <p>These are not all of the possible side effects of INVIRASE. For more information, ask your healthcare provider or pharmacist.</p>   <p>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</p>   <p>You may also report side effects to Genentech at 1-800-835-2555.</p>   <p> <span class="Bold">How should I store INVIRASE?</span> </p>   <ul>    <li>Store INVIRASE at room temperature between 68&deg;F to 77&deg;F (20&deg;C to 25&deg;C).</li>    <li>Keep INVIRASE in a tightly closed container.</li>   </ul>   <p> <span class="Bold">Keep INVIRASE and all medicine out of the reach of children.</span> </p>   <p> <span class="Bold">General information about INVIRASE</span> </p>   <p>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use INVIRASE for a condition for which it was not prescribed. Do not give INVIRASE to other people, even if they have the same symptoms that you have. It may harm them.</p>   <p>This Medication Guide summarizes the most important information about INVIRASE. If you would like more information, talk with your healthcare provider. You can ask your pharmacist or healthcare provider for information about INVIRASE that is written for health professionals.</p>   <p>For more information, go to http://www.gene.com/gene/products/information/invirase or call 1-877-436-3683.</p>   <p> <span class="Bold">What are the ingredients in INVIRASE?</span> </p>   <p>Active ingredient: saquinavir mesylate</p>   <p>Inactive ingredients:</p>   <p>200 mg Capsule: lactose, microcrystalline cellulose, povidone K30, sodium starch glycolate, talc, and magnesium stearate.</p>   <p>Capsule shell: gelatin and water with the following dye systems: red iron oxide, yellow iron oxide, black iron oxide, FD&amp;C Blue #2, and titanium dioxide.</p>   <p>500 mg Tablet: lactose, microcrystalline cellulose, povidone K30, croscarmellose sodium, and magnesium stearate.</p>   <p>Film coat: hypromellose, titanium dioxide, talc, iron oxide yellow, iron oxide red, and triacetin.</p>   <p>The brands listed are trademarks of their respective owners and are not trademarks of Roche Laboratories, Inc. The makers of these brands are not affiliated with and do not endorse Roche Laboratories, Inc. or its products.</p>   <p>INVIRASE is a registered trademark of Hoffmann-La Roche Inc.</p>   <p> <span class="Bold">This Medication Guide has been approved by the U.S. Food and Drug Administration.</span> </p>   <p>Capsules Manufactured by:</p>   <p>Roche Farma, S.A., Leganes, Spain</p>   <p>Tablets Manufactured by:</p>   <p>Roche Farma, S.A., Leganes, Spain</p>   <p>Distributed by:</p>   <p> <span class="Bold">Genentech USA, Inc.</span> <br />A Member of the Roche Group <br />1 DNA Way <br />South San Francisco, CA 94080-4990</p>   <p>Revised: April 2015</p>   <p>&copy; 2015 Genentech, Inc. All rights reserved.</p>   <p>Representative sample of labeling (see the <a href="#S16">HOW SUPPLIED</a> section for complete listing):</p>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">PRINCIPAL DISPLAY PANEL - 500 mg Tablet Bottle Label</a> <div class="Section toggle-content closed" data-sectioncode="51945-4">   <a name="section-18"></a>   <p></p>    <p class="First">NDC 0004-0244-51</p>   <p> <span class="Bold">Invirase</span><span class="Sup">&reg;</span> <br />(saquinavir <br />mesylate) Tablets</p>   <p> <span class="Bold">500 mg</span> </p>   <p>Each tablet contains saquinavir mesylate <br />equivalent to 500 mg saquinavir (free base).</p>   <p> <span class="Bold">ALERT: Find out about medicines that <br />should NOT be taken with INVIRASE.</span> </p>   <p> <span class="Bold">Rx only</span> </p>   <p> <span class="Bold">Attention Pharmacist: Dispense the<br /> enclosed Medication Guide to each<br /> patient. Do not cover ALERT box with<br /> pharmacy label.</span> </p>   <p>120 tablets</p>   <p> <span class="Bold">Genentech</span> </p>   <p>10158427</p>   <div class="Figure">    <img src="image.cfm?setid=c00d1607-ac36-457b-a34b-75ad74f9cf0a&name=invirase%2D02%2Ejpg" alt="PRINCIPAL DISPLAY PANEL - 500 mg Tablet Bottle Label" />  </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">PRINCIPAL DISPLAY PANEL</a> <div class="Section toggle-content closed" data-sectioncode="51945-4">   <a name="section-19"></a>   <p></p>   <p class="First"> <span class="Bold">PRINCIPAL DISPLAY PANEL - 200 mg Bottle Label</span> </p>   <p>NDC 0004-0245-15</p>   <p> <span class="Bold">Invirase</span><span class="Sup">&reg;</span> <br />(saquinavir mesylate) <br />Capsules</p>   <p> <span class="Bold">200 mg</span> </p>   <p>Each capsule contains saquinavir<br /> mesylate equivalent to 200 mg<br /> saquinavir (free base).</p>   <p> <span class="Bold">Rx only</span> </p>   <p> <span class="Bold">ALERT: Find out about <br />medicines that should NOT be<br /> taken with INVIRASE.</span> </p>   <p> <span class="Bold">Attention Pharmacist: Dispense <br />the attached Medication Guide to<br /> each patient. Do not cover ALERT <br />box with pharmacy label.</span> </p>   <p>270 capsules</p>   <p> <span class="Bold">Genentech</span> </p>   <div class="Figure">    <img src="image.cfm?setid=c00d1607-ac36-457b-a34b-75ad74f9cf0a&name=invirase%2D03%2Ejpg" alt="PRINCIPAL DISPLAY PANEL - 200 mg Bottle Label" />  </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">INGREDIENTS AND APPEARANCE</a> <div class="DataElementsTables toggle-content">   <div class="scrollingtable">   <table width="100%" cellpadding="3" cellspacing="0" class="contentTablePetite">     <tbody>      <tr>       <td class="contentTableTitle"><strong>INVIRASE&nbsp; </strong> <br /> <span class="contentTableReg">saquinavir mesylate capsule</span></td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="5" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="4">Product Information</td>          </tr>          <tr class="formTableRowAlt">           <td class="formLabel">Product Type</td>          <td class="formItem">HUMAN PRESCRIPTION DRUG</td>          <td class="formLabel">Item Code (Source)</td>          <td class="formItem">NDC:0004-0245</td>          </tr>          <tr class="formTableRow">           <td class="formLabel" width="30%">Route of Administration</td>          <td class="formItem">ORAL</td>          <td class="formLabel" width="30%">DEA Schedule</td>          <td class="formItem">&nbsp;&nbsp;&nbsp;&nbsp;</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="3">Active Ingredient/Active Moiety</td>          </tr>          <tr>           <th scope="col" class="formTitle">Ingredient Name</th>          <th scope="col" class="formTitle">Basis of Strength</th>          <th scope="col" class="formTitle">Strength</th>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>saquinavir mesylate</strong> (UNII: UHB9Z3841A) (saquinavir - UNII:L3JE09KZ2F)</td>          <td class="formItem">saquinavir</td>          <td class="formItem">200&nbsp;mg</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="2">Inactive Ingredients</td>          </tr>          <tr>           <th scope="col" class="formTitle">Ingredient Name</th>          <th scope="col" class="formTitle">Strength</th>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>anhydrous lactose</strong> (UNII: 3SY5LH9PMK)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>cellulose, microcrystalline</strong> (UNII: OP1R32D61U)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>povidone K30</strong> (UNII: U725QWY32X)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>sodium starch glycolate type A potato</strong> (UNII: 5856J3G2A2)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>talc</strong> (UNII: 7SEV7J4R1U)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>magnesium stearate</strong> (UNII: 70097M6I30)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>gelatin</strong> (UNII: 2G86QN327L)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>ferric oxide red</strong> (UNII: 1K09F3G675)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>ferric oxide yellow</strong> (UNII: EX438O2MRT)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>ferrosoferric oxide</strong> (UNII: XM0M87F357)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>FD&amp;C Blue No. 2</strong> (UNII: L06K8R7DQK)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>titanium dioxide</strong> (UNII: 15FIX9V2JP)</td>          <td class="formItem">&nbsp;</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="4">Product Characteristics</td>          </tr>          <tr class="formTableRowAlt">           <td class="formLabel">Color</td>          <td class="formItem">BROWN,&nbsp;GREEN</td>          <td class="formLabel">Score</td>          <td class="formItem">no score</td>          </tr>          <tr class="formTableRow">           <td class="formLabel">Shape</td>          <td class="formItem">CAPSULE</td>          <td class="formLabel">Size</td>          <td class="formItem">22mm</td>          </tr>          <tr class="formTableRowAlt">           <td class="formLabel">Flavor</td>          <td class="formItem"></td>          <td class="formLabel">Imprint Code</td>          <td class="formItem">ROCHE;0245</td>          </tr>          <tr class="formTableRow">           <td class="formLabel">Contains</td>          <td class="formItem">&nbsp;&nbsp;&nbsp;&nbsp;</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="5">Packaging</td>          </tr>          <tr>           <th class="formTitle" width="1" scope="col">#</th>          <th class="formTitle" scope="col">Item Code</th>          <th class="formTitle" scope="col">Package Description</th>          <th class="formTitle" scope="col">Marketing Start Date</th>          <th class="formTitle" scope="col">Marketing End Date</th>          </tr>          <tr class="formTableRowAlt">           <th class="formItem" scope="row">1</th>          <td class="formItem">NDC:0004-0245-15</td>          <td class="formItem">270 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product</td>          <td class="formItem"></td>          <td class="formItem"></td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td></td>      </tr>      <tr>       <td class="normalizer">        <table class="formTableMorePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingReg" colspan="4"><span class="formHeadingTitle">Marketing Information</span></td>          </tr>          <tr>           <th class="formTitle" scope="col">Marketing Category</th>          <th class="formTitle" scope="col">Application Number or Monograph Citation</th>          <th class="formTitle" scope="col">Marketing Start Date</th>          <th class="formTitle" scope="col">Marketing End Date</th>          </tr>          <tr class="formTableRowAlt">           <td class="formItem">NDA</td>          <td class="formItem">NDA020628</td>          <td class="formItem">12/06/1995</td>          <td class="formItem"></td>          </tr>         </tbody>       </table> </td>      </tr>     </tbody>    </table>  </div>   <div class="scrollingtable">   <table width="100%" cellpadding="3" cellspacing="0" class="contentTablePetite">     <tbody>      <tr>       <td class="contentTableTitle"><strong>INVIRASE&nbsp; </strong> <br /> <span class="contentTableReg">saquinavir mesylate tablet, film coated</span></td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="5" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="4">Product Information</td>          </tr>          <tr class="formTableRowAlt">           <td class="formLabel">Product Type</td>          <td class="formItem">HUMAN PRESCRIPTION DRUG</td>          <td class="formLabel">Item Code (Source)</td>          <td class="formItem">NDC:0004-0244</td>          </tr>          <tr class="formTableRow">           <td class="formLabel" width="30%">Route of Administration</td>          <td class="formItem">ORAL</td>          <td class="formLabel" width="30%">DEA Schedule</td>          <td class="formItem">&nbsp;&nbsp;&nbsp;&nbsp;</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="3">Active Ingredient/Active Moiety</td>          </tr>          <tr>           <th scope="col" class="formTitle">Ingredient Name</th>          <th scope="col" class="formTitle">Basis of Strength</th>          <th scope="col" class="formTitle">Strength</th>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>saquinavir mesylate</strong> (UNII: UHB9Z3841A) (saquinavir - UNII:L3JE09KZ2F)</td>          <td class="formItem">saquinavir</td>          <td class="formItem">500&nbsp;mg</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="2">Inactive Ingredients</td>          </tr>          <tr>           <th scope="col" class="formTitle">Ingredient Name</th>          <th scope="col" class="formTitle">Strength</th>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>lactose monohydrate</strong> (UNII: EWQ57Q8I5X)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>povidone K30</strong> (UNII: U725QWY32X)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>croscarmellose sodium</strong> (UNII: M28OL1HH48)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>magnesium stearate</strong> (UNII: 70097M6I30)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>hypromelloses</strong> (UNII: 3NXW29V3WO)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>titanium dioxide</strong> (UNII: 15FIX9V2JP)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>talc</strong> (UNII: 7SEV7J4R1U)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>ferric oxide red</strong> (UNII: 1K09F3G675)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>triacetin</strong> (UNII: XHX3C3X673)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>cellulose, microcrystalline</strong> (UNII: OP1R32D61U)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>ferric oxide yellow</strong> (UNII: EX438O2MRT)</td>          <td class="formItem">&nbsp;</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="4">Product Characteristics</td>          </tr>          <tr class="formTableRowAlt">           <td class="formLabel">Color</td>          <td class="formItem">ORANGE (light orange to greyish-or brownish-orange)</td>          <td class="formLabel">Score</td>          <td class="formItem">no score</td>          </tr>          <tr class="formTableRow">           <td class="formLabel">Shape</td>          <td class="formItem">OVAL</td>          <td class="formLabel">Size</td>          <td class="formItem">18mm</td>          </tr>          <tr class="formTableRowAlt">           <td class="formLabel">Flavor</td>          <td class="formItem"></td>          <td class="formLabel">Imprint Code</td>          <td class="formItem">ROCHE;SQV;500</td>          </tr>          <tr class="formTableRow">           <td class="formLabel">Contains</td>          <td class="formItem">&nbsp;&nbsp;&nbsp;&nbsp;</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="5">Packaging</td>          </tr>          <tr>           <th class="formTitle" width="1" scope="col">#</th>          <th class="formTitle" scope="col">Item Code</th>          <th class="formTitle" scope="col">Package Description</th>          <th class="formTitle" scope="col">Marketing Start Date</th>          <th class="formTitle" scope="col">Marketing End Date</th>          </tr>          <tr class="formTableRowAlt">           <th class="formItem" scope="row">1</th>          <td class="formItem">NDC:0004-0244-51</td>          <td class="formItem">120 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product</td>          <td class="formItem"></td>          <td class="formItem"></td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td></td>      </tr>      <tr>       <td class="normalizer">        <table class="formTableMorePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingReg" colspan="4"><span class="formHeadingTitle">Marketing Information</span></td>          </tr>          <tr>           <th class="formTitle" scope="col">Marketing Category</th>          <th class="formTitle" scope="col">Application Number or Monograph Citation</th>          <th class="formTitle" scope="col">Marketing Start Date</th>          <th class="formTitle" scope="col">Marketing End Date</th>          </tr>          <tr class="formTableRowAlt">           <td class="formItem">NDA</td>          <td class="formItem">NDA021785</td>          <td class="formItem">12/17/2004</td>          <td class="formItem"></td>          </tr>         </tbody>       </table> </td>      </tr>     </tbody>    </table>  </div>   <div class="scrollingtable">   <table class="formTableMorePetite" cellspacing="0" cellpadding="3" width="100%">     <tbody>     <tr>       <td class="formHeadingReg" colspan="4"><span class="formHeadingTitle">Labeler -&nbsp;</span>Genentech, Inc. (080129000) </td>      </tr>     </tbody>   </table>  </div>   <div class="scrollingtable">   <table class="formTableMorePetite" cellspacing="0" cellpadding="3" width="100%">     <tbody>     <tr>       <td class="formHeadingReg" colspan="4"><span class="formHeadingTitle">Registrant -&nbsp;</span>Genentech, Inc. (080129000)</td>      </tr>     </tbody>   </table>  </div>   <div class="scrollingtable">   <table class="formTableMorePetite" cellspacing="0" cellpadding="3" width="100%">     <tbody>     <tr>       <td class="formHeadingReg" colspan="4"><span class="formHeadingTitle">Establishment</span></td>      </tr>      <tr>       <th class="formTitle" scope="col">Name</th>      <th class="formTitle" scope="col">Address</th>      <th class="formTitle" scope="col">ID/FEI</th>      <th class="formTitle" scope="col">Business Operations</th>      </tr>      <tr class="formTableRowAlt">       <td class="formItem">F. Hoffmann-La Roche Ltd</td>      <td class="formItem"></td>      <td class="formItem">482242971</td>      <td class="formItem">API MANUFACTURE(0004-0245, 0004-0244) , MANUFACTURE(0004-0245)</td>      </tr>     </tbody>   </table>  </div>   <div class="scrollingtable">   <table class="formTableMorePetite" cellspacing="0" cellpadding="3" width="100%">     <tbody>     <tr>       <td class="formHeadingReg" colspan="4"><span class="formHeadingTitle">Establishment</span></td>      </tr>      <tr>       <th class="formTitle" scope="col">Name</th>      <th class="formTitle" scope="col">Address</th>      <th class="formTitle" scope="col">ID/FEI</th>      <th class="formTitle" scope="col">Business Operations</th>      </tr>      <tr class="formTableRowAlt">       <td class="formItem">ROCHE FARMA SA</td>      <td class="formItem"></td>      <td class="formItem">462083082</td>      <td class="formItem">MANUFACTURE(0004-0245, 0004-0244) , PACK(0004-0244) , LABEL(0004-0244) , ANALYSIS(0004-0245, 0004-0244)</td>      </tr>     </tbody>   </table>  </div>   <div class="scrollingtable">   <table class="formTableMorePetite" cellspacing="0" cellpadding="3" width="100%">     <tbody>     <tr>       <td class="formHeadingReg" colspan="4"><span class="formHeadingTitle">Establishment</span></td>      </tr>      <tr>       <th class="formTitle" scope="col">Name</th>      <th class="formTitle" scope="col">Address</th>      <th class="formTitle" scope="col">ID/FEI</th>      <th class="formTitle" scope="col">Business Operations</th>      </tr>      <tr class="formTableRowAlt">       <td class="formItem">F. Hoffmann-La Roche Ltd</td>      <td class="formItem"></td>      <td class="formItem">485244961</td>      <td class="formItem">ANALYSIS(0004-0245)</td>      </tr>     </tbody>   </table>  </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li>                                            </ul>                                        <div class="control-nav">                                            <a class="open-all" href="#">View All Sections</a><a class="close-all" href="#">Close All Sections</a>                                        </div>                                        </div>                                    </div>                        </article>                       <div class="articlefooternav">                       <h2>Find additional resources</h2> <strong>(also available in the <a href="#leftmenu">left menu</a>)</strong>                                              <h3>Safety</h3>                       <p>                                                                                                                    <a href="/www.accessdata.fda.gov/scripts/medwatch/ " target="_blank">Report Adverse Events</a>,                                 <a href="http://www.fda.gov/Safety/Recalls/" target="_blank">FDA Safety Recalls</a>,                                 <a href="http://toxnet.nlm.nih.gov/cgi-bin/sis/search2/r?dbs+lactmed:@or+%28@na+%22saquinavir%22+%29" target="_blank">Presence in Breast Milk</a>                                                   </p>                       <h3>Related Resources</h3>                       <p>                                                                                          <a href="http://vsearch.nlm.nih.gov/vivisimo/cgi-bin/query-meta?v:project=medlineplus&query=saquinavir" target="_blank">Medline Plus</a>,                                                       <a href="/www.clinicaltrials.gov/ct/search?submit=Search&term=saquinavir" target="_blank">Clinical Trials</a>,                            <a href="#pubmed-menu" id="pubmed-bottom">PubMed</a>,                            <a href="http://www.drugbank.ca/search?utf8=%E2%9C%93&query=APRD00623&search_type=drugs&button=" target="_blank">Biochemical Data Summary</a>                                                  </p>                       <h3>More Info on this Drug</h3>                       <p>                            <a href="#modal-label-archives" class="modal-open">View Label Archives</a>,                             <a href="#modal-rx-norm" class="modal-open">RxNorm</a>,                             <a href="#modal-label-rss" class="modal-open">Get Label RSS Feed</a>                        </p>                    </div>                </div>                                <div class="divider"></div>            </div>        </div>        <!-- Label Archives Modal --><div class="mfp-hide modal" id="modal-label-archives">        <div class="modal-wrapper">        <header><h2>View Label Archives for this drug</h2></header>        <div class="top">        							    	    																																			    																	    	    	                             		       	                                                                                                                   <h3 class="long-title">INVIRASE- saquinavir mesylate capsule <br>INVIRASE- saquinavir mesylate tablet, film coated <br></h3>            <h4>Number of versions: 11</h4>        </div>        <div class="modal-content">                <table class="modal">                    <tbody><tr>                        <th>Published Date</th>                        <th>Version</th>                               <th>Files</th>                    </tr>                                        <tr>                        <td>May 7, 2015</td>                        <td>							                                16                             							(current)                         </td>                              <td>                        								                                                                                                                      <a download target="_blank" class="download-link" href="dailymed/getArchivalFile.cfm?archive_id=174224">download</a>                                                    </td>                    </tr>                                        <tr>                        <td>Apr 16, 2015</td>                        <td>							                                15                             							                        </td>                              <td>                        								                                                                                                                      <a download target="_blank" class="download-link" href="dailymed/getArchivalFile.cfm?archive_id=172213">download</a>                                                    </td>                    </tr>                                        <tr>                        <td>Dec 17, 2012</td>                        <td>							                                14                             							                        </td>                              <td>                        								                                                                                                                      <a download target="_blank" class="download-link" href="dailymed/getArchivalFile.cfm?archive_id=95789">download</a>                                                    </td>                    </tr>                                        <tr>                        <td>Apr 23, 2012</td>                        <td>							                                13                             							                        </td>                              <td>                        								                                                                                                                      <a download target="_blank" class="download-link" href="dailymed/getArchivalFile.cfm?archive_id=77794">download</a>                                                    </td>                    </tr>                                        <tr>                        <td>Oct 21, 2010</td>                        <td>							                                12                             							                        </td>                              <td>                        								                                                                                                                      <a download target="_blank" class="download-link" href="dailymed/getArchivalFile.cfm?archive_id=41816">download</a>                                                    </td>                    </tr>                                        <tr>                        <td>Jul 12, 2010</td>                        <td>							                                11                             							                        </td>                              <td>                        								                                                                                                                      <a download target="_blank" class="download-link" href="dailymed/getArchivalFile.cfm?archive_id=20767">download</a>                                                    </td>                    </tr>                                        <tr>                        <td>May 11, 2010</td>                        <td>							                                9                             							                        </td>                              <td>                        								                                                                                                                      <a download target="_blank" class="download-link" href="dailymed/getArchivalFile.cfm?archive_id=19101">download</a>                                                    </td>                    </tr>                                        <tr>                        <td>Feb 16, 2010</td>                        <td>							                                8                             							                        </td>                              <td>                        								                                                                                                                      <a download target="_blank" class="download-link" href="dailymed/getArchivalFile.cfm?archive_id=16292">download</a>                                                    </td>                    </tr>                                        <tr>                        <td>Feb 8, 2008</td>                        <td>							                                5                             							                        </td>                              <td>                        								                                                                                                                      <a download target="_blank" class="download-link" href="dailymed/getArchivalFile.cfm?archive_id=6907">download</a>                                                    </td>                    </tr>                                        <tr>                        <td>Aug 30, 2007</td>                        <td>							                                3                             							                        </td>                              <td>                        								                                                                                                                      <a download target="_blank" class="download-link" href="dailymed/getArchivalFile.cfm?archive_id=5385">download</a>                                                    </td>                    </tr>                                        <tr>                        <td>Jul 18, 2006</td>                        <td>							                                1                             							                        </td>                              <td>                        								                                                                                                                      <a download target="_blank" class="download-link" href="dailymed/getArchivalFile.cfm?archive_id=780">download</a>                                                    </td>                    </tr>                                    </tbody></table>        </div>        </div></div>        <!-- RxNorm Modal --><div class="mfp-hide modal" id="modal-rx-norm">        <div class="modal-wrapper">        <header><h2>RxNorm</h2></header>        <div class="top">            <h3 class="long-title">INVIRASE- saquinavir mesylate capsule <br>INVIRASE- saquinavir mesylate tablet, film coated <br></h3>        </div>        <div class="modal-content">        							    	    																																			    																	    	    	                             		       	                                                                                                       			                            <table class="modal">                    <tbody><tr>                        <th></th>                        <th>RxCUI</th>                               <th>RxNorm NAME</th>                        <th>RxTTY</th>                    </tr>                                                                                                    <tr class="psn-rxtty">                                                                    <td>1</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=200105">200105</a></td>                              <td>saquinavir 200 MG Oral Capsule</td>                        <td>PSN</td>                    </tr>                   	                                                    <tr>                                                                    <td>2</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=200105">200105</a></td>                              <td>Saquinavir 200 MG Oral Capsule</td>                        <td>SCD</td>                    </tr>                   	                                                                                <tr class="psn-rxtty">                                                                    <td>3</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=859861">859861</a></td>                              <td>Invirase 200 MG Oral Capsule</td>                        <td>PSN</td>                    </tr>                   	                                                    <tr>                                                                    <td>4</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=859861">859861</a></td>                              <td>Saquinavir 200 MG Oral Capsule [Invirase]</td>                        <td>SBD</td>                    </tr>                   	                                                    <tr>                                                                    <td>5</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=859861">859861</a></td>                              <td>Invirase 200 MG Oral Capsule</td>                        <td>SY</td>                    </tr>                   	                                                                                <tr class="psn-rxtty">                                                                    <td>6</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=859863">859863</a></td>                              <td>saquinavir mesylate 500 MG Oral Tablet</td>                        <td>PSN</td>                    </tr>                   	                                                    <tr>                                                                    <td>7</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=859863">859863</a></td>                              <td>saquinavir mesylate 500 MG Oral Tablet</td>                        <td>SCD</td>                    </tr>                   	                                                                                <tr class="psn-rxtty">                                                                    <td>8</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=859865">859865</a></td>                              <td>Invirase 500 MG Oral Tablet</td>                        <td>PSN</td>                    </tr>                   	                                                    <tr>                                                                    <td>9</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=859865">859865</a></td>                              <td>saquinavir mesylate 500 MG Oral Tablet [Invirase]</td>                        <td>SBD</td>                    </tr>                   	                                                    <tr>                                                                    <td>10</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=859865">859865</a></td>                              <td>Invirase 500 MG Oral Tablet</td>                        <td>SY</td>                    </tr>                   	                </tbody></table>                    </div>        </div></div><!-- Label RSS Modal --><div class="mfp-hide modal" id="modal-label-rss">        <header><h2>Get Label RSS Feed for this Drug</h2></header>        <div class="top">            <h3 class="long-title">INVIRASE- saquinavir mesylate capsule <br>INVIRASE- saquinavir mesylate tablet, film coated <br></h3>        </div>        <div class="modal-content">            <h4>To receive this label RSS feed</h4>            <p>Copy the URL below and paste it into your RSS Reader application.			<p><a href="https://dailymed.nlm.nih.gov/dailymed/labelrss.cfm?setid=c00d1607-ac36-457b-a34b-75ad74f9cf0a" target="_blank">https://dailymed.nlm.nih.gov/dailymed/labelrss.cfm?setid=c00d1607-ac36-457b-a34b-75ad74f9cf0a</a></p>            <h4>To receive all DailyMed Updates for the last seven days</h4>            <p>Copy the URL below and paste it into your RSS Reader application.</p>            <p><a href="https://dailymed.nlm.nih.gov/dailymed/rss.cfm" target="_blank">https://dailymed.nlm.nih.gov/dailymed/rss.cfm</a></p>            <h4>What will I get with the DailyMed RSS feed?</h4>            <p>DailyMed will deliver notification of updates and additions to Drug Label information currently shown on this site through its RSS feed.</p>            <p>DailyMed will deliver this notification to your desktop, Web browser, or e-mail depending on the RSS Reader you select to use. To view updated drug label links, paste the RSS feed address (URL) shown below into a RSS reader, or use a browser which supports RSS feeds, such as Safari for Mac OS X.</p>            <h4>How to discontinue the RSS feed</h4>            <p>If you no longer wish to have this DailyMed RSS service, simply delete the copied URL from your RSS Reader.</p>            <a href="dailymed/rss-updates.cfm" class="rss-icon"></a> <a href="dailymed/rss-updates.cfm">More about getting RSS News & Updates from DailyMed</a>        </div></div>    <!-- this div is only for jQuery --><div class="search-results">    <div class="filter-drop"></div></div><div class="webview"></div><div class="hide-on-mobile"></div>    <div class="mobilenav no-js">        <ul>            <li><a href="dailymed/index.cfm">Home</a></li>            <li>News                <ul>                    <li><a href="dailymed/dailymed-announcements.cfm">DailyMed Announcements</a></li>                    <li><a href="dailymed/rss-updates.cfm">Get RSS News &amp; Updates</a></li>                </ul>            </li>            <li>Search                <ul>                    <li><a href="dailymed/advanced-search.cfm">Advanced Search</a></li>	                    <li><a href="dailymed/browse-drug-classes.cfm">Browse Drug Classes</a></li>	                    <li><a href="dailymed/archives/index.cfm">Labels Archives</a></li>                    <li><a href="http://pillbox.nlm.nih.gov">Tablet/Capsule ID Tool</a></li>                </ul>            </li>                <li><a href="dailymed/fda-drug-guidance.cfm">FDA Guidances &amp; Information</a></li>                <li>NLM SPL Resources                    <ul>                        <li><a href="dailymed/spl-resources.cfm">Download Data</a>                            <ul>                                <li><a href="dailymed/spl-resources-all-drug-labels.cfm">All Drug Labels</a></li>                                <li><a href="dailymed/spl-resources-all-indexing-files.cfm">All Index Files</a></li>                                <li><a href="dailymed/spl-resources-all-mapping-files.cfm">All Mapping Files</a></li>                            </ul>                        </li>                        <li><a href="dailymed/splimage-guidelines.cfm">SPL Image Guidelines</a></li>                        <li><a href="dailymed/spl-resources-presentations-articles.cfm">Presentations &amp; Articles</a></li>                    </ul>                </li>                <li>Application Development Support                    <ul>                        <li><a href="dailymed/app-support.cfm">Resources</a>                            <ul>                                <li><a href="dailymed/app-support-web-services.cfm">Web Services</a></li>                                <li><a href="dailymed/app-support-mapping-files.cfm">Mapping Files</a></li>                            </ul>                        </li>                    </ul>                </li>            <li><a href="dailymed/help.cfm">Help</a></li>                    </ul>    </div>    <footer class="mainFooter">        <div class="container">            <div class="three columns">             <div class="nihnlmlogoprint"><img src="/dailymed/images/nihnlmlogoprint.png" alt="NIH NLM Logo"></div>                <a href="/www.nlm.nih.gov/" class="logo" title="National Library of Medicine | National Institutes of Health"><img src="/dailymed/images/footer-logo.png" width="109" height="37" alt="National Library of Medicine | National Institutes of Health" title="National Library of Medicine | National Institutes of Health" /></a>            </div>                        <div id="share" class="thirteen columns">                <div class="footer-links">                    <ul class="primary">                        <li><a href="dailymed/about-dailymed.cfm" title="About DailyMed">About DailyMed</a><span>|</span></li>                        <li><a href="dailymed/contact-us.cfm" title="Contact Us">Contact Us</a><span>|</span></li>                        <li><a href="/www.nlm.nih.gov/copyright.html" title="Copyright" target="_blank" rel="bookmark">Copyright</a><span>|</span></li>                        <li><a href="/www.nlm.nih.gov/privacy.html" title="Privacy" target="_blank" rel="bookmark">Privacy</a><span>|</span></li>                        <li><a href="/www.nlm.nih.gov/accessibility.html" title="Web Accessibility" target="_blank" rel="bookmark">Web Accessibility</a><span>|</span></li>                        <li><a href="/www.hon.ch/HONcode/Conduct.html?HONConduct393117" target="_blank" title="HONCode Certification">DailyMed is HONCode Certified</a></li>                    </ul>                    <ul class="secondary">                        <li><a href="http://www.nih.gov/" title="National Institutes of Health" target="_blank" rel="bookmark">National Institutes of Health</a><span>|</span></li>                        <li><a href="/www.nlm.nih.gov/" title="U.S. National Library of Medicine" target="_blank" rel="bookmark">U.S. National Library of Medicine</a><span>|</span></li>                        <li><a href="http://www.hhs.gov/" title="Health &amp; Human Services" target="_blank" rel="bookmark">Health &amp; Human Services</a></li>                    </ul>                    <ul class="secondary mobile">                        <li><a href="http://www.nih.gov/" title="National Institutes of Health" target="_blank" rel="bookmark">NIH</a><span>|</span></li>                        <li><a href="/www.nlm.nih.gov/" title="U.S. National Library of Medicine" target="_blank" rel="bookmark">NLM</a><span>|</span></li>                        <li><a href="http://www.hhs.gov/" title="Health &amp; Human Services" target="_blank" rel="bookmark">Health &amp; Human Services</a></li>                    </ul>                    <div class="social">                        Share                         <!-- AddThis Button BEGIN -->                        <noscript>: JavaScript needed for Sharing tools</noscript>                        <div class="addthis_toolbox addthis_default_style addthis_16x16_style">							                                                            	                                	            			        	                                                                        <a class="email-share" href="mailto:?subject=DailyMed%20Web%20site%20information&amp;Body=I%20would%20like%20to%20share%20this%20page%20from%20the%20DailyMed%20website%20with%20you%3A%0A%0AINVIRASE%2D%20Saquinavir%20Mesylate%20Capsule%20INVIRASE%2D%20Saquinavir%20Mesylate%20Tablet%2C%20Film%2E%2E%2E%0Ahttps%3A%2F%2Fdailymed%2Enlm%2Enih%2Egov%2Fdailymed%2FdrugInfo%2Ecfm%3Fsetid%3Dc00d1607%2Dac36%2D457b%2Da34b%2D75ad74f9cf0a%0A%0ADailyMed%20is%20a%20site%20provided%20by%20The%20National%20Library%20of%20Medicine%20%28NLM%29%20and%20is%20the%20official%20provider%20of%20FDA%20drug%20label%20information%20%28package%20inserts%29%2E" title="Share by Email"></a>                            <a class="addthis_button_facebook"></a>                            <a class="addthis_button_twitter"></a>                            <a class="at300bs at15nc at15t_compact reveal" title="Bookmark &amp; Share" href="/www.addthis.com/bookmark.php?pub=DailyMed&amp;title=DailyMed" target="_blank" style="width: 16px; height: 16px">                                <span style="left: -9999px; position: absolute;">Bookmark &amp; Share</span>                                <img style="width:17px; margin-top: -2px;" src="/dailymed/images/addthis-image.jpg" alt="Bookmark &amp; Share">                            </a>                        </div>                                                <!-- AddThis Button END -->                    </div>                                    </div>            </div>        </div>                <div class="divider"></div>    </footer>    <div class="divider"></div></div><div class="to-top"></div><!-- this div is only for jQuery --><div class="search-results">    <div class="filter-drop"></div></div><div class="webview"></div> <div class="hide-on-mobile"></div><script> var ignore_onbeforeunload = false; $("a").on('click',function(){    if(ignore_onbeforeunload){        ignore_onbeforeunload = false;    }})$("a[href^='mailto'], a[href$='zip']").on('click',function(){    ignore_onbeforeunload = true;});$(window).on('beforeunload', function(){    if (!ignore_onbeforeunload){        // Only run the loading icon if changing the page takes longer than 200ms        setTimeout(function(){            // Fade in the grey screen            $('body').prepend($('<div class="loading-wrapper" style="width: 100%;height: 100%;background-color: rgba(0, 0, 0, 0.50);position: fixed;top:0;z-index: 100000;"></div>').fadeIn('fast'));            var opts = {                  lines: 12 // The number of lines to draw                , length: 14 // The length of each line                , width: 5 // The line thickness                , radius: 14 // The radius of the inner circle                , scale: 1 // Scales overall size of the spinner                , corners: 1 // Corner roundness (0..1)                , color: '#fff'                 , opacity: 0.25 // Opacity of the lines                , rotate: 0 // The rotation offset                , direction: 1 // 1: clockwise, -1: counterclockwise                , speed: 1 // Rounds per second                , trail: 60 // Afterglow percentage                , fps: 20 // Frames per second when using setTimeout() as a fallback for CSS                , zIndex: 2e9 // The z-index (defaults to 2000000000)                , className: 'spinner' // The CSS class to assign to the spinner                , top: '50%' // Top position relative to parent                , left: '50%' // Left position relative to parent                , shadow: false // Whether to render a shadow                , hwaccel: false // Whether to use hardware acceleration                , position: 'absolute' // Element positioning                }            var spinner = new Spinner(opts).spin();            $('.loading-wrapper').append(spinner.el);        }, 200);    }    //ignore_onbeforeunload = false;});</script><!-- START OF SmartSource Data Collector TAG --><!-- Copyright (c) 1996-2012 Webtrends Inc.  All rights reserved. --><!-- Version: 9.4.0 --><!-- Tag Builder Version: 3.3  --><!-- Created: 1/25/2012 11:57:33 PM --><script type="text/javascript" src="/dailymed/scripts/webtrends.min.js"></script><!-- ----------------------------------------------------------------------------------- --><!-- Warning: The two script blocks below must remain inline. Moving them to an external --><!-- JavaScript include file can cause serious problems with cross-domain tracking.      --><!-- ----------------------------------------------------------------------------------- --><script type="text/javascript">//<![CDATA[var _tag=new WebTrends();_tag.dcsGetId();//]]></script><script type="text/javascript">//<![CDATA[_tag.dcsCustom=function(){// Add custom parameters here.//_tag.DCSext.param_name=param_value;_tag.DCSext.dcsid=_tag.dcsid}_tag.trackAllEvents=true;_tag.dcsCollect();//]]></script><noscript><div><img alt="DCSIMG" id="DCSIMG" width="1" height="1" src="//wtsdc.nlm.nih.gov/dcsm7fmt310000o265ioub7ib_2b7v/njs.gif?dcsuri=/nojavascript&amp;WT.js=No&amp;WT.tv=9.4.0&amp;dcssip=dailymed.nlm.nih.gov&amp;dcsid=dcsm7fmt310000o265ioub7ib_2b7v"/></div></noscript><!-- END OF SmartSource Data Collector TAG --><script type="text/javascript">    setTimeout(function(){var a=document.createElement("script");    var b=document.getElementsByTagName("script")[0];    a.src=document.location.protocol+"//dnn506yrbagrg.cloudfront.net/pages/scripts/0027/2050.js?"+Math.floor(new Date().getTime()/3600000);    a.async=true;a.type="text/javascript";b.parentNode.insertBefore(a,b)}, 1);</script><script type="text/javascript">    function getParameterByName(name) {        name = name.replace(/[\[]/, "\\[").replace(/[\]]/, "\\]");        var regex = new RegExp("[\\?&]" + name + "=([^&#]*)"),            results = regex.exec(location.search);        return results === null ? "" : decodeURIComponent(results[1].replace(/\+/g, " "));    }    /* Tracking label type on search pages */    function CE_READY() {        if(!getParameterByName('labeltype')){           CE2.set(1, "No Label Type");        }        else{            var labeltype = getParameterByName('labeltype');            if(labeltype == 'all'){                CE2.set(1, "All");            }            else if(labeltype == 'human'){                CE2.set(1, "Human");            }            else if(labeltype == 'animal'){                CE2.set(1, "Animal");            }            else{                CE2.set(1, "Unknown");            }        }    }</script>                    <!-- DAP Universal Analytics -->    <script language="javascript" id="_fed_an_ua_tag" src="/dailymed/scripts/Universal-Federated-Analytics-Min.2.01.js?agency=HHS&subagency=NIH&enhlink=true&dclink=true"></script>    <script src="/dailymed/scripts/preview-text.min.js"></script></body></html>    